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Summary 
 
Human essential hypertension is a substantial public health problem with greater 
than 25% of the adult population affected worldwide.  It is a complex disorder 
and a major risk factor for various cardiovascular diseases such as heart disease, 
renal  disease  and  stroke.    The  stroke prone  spontaneously  hypertensive  rat 
(SHRSP) is a commonly used model of human essential hypertension.  Previous 
studies identified a quantitative trait locus (QTL) for blood pressure regulation 
on rat chromosome 2.  To further enhance the investigation of this QTL, rat 
chromosome  2  congenic  strains  were  generated  by  transferring  regions  of 
chromosome 2 from the normotensive WKY onto the genetic background of the 
SHRSP.  Congenic strains exhibited significantly lower blood pressure than the 
SHRSP  parental  strain  indicating  that  genes  within  the  congenic  region  are 
important for blood pressure regulation.  Renal microarray analysis of congenic 
2c* and parental strains led to the identification of glutathione s transferase mu 
type  1  (Gstm1)  as  a  positional  and  possible  functional  candidate  gene  for 
hypertension in the SHRSP.  Expression of Gstm1 was significantly lower in the 
SHRSP kidney than in 2c* and WKY and renal oxidative stress was increased in 
SHRSP.    Glutathione  s transferase  mu  type  1  is  part  of  a  large  family  of 
antioxidant enzymes and may play a role in hypertension by modulating levels of 
oxidative stress. 
 
This  study  has  utilised  small  RNAs  to  examine  the  role  of  Gstm1  in  cellular 
oxidative stress and also investigated microRNA (miRNA) expression in the rat 
congenic strains.  RNA interference (RNAi) was utilised to knock down expression 
of Gstm1 in a rat kidney tubular epithelial cell line (NRK 52E).  Three different 
short  interfering  RNA  (siRNA)  sequences  designed  to  target  Gstm1  were 
evaluated.  Each sequence significantly reduced expression of Gstm1 and was 
confirmed at both mRNA and protein level.  Off target effects on other Gstm 
isoforms  and  the  interferon  response  gene,  oligoadenylate  synthetase  1  were 
prevented by reducing the concentration of siRNA used.  To take knock down of 
Gstm1 expression into an in vivo setting, local delivery to the kidney via the 
renal artery was  assessed  but  was found  to cause  significant kidney  damage.  
Instead,  kidney  targeted  vectors  that  can  be  delivered  systemically  were 
evaluated in the SHRSP.  Immunohistochemistry confirmed specific targeting of   17 
kidney  tubules.    Plasmid  vectors  were  then  generated  that  express  Gstm1 
specific  short hairpin  RNA  (shRNA)  molecules  based  on  the  sequences  that 
successfully  knocked  down  Gstm1  expression  in  vitro.    Transfection  of  these 
plasmids into NRK 52E cells was poor and knock down of Gstm1 could not be 
confirmed.   
 
The role of Gstm1 in protection against cellular oxidative stress was evaluated in 
NRK 52E cells by measuring markers of oxidative stress following knock down of 
Gstm1 expression.  Total GST activity was not reduced in cells transfected with 
Gstm1 specific siRNA however activity was increased following over expression 
of Gstm1.  No change in the levels of reduced glutathione was observed in cells 
following knock down of Gstm1.  Oxidative stress was determined by measuring 
8 isoprostane (a marker of lipid peroxidation), 8 hydroxy 2 deoxyguanosine (8 
OH dG)  (a  marker  of  oxidative  DNA  damage)  and  by  the  comet  assay  (DNA 
damage).  No significant difference in the levels of 8 isoprostane or 8 OH dG was 
observed in cells treated with Gstm1 specific siRNA compared to control siRNA.  
However a small but significant increase in ‘comet’ tail length was observed in 
cells  with  reduced  Gstm1  expression  indicating  greater  DNA  damage  in  these 
cells. 
 
Two miRNAs that map to the chromosome 2 congenic regions were investigated 
(miR 137  and  miR 9 1).    The  expression  of  each  miRNA  was  investigated  in 
kidney from SHRSP, WKY and congenic rat strains at 5, 16 and 21 weeks of age.  
Expression of miR 9 1 was unchanged in the SHRSP but was significantly reduced 
in  16  week  2c*  and  WKY  compared  to  5  week.    Expression  of  miR 137  was 
unchanged in both WKY and 2k but was significantly increased in 21 week old 
salt loaded  SHRSP  compared  to  21  week  old  SHRSP  without  salt.    Successful 
over expression of each miRNA was demonstrated in NRK 52E cells but inhibition 
of each miRNA could not be confirmed.  MicroRNA target prediction methods 
were  employed  to  identify  potential  gene  targets  for  each  miRNA.    A  list  of 
predicted  targets  for  each  miRNA  was  generated  and  combined  with  gene 
expression datasets generated from 5 week, 16 week, 21 week and 21 week plus 
salt  kidney microarray analysis carried out previously.  Using Ingenuity Pathway 
Analysis software, predicted target genes were identified according to patterns 
of expression.  Analysis of predicted miR 137 targets failed to find any genes   18 
that followed the correct pattern of expression (down regulated in SHRSP but 
unchanged in both WKY and 2k).  Of the targets predicted for miR 9 1, seven 
were  identified  that  were  up regulated  in  both  WKY  and  2c* but  not SHRSP.   
The expression levels of each of the seven genes were assessed in kidney and 
NRK 52E cells over expressing miR 9 1 however none  of the predicted targets 
could be validated. 
 
In summary, a wide range of techniques have been employed in an attempt to 
investigate the function of Gstm1 and the possible role of miRNA that map to the 
congenic regions implicated in blood pressure regulation.  Although a specific 
role  for  Gstm1  in  protection  against  oxidative  stress  has  yet  to  be  fully 
determined,  the  integration  of  targeted  vectors  and  modulation  of  Gstm1 
expression will allow the role of Gstm1 to be investigated more fully in vivo.   
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Chapter 1: Introduction   20 
1.1 Cardiovascular Disease 
 
The Global Burden of Disease Study carried out by the World Health Organisation 
(WHO) identified cardiovascular disease (CVD) as the leading cause of death in 
the world, accounting for ~32% of all deaths in women and ~27% in men in 2004 
(1).  Cardiovascular  diseases  are  disorders  of  the  heart  and  vascular  system 
serving  the  heart,  brain,  kidney  and  other  vital  organs  and  include  coronary 
heart  disease,  heart  failure,  stroke,  peripheral  vascular  disease  and  renal 
disease.    Of  these  disorders,  ischaemic  heart  disease  and  cerebrovascular 
disease  are responsible for  the majority  of deaths  worldwide  with 12.2%  and 
9.7% of total deaths attributed to each cardiovascular disorder respectively.  In 
2004, CVD was responsible for 17.1 million deaths globally and this has been 
projected to increase to 23.4 million by 2030 (1).  According to the British Heart 
Foundation Statistics Website, CVD is responsible for ~40% of deaths in the UK 
with  coronary  heart  disease  (CHD)  as  the  most  common  cause.    In  terms  of 
economic costs, CVD is a substantial problem.  It is estimated that CVD costs the 
UK economy ~£30.7 billion a year, with CHD alone costing ~£9 billion (2).  It is 
clear  that  investigation  into  the  causes  of  CVD  is  of  great  benefit  to  public 
health. 
 
1.1.1 Risk Factors 
 
There are various modifiable risk factors for CVD including being overweight or 
obese,  smoking,  dyslipidaemia,  type  2  diabetes  and  hypertension.    Mortality 
from CHD is approximately 60% higher in smokers than non smokers and this is 
increased to 80% in heavy smokers.  Passive smoking is also detrimental to CV 
health,  with  an  approximate  25%  increased  risk  of  CHD  in  those  regularly 
exposed to second hand smoke.  Estimates from the INTER HEART case control 
study suggest that smoking is responsible for ~30% of heart attacks in Western 
Europe.  As well as smoking, abdominal obesity has also been identified as a 
major cause of heart attacks and is deemed to be a more significant risk factor 
than  body  mass  index  (BMI)  (3).    Studies  on  obesity  and  weight  gain  have 
demonstrated increased incidence of CV events.  Being overweight or obese is 
also a risk factor for raised blood cholesterol, hypertension and type 2 diabetes,   21 
further  contributing  to  CVD  risk  (4).    Increased  total  blood  cholesterol  is 
estimated to be responsible for ~60% of cases of CHD and ~40% of strokes in 
developed  countries.    Abnormal  lipids  have  also  been  identified  as  a  major 
contributing factor to heart attack risk (3).  Cardiovascular disease is a major 
cause of death in people with type 2 diabetes accounting for approximately 50% 
of all diabetic fatalities.  Those with type 2 diabetes are 2 times more likely to 
suffer a heart attack or stroke.  Coronary heart disease risk is 2 to 4 fold greater 
in men and 3 to 5 fold greater in women with diabetes (5).                
 
1.1.1.1 Hypertension 
 
Hypertension is responsible for approximately 6% of adult deaths worldwide and 
is a major contributing factor to cardiovascular disease. Hypertensive patients 
present  an  increased  risk  of  developing  various  cardiovascular  complications 
such as stroke, heart disease, heart failure and end stage renal disease (6 10).  
Many studies have been carried out that show that even mild increases in blood 
pressure can dramatically increase the risk of a cardiovascular event.  For every 
20mmHg increase in SBP and 10mmHg increase in DBP, the mortality rate from 
cardiovascular disease doubles (11).  It has also been shown that having high 
normal blood pressure, defined as systolic BP 130 139mmHg and diastolic BP of 
85 89mmHg  (see  Table  1.1),  can  result  in  an  increased  risk  of  developing 
cardiovascular disease in both men and women (12).  
 
Table 1.1: Blood Pressure Classification  
Blood Pressure Category  Systolic BP (mmHg)  Diastolic BP (mmHg) 
NORMAL  <120  <80 
HIGH NORMAL   130 139  85 89 
HYPERTENSION  >140  >90 
STAGE 1  140 159  90 99 
STAGE 2  >160  >100 
 
Adapted from (11) 
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Clinical  trials  investigating  the  efficacy  of  antihypertensive  therapies 
demonstrate that even small reductions in blood pressure can quite considerably 
reduce incidence of stroke, heart disease and other CV events (13). 
 
Hypertension is often found in conjunction with other cardiovascular risk factors 
such  as,  insulin  resistance,  dyslipidaemia  and  obesity  (14).    These  features 
together  comprise  what  is  commonly  described  as  the  metabolic  syndrome.  
Data  collected  from  the  Framingham  Heart  Study  found  that  hypertension  is 
present as a single CVD risk factor in less than 20% of cases (15).  The presence 
of  a  single  risk  factor  at  age  50  is  associated  with  increased  risk  of 
cardiovascular  disease,  this  risk  increases  substantially  when  2  or  more  risk 
factors  are  present.    As  well  as  a  greater  likelihood  of  developing  CVD,  risk 
factor clusters also substantially reduce survival.  
  
1.1.1.2 Blood Pressure Regulation 
 
Normal blood pressure is defined as systolic blood pressure less than 120mmHg 
and diastolic pressure less than 80mmHg and can be described as the product of 
cardiac  output  and  total  peripheral  resistance  (11).    Blood  pressure  is 
determined by many, complex regulatory mechanisms including the sympathetic 
nervous  system,  various  chemical  and  hormonal  controls  that  affect  vascular 
resistance (see Figure 1.1) and local controls such as flow auto regulation with 
the kidneys playing a major role in blood pressure control by regulating sodium 
and fluid balance (Figure 1.2).  The importance of the kidney in blood pressure 
regulation  was  demonstrated  in  rat  kidney  transplant  studies.    Young 
hypertensive  rats  receiving  kidneys  from  a  normotensive  rat  strain  did  not 
develop hypertension, conversely, when kidneys from young hypertensive rats 
(before the  onset  of  hypertension)  were transplanted into normotensive rats, 
blood pressure was found to increase (16;17).  
 
The renin angiotensin system (RAS) is an important regulator of blood pressure 
and fluid balance.  This system comprises an enzymatic cascade that results in 
the production of the potent vasoconstrictor angiotensin II (Ang II) (18).  The 
cascade  begins  with  the  synthesis  and  release  of  the  enzyme  renin  from  the 
juxtaglomerular cells in response to various stimuli.     23 
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Figure 1.1 Factors regulating vascular tone 
Vascular  tone  is  subject  to  various  hormonal,  local  and  neuronal  controls 
contributing to both vasoconstriction and vasodilation. 
α1 AR:  alpha  1 adrenergic  receptor,  β2 AR:  beta  2 adrenergic  receptor,  NO: 
nitric oxide   
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Figure 1.2 Factors contributing to blood pressure regulation 
Arterial  pressure  can  be  defined  as  the  product  of  cardiac  output  and  total 
peripheral  resistance  and  is  affected  by  a  range  of  complex  regulatory 
mechanisms. 
 
Adapted from (19)  
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Figure 1.3 Renin Angiotensin System 
ACE: angiotensin converting enzyme, ACE2: ACE related carboxypeptidase, AT1: 
angiotensin II type 1 receptor, AT2: angtiotensin II type 2 receptor 
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Angiotensinogen,  produced  in  the  liver,  is  the  substrate  for  renin  and  is 
converted to the inactive angiotensin I.  Angiotensin I is then cleaved to produce 
the active angiotensin II by angiotensin converting enzyme (ACE).  Angiotensin 
converting  enzyme can also cleave bradykinin, a vasodilator  and in  doing so, 
further  contributes  to  vasoconstriction.    Angiotensin  II  mediates  its  actions 
through two receptors; AT1 and AT2 (20).   Binding of Ang II to the AT1 receptor 
leads to vasoconstriction and increased retention of sodium in the kidneys.  Ang 
II also stimulates secretion of aldosterone leading to further re absorption in the 
kidney resulting in increased blood pressure. The AT2 receptor when bound by 
Ang  II  counteracts  the  effects  produced  via  the  AT1  receptor  by  stimulating 
vasodilation.  More recently, a human homologue of ACE has been discovered.  
This  ACE related  carboxypeptidase  (ACE2)  acts  on  Ang  I  and  catalyses  its 
cleavage  to  produce  angiotensin  1 9  (Ang  1 9)  and  subsequent  generation  of 
angiotensin 1 7 (Ang 1 7) (21).  Ang 1 7 has also been shown to interact with the 
G  protein  coupled  receptor  Mas.    Deletion  of  this  receptor  in  mouse  kidney 
completely abolished Ang 1 7 binding and receptor deficiency in aortas resulted 
in diminished dilatory response, indicating that Ang 1 7 interacts with the Mas 
receptor and in doing so induces vasodilation (22) (Figure 1.3). 
 
1.2 Essential Hypertension 
 
Human  essential  hypertension  is  a  substantial  public  health  problem,  with 
greater than 25% of the adult population affected (23).  It is commonly defined 
as systolic pressure greater than 140mmHg and diastolic pressure greater than 
90mmHg (11).  Most cases of hypertension (>90%) are of unknown cause with 
many possible contributing factors.  Hypertension is a complex disorder that is 
subject to both environmental and genetic factors.  Non modifiable risk factors 
such  as  gender,  age  and  race  have  been  shown  to  influence  blood  pressure.  
Blood  pressure  is  sexually  dimorphic  where  men  tend  to  have  higher  blood 
pressure than women and systolic pressure is found to increase with age (24).  
Diastolic  pressure  also  increases  progressively  in  both  men  and  women  until 
approximately sixty years of age, after which time it begins to decrease.  
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1.2.1 Environmental Factors 
 
Environmental factors such as diet, salt intake and weight all have an impact on 
blood pressure and it has been shown that by modifying diet or losing weight, 
blood pressure can be reduced (25 28).  The DASH (Dietary Approaches to Stop 
Hypertension) trial investigated the blood pressure lowering effects of adopting 
a  diet  rich  in  fruits  and  vegetables  and  placed  emphasis  on  low  fat  dairy 
products to help reduce total fat and saturated fat consumption.  By modifying 
diet in this way a significant reduction in both systolic and diastolic pressure was 
observed  (25).  A  minimal  increase  in  age  related  blood  pressure  has  been 
observed in populations where a very low sodium diet is consumed.  However, in 
those populations consuming greater than 20g of salt per day, there is a much 
higher  prevalence  of  hypertension  (17).    Alcohol  consumption  has  also  been 
associated with hypertension and studies have shown that by decreasing alcohol 
intake, blood pressure can be reduced (29;30).   
 
Within  the  general  population  being  overweight  (assessed  by  BMI)  is  a  major 
contributor to the onset of hypertension with greater than 40% of new onset 
hypertension attributable to being overweight.  Increased body fat has also been 
found to be associated with hypertension, particularly centrally located body fat 
(4;11).   
 
1.2.2 Genetics and Hypertension 
 
Genetics  play  an  important  role  in  hypertension  with  approximately  30% 
attributed to genetics in combination with the environmental issues mentioned.  
Population  studies  found  that  blood  pressure  varied  less  within  families  than 
between  families  (31)  and  the  NHLBI  twin  study  identified  greater  genetic 
heritability of blood pressure in monozygotic twins than dizygotic twins (32).   
 
1.2.2.1 Mendelian Forms of Hypertension 
 
Most genetic studies of hypertension have focused on the Mendelian forms of the 
disorder, which are characterised by altered renal salt handling.  Glucocorticoid 
remediable aldosteronism (GRA) is an autosomal dominant disorder that results   28 
in hypertension due to aberrant aldosterone synthesis and can be inhibited by 
treatment with glucocorticoids.  It is characterised by low plasma renin activity 
and normal or raised aldosterone levels (33).  Those with GRA have a form of 
salt  sensitive  hypertension,  often  associated  with  metabolic  alkalosis  and 
hypokalaemia.  The disorder is caused by unequal crossing over between two 
closely  related  genes.    These  genes  are  CYP11B1,  which  encodes  11  β 
hydroxylase and CYP11B2, which encodes aldosterone synthase.  This crossing 
over results in the production of a chimeric gene where aldosterone synthase is 
under  the  control  of  an  adrenocorticotropic  hormone  (ACTH)  dependent 
promoter.  Instead of responding to Ang II, which normally regulates aldosterone 
synthase,  aldosterone  synthesis  is  stimulated  by  ACTH  and  is  continuously 
produced.    This  increase  in  aldosterone  causes  salt  retention  leading  to 
increased plasma volume and suppression of renin excretion.     
 
Liddle’s syndrome is an autosomal dominant hypertensive disorder characterised 
by low renin levels and suppressed aldosterone secretion.  It is caused by gain of 
function mutations in the β or γ subunits of the epithelial Na
+ channel (ENaC) so 
that the channel remains activated allowing for continued sodium re absorption 
(34).  This increase in salt retention leads to hypertension.  
 
Pseudohypoaldosteronism  type  II  (PHAII)  or  Gordon’s  syndrome  is  caused  by 
mutations in two genes belonging to the WNK family of kinases.  These genes are 
WNK1  and  WNK4  and  are  expressed  in  the  distal  part  of  the  nephron  (35).  
Gordon’s  syndrome  is  associated  with  increased  renal  salt  absorption, 
hyperkalaemia and low plasma renin and aldosterone levels.  
 
Apparent mineralocorticoid excess (AME) is an autosomal recessive disorder that 
is  associated  with  hypokalaemia,  metabolic  alkalosis  and  suppressed  plasma 
renin activity with almost no circulating aldosterone present.  It is caused by the 
absence of 11β hydroxysteroid dehydrogenase (11βHSD), the enzyme responsible 
for conversion of cortisol to cortisone.  Studies involving the use of antagonists 
of  the  mineralocorticoid  receptor  (MR)  resulted  in  reduced  blood  pressure  in 
patients with AME  suggesting  that a mineralocorticoid  other than aldosterone 
can activate MR (36).  Further investigation did not indentify another circulating 
mineralocorticoid  but  instead  found  that  patients  with  AME  do  not  produce   29 
11βHSD  thereby  reducing  their  ability  to  convert  cortisol  to  cortisone.  
Subsequent in vitro studies and cloning of MR found that cortisol can bind and 
activate  MR  to  a  similar  degree  as  aldosterone  so  that  in  the  absence  of 
aldosterone in these patients, MR can still be activated and result in increased 
ENaC activity.      
 
 
1.2.2.2 Genetics of Essential Hypertension 
 
These  studies  have  identified  various  mechanisms  by  which  hypertension  can 
occur but do not provide the answer to the problems posed by the more complex 
and  polygenic  nature  of  essential  hypertension.    Monogenic  forms  of 
hypertension  are  very  rare  and  account  for  less  than  1%  of  all  human 
hypertension.   
 
1.2.2.3 Candidate Gene Analysis 
 
Many candidate gene studies have been carried out to assess the association of 
genes  that  are  implicated  in  BP  variation  with  essential  hypertension.    Such 
genes  fall  into  five  broad  categories:  renin  angiotensin  aldosterone  system 
(RAAS),  adrenergic,  vascular,  metabolic  and  those  with  miscellaneous  roles.  
However results within each category are conflicting and no candidate gene has 
shown  consistent  association  with  hypertension.    This  lack  of  reproducibility 
demonstrates the difficulty of trying to identify the genetic causes of complex 
disease.   
 
The angiotensinogen gene (AGT) has been extensively studied in an attempt to 
identify  an  association  with  essential  hypertension.    Sib pair  linkage  analysis 
identified  significant  linkage  of  the  AGT  gene  locus  to  hypertension  in  two 
separate populations.  However, in one of these populations, only a subset of 
participants with more severe hypertension demonstrated linkage.  A common 
variant in this gene (M235T) was identified and found to be significantly more 
frequent  in  hypertensive  subjects  than  controls  (37).    This  variant  has  been 
shown to associate with hypertension in several but not all populations studied 
(38;39).    A  meta analysis  of  combined  case control  studies  found  that  the  T   30 
allele associated with risk of hypertension in Caucasians but not Blacks or Asians 
(40).  However this association found in Caucasians may be due to a publication 
bias with a lack of studies with negative results present in the meta analysis.   
 
Another  candidate  gene  related  to  RAAS  is  the  gene  encoding  angiotensin 
converting enzyme (ACE).  Much work has been done to identify an association 
between  ACE  and  essential  hypertension  but  again  the  results  have  been 
conflicting.  Jeunemaitre et al reported that there is no linkage between the 
ACE  locus  and  essential  hypertension  following  sib pair  linkage  analysis  of  a 
marker linked to the ACE locus. The total population was then split into sub 
groups to try and reduce heterogeneity in the population, but still no linkage 
with hypertension was found (41).  However, a further two population studies 
identified  association  of  ACE  with  hypertension  in  men  but  not  women 
suggesting  that  ACE  may  be  a  sex  specific  candidate  gene  for  hypertension 
(42;43).    Again,  no  definitive  conclusion  can  be  drawn  as  results  are  not 
consistent (44).  
 
The  cytoskeletal  protein  adducin  has  also  been  implicated  in  hypertension.  
Adducin is composed of three subunits; α, β and γ encoded by ADD1, ADD2 and 
ADD3  respectively  and  may  play  a  role  in  sodium  re absorption  in  the  renal 
tubule.  Studies in the Milan hypertensive rat strain identified point mutations in 
α  and  β adducin  coding  sequence  resulting  in  amino  acid  substitutions.    The 
Add1  gene  mutation  was found  to  associate  with  blood  pressure  and  when  a 
region encompassing the Add1 locus was transferred from a hypertensive donor 
to a normotensive rat strain, blood pressure in the recipient increased (45 47).  
Several human studies have sought to establish a relationship between the α 
adducin  gene  (ADD1)  and  blood  pressure  (17;45).    A  case  control  study 
performed  in  190  hypertensive  patients  and  126  control  subjects  found 
significant linkage of markers surrounding the ADD1 locus to hypertension.  The 
greatest  association  was  found  with  the  marker  closest  to  the  adducin  locus 
however this does not exclude the possibility that another gene in this region 
contributes  to  the  blood  pressure  variation  observed  (48).    Linkage  of 
hypertension to the ADD1 locus was confirmed in another population and cDNA 
analysis identified a mutation causing an amino acid substitution (G460W).  This 
polymorphism  was  found  to  significantly  associate  with  hypertension  in  both   31 
populations used in this study (49).  However, a more recent study found no 
association of the G460W polymorphism with hypertension (50).  The ADD2 gene 
encoding  the  β adducin  subunit  has  also  been  investigated  for  its  association 
with hypertension, with conflicting results.  A study of the C1797T polymorphism 
in three European populations found that presence of the T allele was associated 
with increased blood pressure in two out of the three populations (51).         
 
1.2.2.4 Genetic Linkage and Association Studies 
 
Various genome wide linkage and association studies have been undertaken to 
attempt  to  identify  genetic  regions  that  are  responsible  for  blood  pressure 
phenotype in essential hypertension.  One advantage of such studies is that no 
prior information of genetic function is required.    
 
1.2.2.5 Linkage Analysis 
 
Genome  wide  linkage  studies  are  possible  due  to  the  vast  number  of 
microsatellite  and  single  nucleotide  polymorphism  (SNP)  markers  spread 
throughout  the  genome.    This  combined  with  recent  technological  advances 
allow the location of chromosomal regions or quantitative trait loci (QTLs) linked 
to hypertension to be identified.  By finding markers that associate with blood 
pressure  phenotype,  the  location  of  a  QTL  can  be  determined.      Using  this 
approach, numerous QTLs relating to hypertension or blood pressure have been 
found throughout the human genome.  However these studies have been poorly 
replicated  due  to  the  polygenic  and  multi factorial  nature  of  hypertension. 
Multiple loci have been found on some chromosomes suggesting that it is unlikely 
that a single genomic region is responsible for  predisposition  to hypertension 
(19;52).   
 
In  an  attempt  to  improve  the  likelihood  of  detecting  QTLs  for  essential 
hypertension,  the  MRC  British  Genetics  of  Hypertension  (BRIGHT)  study  was 
performed on sibling pairs from families with severe early onset hypertension.  
Individuals were only selected for the study if non diabetic, non obese with no 
history of secondary hypertension and with blood pressure in the top 5% of the   32 
blood  pressure  distribution  in  the UK.    Linkage  analysis  identified  a  locus  on 
chromosome  6  and  3  further  regions  that  have  suggested  linkage  on 
chromosomes  2,  5  and  9  (53).    Further  analysis  of  this  data  with  additional 
microsatellite markers reinforced support for linkage of essential hypertension 
with chromosome 5 (54).  However, analysis supporting linkage to chromosome 6 
should  be  regarded  with  care  as  the  locus  is  present  near  the  end  of  the 
chromosome.    Analysis  of  such  regions  by  linkage  computer  programs  can 
produce  misleading  results  (55).    The  Family  Blood  Pressure  Program  (FBPP) 
study was a meta analysis of four separate family studies designed to identify 
linkage to hypertension through genome wide linkage scans.  The study involved 
over  6000  individuals  but  failed  to  identify  any  hypertension  related  QTLs, 
indicating that blood pressure is not subject to control by single genomic regions 
but by many loci imparting small effects on phenotype (56). 
 
1.2.2.6 Genome Wide Association Studies 
 
Genome wide association studies utilise the availability of SNP markers to carry 
out large scale association mapping and involve comparisons of allele frequency 
throughout the genome in a case control design.  This approach is unbiased as no 
assumptions are made regarding the genomic location of genetic variants that 
may have an affect on phenotype.  Such studies have been made possible due to 
the availability of high throughput technologies and genome wide determination 
of genetic variation by the HapMap project (52;57).   
 
The Welcome Trust Case Control Consortium (WTCCC) carried out a large scale 
genome wide  association  study in an attempt to identify genes involved in 7 
common human diseases, including hypertension (58).  For each disease 2000 
individuals  were  examined  with  a  shared  set  of  3000  controls  all  of  whom 
identified themselves as white Europeans.  Following analysis, 24 independent 
association  signals  were  identified  at  p<5x10
 7,  the  genome  wide  significance 
level  set  for  this  experiment.    The  association  signals  included  1  in  bipolar 
disorder, 1 in coronary artery  disease, 9 in Crohn’s  disease,  3  in rheumatoid 
arthritis, 7 in type 1 diabetes and 3 in type 2 diabetes.  For hypertension, none 
of the previously suggested associated variants were identified and no further 
SNPs were discovered with significance below the set threshold level.  There are   33 
many reasons that may explain why no significant associations were detected for 
hypertension, such as poor gene coverage  in the Affymetrix chip used in  the 
study.  For example, WNK1, which has been previously identified as a candidate 
gene for hypertension but is poorly tagged on the Affymetrix chip.  Another issue 
with this study is the use of a shared set of common controls, as this increases 
the likelihood that a proportion of controls may have hypertension or may go on 
to develop it in the future.  This could significantly reduce the power of the 
study for identifying associations with hypertension.  It has been estimated that 
“if 5% of controls would meet the definition of cases at the same age, the loss of 
power is approximately the same as that due to a reduction of sample size by 
10%” (58).         
 
1.3 Animal Models 
 
In order to better understand the mechanisms contributing to complex human 
disease, such as hypertension, animal models can be studied.  The rat is the 
most commonly used model for investigating hypertension.  There are various 
non genetic models of hypertension that are useful for investigation of secondary 
hypertension.   These include the 2 kidney, 1 clip rat and DOCA salt rats for 
investigating renovascular and endocrine causes of hypertension. 
 
1.3.1 Genetic Models of Hypertension 
 
The spontaneously hypertensive rat or SHR is an example of a selectively bred 
animal  model  that  can  be  utilised  for  the  genetic  analysis  of  hypertension.  
Other  genetic  models  of  hypertension  include  the  stroke prone  SHR,  the 
genetically  hypertensive  rat,  Sabra  model,  Lyon  hypertensive  rat,  Milan 
hypertensive rat and Dahl salt sensitive rats.  The SHR was generated from the 
Wistar  rat  strain.    Male  Wistar  rats  exhibiting  spontaneous  hypertension  (SBP 
>150mmHg) were mated  with female rats with  above  average  blood pressure 
(SBP  >130mmHg).    Pairs  of  rats  from  the  F1  generation  with  spontaneous 
hypertension were then mated.  This process was repeated so that in subsequent 
generations, spontaneous hypertension was observed approximately 100% of the 
time.  In this strain, blood pressure increases with age, as is the case in human   34 
hypertension.    Blood  pressure  rises  steadily  from  ~140mmHg  SBP  at  about  5 
weeks of age to ~200mmHg at 25 weeks (59).  The stroke prone spontaneously 
hypertensive rat (SHRSP) is a sub strain of the SHR that displays extremely high 
blood pressure and has a high incidence of stroke.  Both strains are excellent 
genetic models of human hypertension as they exhibit many features that are 
common  to  the  human  disorder,  such  as  endothelial  dysfunction,  cardiac 
hypertrophy,  renal  dysfunction  and  heart  failure  (60;61).    The  high  blood 
pressure phenotype observed in the SHR and SHRSP models is independent of 
dietary  salt  or  other  environmental  influence  unlike  Dahl  salt  sensitive  rats 
which develop high blood pressure following a high salt diet.  However, when 
fed a 1% salt solution, spontaneously hypertensive rats do have increased blood 
pressure (62).  Both SHR and SHRSP exhibit salt sensitivity. 
 
1.3.2 Congenic Strains 
 
Genetic linkage studies carried out in rat models of hypertension have led to the 
identification  of  numerous  QTLs  for  blood  pressure  regulation  across  many 
chromosomes.  However QTLs usually encompass regions that are too large to 
yield a small number of genes that can easily be investigated.  To overcome this, 
congenic strains can be generated to narrow down the region for investigation.  
This  involves  the  transfer  of  one  chromosomal  region  from  one  rat  strain  to 
another.  A donor and recipient strain are crossed and the progeny containing 
the region of interest are then backcrossed to the recipient strain.  Backcrossing 
is carried out until the progeny are entirely of recipient genetic background with 
the exception of the region transferred (63).  It is estimated that following eight 
generations of back crossing that more than 99% will be from the recipient.  This 
process  can  be  accelerated  by  using  a  speed  congenic  strategy,  where  back 
crossed male rats are screened for genetic markers allowing for rats with the 
least donor genetic background to be selected for future crosses (Figure 1.4).  By 
narrowing  down  the  congenic  region,  the  possibility  of  identifying  causative 
genes is increased. 
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Figure 1.4 Traditional and speed congenic breeding 
Construction  of  congenic  strains  demonstrating  the  differences  between 
traditional and marker assisted speed congenic breeding.  Decreasing shades of 
grey  represent  dilution  of  the  donor  genome.    D:  donor  strain  alleles,  R: 
recipient strain alleles, B: backcross, F1: first filial generation 
 
Taken from (60).  Permission to reproduce this figure has been granted by John 
Wiley & Sons, Inc. 
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The  congenic  strategy  to  discover  candidate  genes  as  described  above  was 
successfully utilised by Aitman  et al to identify Cd36 as an insulin resistance 
gene.    Previous  studies  identified  a  QTL  on  chromosome  4  in  spontaneously 
hypertensive rats for defective glucose and fatty acid metabolism in adipocytes 
(64).    In  order  to  further  investigate  the  QTL  region,  Aitman  and  colleagues 
generated a congenic strain where the SHR QTL on chromosome 4 was replaced 
with the equivalent region from the Brown Norway (BN) rat.  The congenic strain 
showed improved insulin mediated glucose uptake and complete restoration of 
the normal lipid metabolism phenotype, thus confirming that genes with the QTL 
are  responsible.    To  further  dissect  which  genes  may  be  responsible,  cDNA 
microarray  analysis  was  performed  to  identify  genes  that  are  differentially 
expressed  across  strains.    In  this  way  Cd36  was  identified  and  pursued  as  a 
candidate gene.  This gene maps to the chromosome 4 QTL region and encodes a 
fatty  acid  translocase  with  expression  in  adipose  tissue  and  in  skeletal  and 
cardiac  muscle.    However,  in  the  SHR,  Cd36  protein  was  undetectable  in 
adipocyte plasma membrane.  A transgenic mouse over expressing Cd36 in heart 
and  skeletal  muscle  was  found  to  have  lower  blood  triglycerides.    This 
investigation identified that Cd36 deficiency is responsible for insulin resistance 
and defects in fatty acid metabolism in the SHR (65).  Further studies involving 
transgenic overexpression of Cd36 in the SHR found that Cd36 decreases serum 
fatty acid levels, increases sensitivity to insulin and improves glucose tolerance 
but has no effect on mean arterial blood pressure (66).  More recently, renal 
expression of Cd36 has been shown to have an inverse correlation with blood 
pressure.    Renal  transplantation  experiments  have  demonstrated  that  rats 
receiving  kidneys  expressing  wild  type  Cd36  result  in  reduced  blood  pressure 
compared to those receiving kidneys lacking Cd36 (67). 
 
A similar congenic strategy has been utilised in our own laboratory to identify 
candidate genes for hypertension.  Genome wide linkage analysis of the SHRSP 
led  to  the  identification  of  2  QTL  for  blood  pressure  regulation  within  rat 
chromosome  2  (68).    In  order  to  further  dissect  the  contribution  of  the  QTL 
region of rat chromosome 2 to blood pressure regulation, congenic strains were 
generated.     37 
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Figure 1.5 Rat chromosome 2 congenic strain SP.WKYGla2c* 
The  2c*  congenic  strain  was  generated  by  transferring  a  chromosomal  region 
from WKY onto the SHRSP background.  This region, between markers D2Wox9 
and D2Mgh12, encompasses a blood pressure quantitative trait locus (QTL). 
 
Adapted from (69) 
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Figure 1.6 Day and night time average systolic and diastolic blood pressure 
Blood pressure measured by radiotelemetry in SHRSP, WKY and congenic 2c*.  
SBP: systolic pressure (top panel), DBP: diastolic pressure (bottom panel) 
 
Adapted from (69) 
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In  this  case,  a  region  encompassing  the  lower  QTL  on  chromosome  2  from  a 
normotensive strain (WKY) was transferred onto the genetic background of the 
SHRSP  using  a  marker  assisted  breeding  strategy  (70)  to  generate  the 
SP.WKYGla2c* (2c*) (Figure 1.5).  Initial studies with the congenic SP.WKYGla2c* 
found  that  blood  pressure  was  significantly  lower  in  the  congenic  when 
compared to the SHRSP (Figure 1.6). This indicates that genes found within the 
congenic region are indeed responsible for blood pressure regulation.  To further 
examine which genes may be playing a role, microarray analysis was carried out 
on  the  congenic  strains.    Of  the  many  probe  sets  that  were  found  to  be 
differentially expressed, three mapped to the congenic region.  All three probes 
corresponded to the gene encoding glutathione S transferase mu type 1 (Gstm1) 
(69).    Gstm1  was  found  to  have  significantly  lower  expression  in  the  SHRSP 
compared to the congenic and WKY.  As the congenic strain has lower blood 
pressure  than  the  SHRSP,  genes  within  the  congenic  region  appear  to  be 
important and due to its position and differential expression, Gstm1 has been 
identified  as  a  positional  candidate  gene  for  rat  and  possibly  human 
hypertension. 
 
The microarray analysis that led to identification  of Gstm1 was performed in 
kidney tissue from SHRSP, WKY and 2c* congenic strains.  The kidney was chosen 
for  investigation  of  candidate  genes  in hypertension  as  it  is  the  major  organ 
responsible  for  long  term  blood  pressure  control  and  evidence  from  kidney 
transplant studies in rats have shown that blood pressure phenotype follows the 
kidney  (71).    In  experimental  models  of  hypertension,  the  induction  of 
hypertension involves some reduction of renal function (72).  It has been well 
documented that the kidney plays an important role in blood pressure regulation 
where control of sodium and water excretion has been suggested as the main 
mechanism  contributing  to  pressure  control  (73).    As  described  in  section 
1.1.1.2, the renin angiotensin system contributes to blood pressure control and 
in the kidney stimulates retention of sodium and water, thereby raising blood 
volume and consequently raising blood pressure.  The activation of AT1 receptors 
by  angiotensin  II  leads  to  vasoconstriction  and  a  study  has  shown  that  the 
absence of kidney AT1 receptors in mice was enough to enable a blood pressure 
reduction of almost 20 mmHg even with normal expression of the receptor in 
other tissues (74).  Another action of angiotensin II is to stimulate release of   40 
aldosterone from the adrenal cortex.  Aldosterone promotes sodium and water 
retention  in  the  kidney  via  the  epithelial  sodium  channel  (ENaC).    Elevated 
levels  of  circulating  aldosterone  in  Sprague  Dawley  rats  led  to  an  increased 
abundance of the α subunit of ENaC and caused redistribution of ENaC subunits 
to the apical region of principal cells of the collecting duct (75).   
The absorption of sodium and water by the collecting duct is important as it is 
here that sodium and water excretion is subjected to ‘fine tuning’ by the kidney 
(76).    Studies  performed  to  identify  where  Gstm1  was  expressed  found  that 
Gstm1 expression was present in kidney tubular epithelium and in particular was 
found in the principal cells of the collecting duct (77).  Due to the localisation of 
Gstm1 expression to kidney tubules and its reduced expression in renal tissue 
from hypertensive rats, the focus of the work presented in this thesis has been 
the kidney and in particular has utilised a rat kidney tubular epithelial cell line 
(NRK 52E). 
At  present  very  little  is  known  about  the  specific  role  of  Gstm1  in  the  rat 
however a gene mapping study in the mouse identified Gstm1 as a positional 
candidate gene for susceptibility to renal vascular injury.  A study of a genetic 
model  of  angiotensin  II  type  1A  receptor  deficiency  found  that  the  genetic 
background  of  these  mice  could  modify  their  susceptibility  to  renal  vascular 
hypertrophy (78).  Those with a C57BL/6 genetic background were found to be 
more susceptible to renal vascular hypertrophy and linkage analysis identified a 
locus  on  chromosome  3  with  significant  linkage  to  the  vascular  phenotype.  
Screening for candidate genes found that Gstm1 mapped to this region and was 
differentially expressed between C57BL/6 susceptible and 129 resistant strains 
suggesting that Gstm1 may play a role in vascular homeostasis (79).  Expression 
of  Gstm1  was  significantly  lower  in  aortic  VSMCs  isolated  from  C57BL/6 
compared to VSMCs from 129 mice.  The C57BL/6 VSMCs also exhibited a higher 
cell proliferation rate and increased reactive oxygen species when compared to 
129 VSMCs.  Transfection of VSMCs with Gstm1 siRNA to reduce Gstm1 expression 
resulted in a significant increase in VSMC proliferation, migration and superoxide 
levels.  It may be that Gstm1 modulates VSMC proliferation and migration by 
protecting cells from products of oxidative stress which could influence VSMC 
proliferation, although the exact mechanism is not yet known (79). 
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1.4 Oxidative Stress 
 
The  term  oxidative  stress  refers  to  a  state  where  cellular  antioxidants  are 
overwhelmed by pro oxidants resulting in an increased production of reactive 
oxygen species (ROS).  Reactive oxygen species are produced by all cells of the 
vasculature and play an important role in cellular homeostasis and signalling.  
Reactive  oxygen  species  include  non radical  molecules  such  as  hydrogen 
peroxide (H2O2) and peroxynitrite (ONOO
 ) and free radicals such as superoxide 
(O2
 ), nitric oxide (NO) and hydroxyl radical (OH
 ). 
 
There is much evidence available that suggests a role for oxidative stress in the 
development  of  hypertension  (80).    Increased  levels  of  ROS  can  cause 
remodelling of the vasculature due to inflammation and cellular damage (Figure 
1.7).  This leads to an increase in total peripheral resistance thus causing blood 
pressure to become elevated (81).  Oxidative stress, induced by depletion of 
glutathione,  has  been  shown  to  cause  normotensive  Sprague Dawley  rats  to 
become  hypertensive  (82).    Treating  pre hypertensive  spontaneously 
hypertensive  rats  (SHR)  with  Tempol,  a  SOD  mimetic,  prevents  rats  from 
becoming  hypertensive.    This  indicates  that  by  lowering  levels  of  oxidative 
stress, hypertension can be prevented (83). 
 
1.4.1 Superoxide and Vascular NAD(P)H Oxidase 
 
Superoxide  is  a  key  molecule  in  the  production  of  oxidative  stress  as  it  is  a 
precursor  for  various  other  reactive  oxygen  species.    Superoxide  is  produced 
from the one electron reduction of molecular oxygen.  There are many sources 
of superoxide such as xanthine oxidase and the mitochondrial respiratory chain 
but  within  the  vasculature,  the  principal  source  is  NAD(P)H  (nicotinamide 
adenine  dinucleotide  phosphate)  oxidase  (84).    Vascular  NAD(P)H  oxidase  is 
similar  in  structure  to  the  phagocytic  type  oxidase  but  instead  of  producing 
superoxide in short bursts, it is generated at a much lower level over a longer 
period  of  time.    NAD(P)H  oxidase  is  a  multi subunit  enzyme  comprising  2 
membrane associated and 3 cytosolic components, see Figure 1.8.     42 
 
 
Figure 1.7 Oxidative stress   
Increased  production  of  superoxide  can  lead  to  endothelial  dysfunction  by 
diminishing nitric oxide bioavailability. Superoxide also results in the generation 
of various other reactive oxygen and nitrogen species that can inflict cellular 
damage and vascular remodelling contributing to increased peripheral resistance 
and blood pressure. 
O2
 :  superoxide,  H2O2:  hydrogen  peroxide,  NO:  nitric  oxide,  ONOO
 : 
peroxynitrite,  SOD:  superoxide  dismutase,  eNOS:  endothelial  nitric  oxide 
synthase, BP: blood pressure 
Adapted from (81) 
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The  membrane  associated  subunits  are  p22
phox  and  Nox,  a  homologue  of  the 
gp91
phox found in phagocytic NAD(P)H oxidase.  Together, the 2 subunits form the 
cytochrome b558.  Studies carried out in vascular smooth muscle cells identified 
p22
phox as a critical factor in NAD(P)H oxidase mediated superoxide production.  
Cells transfected  with  p22
phox  antisense  cDNA  have  reduced  Ang  II  stimulated 
NAD(P)H  oxidase  activity,  producing  less  superoxide  thus  indicating  the 
importance of p22
phox for enzyme function (85).  The 3 cytosolic components are 
p40
phox, p47
phox and p67
phox all of which reside in the cytosol and translocate to 
the  membrane  upon  activation.    When  cells  are  stimulated,  p47
phox  becomes 
phosphorylated allowing interaction with the cytochrome b558 complex.  The G 
protein, Rac1, is also required for enzyme activation through its interaction with 
p67
phox.  When all of the components assemble at the cell membrane, the active 
enzyme  complex  is  formed  (86).    Evidence  from  studies  in  endothelial  and 
vascular smooth muscle cells suggests that NADH is the preferred substrate for 
superoxide generation with NADPH used to a lesser degree (87). 
 
Increased NAD(P)H oxidase activity has been implicated in the development of 
hypertension (86;88).  Chabrashvili et al reported that expression of p47
phox was 
greater in SHR kidney than kidneys from WKY rats; this increased expression was 
also found in younger, pre hypertensive rats (89).  NAD(P)H oxidase activation 
has  been  observed  in  Sprague  Dawley  rats  infused  with  Ang  II  to  induce 
hypertension.  Following Ang II infusion, superoxide production and SBP increase 
but when infused with NE, only SBP increases indicating that Ang II activates 
NAD(P)H oxidase and is associated with the onset of hypertension (90).  In mice 
treated with an NAD(P)H oxidase inhibitor that prevents assembly of the enzyme 
complex, superoxide production was attenuated and SBP was significantly lower 
further  adding  support  to  a  role  for  increase  NAD(P)H  oxidase  activity  and 
subsequent superoxide production in the development of hypertension (91). 
 
1.4.2 Nitric Oxide 
   
Superoxide readily reacts with the free radical nitric oxide (NO).  First described 
as endothelium derived relaxing factor, NO is a potent vasodilatory signalling 
molecule that plays an important role in the regulation of platelet aggregation 
and vascular tone.         44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Active NAD(P)H oxidase complex structure  
NAD(P)H oxidase is composed of 5 subunits, comprising 2 membrane bound (Nox 
and  p22
phox)  and  3  cytosolic  subunits  (p40
phox,  p47
phox  and  p67
phox).    The 
activation of the enzyme complex is regulated by Rac1.  
NAD(P)H:  nicotinamide  adenine  dinucleotide  phosphate,  O2:  oxygen,  O2
 : 
superoxide,    Phox:  phagocytic  oxidase,  Nox:  NAD(P)H  oxidase  (gp91
phox 
homologue) 
 
Adapted from (92) 
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Nitric  oxide  is  produced  by  nitric  oxide  synthase  of  which  there  are  three 
isoforms;  neuronal,  inducible  and  endothelial  (NOSI,  NOSII  and  NOSIII 
respectively).    Endothelial  nitric  oxide  synthase  (eNOS)  produces  nitric  oxide 
during  the  conversion  of  L arginine  to  L citrulline  and  requires  various  co 
factors.  Enzyme activity is Ca
2+/calmodulin dependent and also requires NADPH, 
flavin  adenine  dinucleotide  (FAD),  flavin  mononucleotide  (FMN)  and 
tetrahydrobiopterin (BH4).   
 
Endothelial NOS is activated in response to increased intracellular Ca
2+ resulting 
in NO generation.  Nitric oxide can then diffuse from the endothelium and exert 
its  vasodilatory  effects  on  nearby  smooth  muscle  cells  via  cyclic  guanosine 
monophosphate (cGMP).  Nitric oxide activates soluble guanylate cyclase (sGC) 
by binding to its haem group which in turn converts GTP to cGMP.  Accumulation 
of cGMP leads to activation of cGMP dependent protein kinase (PKG) triggering a 
decrease  in  [Ca
2+]i  through  various  mechanisms  (93).    PKG  mediated 
phosphorylation of K
+ ion channels results in membrane hyperpolarisation  and 
inhibition  of  Ca
2+  influx  (94).    PKG  can  also  inhibit  Ca
2+  channels  directly  to 
reduce [Ca
2+]i.  Reduced Ca
2+ levels result in diminished myosin light chain kinase 
(MLCK) activity and subsequent reduction of myosin light chain phosphorylation 
leading to smooth muscle relaxation (Figure 1.9).   
 
 
1.4.2.1 eNOS Uncoupling and Endothelial Dysfunction 
 
As well as producing NO, eNOS can also generate superoxide.  Elevated levels of 
superoxide are present in SHRSP aorta but can be attenuated by removing the 
endothelium or by adding NOS inhibitors, indicating that in the aortas of these 
animals superoxide is being produced by eNOS (95). This phenomenon, known as 
eNOS  uncoupling  occurs  when  L arginine  or  BH4  levels  are  depleted.    The 
production of superoxide by uncoupled eNOS leads to diminished bioavailability 
of nitric oxide, which has been associated with endothelial dysfunction in the 
vasculature.     46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 Nitric oxide signalling in vascular smooth muscle 
Nitric oxide regulates vascular smooth muscle relaxation through activation of 
soluble  guanylate  cyclase  and  accumulation  of  cGMP  resulting  in  decreased 
intracellular calcium concentration.   
VSMC: vascular smooth muscle cell, EC: endothelial cell, eNOS: endothelial nitric 
oxide synthase, NO: nitric oxide, sGC: soluble guanylate cyclase, cGMP: cyclic 
guanosine  monophosphate,  guanosine  triphosphate,  PKG:  cGMP  dependent 
protein kinase, P: phosphorylation 
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Endothelial  dysfunction  is  characterised  by  impaired  endothelium  dependent 
vasorelaxation due to reduced bioavailability of nitric oxide and is a feature of 
many  cardiovascular  risk  factors  such  as  hypertension  and  atherosclerosis.  
Coronary  endothelial  dysfunction  has  been  associated  with  atherosclerosis 
progression  and  subsequent  coronary  artery  disease  (96).    Impaired 
vasorelaxation is also found in rat models of hypertension (97) and hypertensive 
patients (98).  In rat models of hypertension, superoxide levels are elevated and 
this contributes to the reduced NO bioavailability observed.  Nitric oxide rapidly 
interacts  with  superoxide  resulting  in  the  production  of  the  highly  reactive 
peroxynitrite  (ONOO
 ).    Peroxynitrite  can  cause  damage  to  DNA,  protein  and 
lipids and can also oxidise the co factors required by eNOS, contributing further 
to eNOS uncoupling.   
 
1.4.3 Antioxidant Systems 
 
In order to counteract the production of ROS there are many antioxidant systems 
in place to help prevent oxidative damage (99;100).   These defences include 
small  non protein  antioxidants  such  as  vitamins  and  glutathione  and  enzymes 
such  as  superoxide  dismutase  (SOD),  catalase  (CAT),  glutathione  transferases 
(GST) and glutathione peroxidase (GPx). 
 
1.4.3.1 Antioxidant Vitamins 
 
Vitamin E (α tocopherol) effectively scavenges lipid peroxides but in doing so 
can  become  a  radical  itself.    Data  from  epidemiological  studies  suggests  an 
inverse association between vitamin E intake and risk of cardiovascular disease 
(101).    However,  studies  designed  to  test  the  effect  of  vitamin  E 
supplementation on cardiovascular risk have shown no significant decrease in the 
number  of  CV  events  and  in  some  cases  increased  intake  of  vitamin  E  was 
associated with a greater risk of heart failure (102;103).  Vitamin C (ascorbate) 
can  reduce  oxidative  stress  by  scavenging  ROS  directly  and  by  recycling  α 
tocopherol,  preventing  its  radical  formation  thus  helping  to  prevent  lipid 
oxidation  (104).    It  has  also  been  shown  to  be  effective  in  the  reduction  of 
endothelial dysfunction in patients with coronary artery disease (105;106) and   48 
hypertension  (107).    Studies  in  endothelial  cells  show  that  treatment  with 
ascorbate leads to increased production of nitric oxide and stabilisation of the 
eNOS co factor BH4, preventing eNOS uncoupling and maintaining bioavailability 
of NO (108;109).  
 
1.4.3.2 Superoxide Dismutase 
 
Superoxide can be scavenged by SOD by catalysing the conversion of superoxide 
to oxygen and H2O2.  The reaction involves the binding of two superoxide anions 
and  two protons  by  SOD leading  to  the production  of  hydrogen peroxide  and 
oxygen.  Three SOD isoforms have been identified in mammals, encoded by three 
distinct genes.  SOD1 encodes a dimeric copper zinc (Cu/Zn) SOD that is located 
in the cytoplasm.  The second isoform, manganese (Mn) SOD, is found in the 
mitochondria as a tetrameric enzyme and is encoded by SOD2.  SOD3 encodes a 
tetrameric Cu/Zn SOD isoform that is found mainly in extracellular spaces and is 
commonly described as ecSOD.  
 
Superoxide  dismutase  helps  to  increase  NO  bioavailability  and  improve 
endothelium dependent vasodilatation in a rabbit model of diabetes.  In afferent 
arterioles from diabetic rabbits, acetylcholine induced vasodilatation is inhibited 
but  when  treated  with  the  SOD  mimetic  Tempol,  the  dilatory  response  is 
restored  (110).    Gene  transfer  studies  have  shown  that  ecSOD  can  cause  a 
decrease in arterial blood pressure in SHR and improve carotid artery relaxation 
in  response  to  acetylcholine  (111).    The  benefits  of  SOD  activity  are  clear, 
superoxide mediated cytotoxicity is reduced and NO bioavailability is increased. 
However, SOD generates H2O2, a stable molecule with oxidising properties that in 
turn can lead to production of the highly reactive OH
 . 
 
Hydrogen peroxide has been shown to function in vascular smooth muscle cell 
(VSMC)  proliferation  and  hypertrophy,  features  that  are  common  to  vascular 
disease.    Upon  stimulation  with  phenylephrine,  the  level  of  H2O2  in  VSMC  is 
increased  and  proliferation  is  induced.    However,  when  H2O2  is  inhibited  by 
catalase, phenylephrine induced proliferation is also inhibited (112). Hydrogen 
peroxide itself can be scavenged by enzymes such as catalase and glutathione 
peroxidase.  In the presence of metal containing molecules, H2O2 can be reduced   49 
to  form  hydroxyl  (OH
 )  radical  another  reactive  species  that  can  inflict  local 
damage (113).   
 
1.4.3.3 Catalase 
 
Catalase is a tetrameric enzyme that reacts with H2O2 and generates water and 
molecular oxygen.  The protective benefit of catalase has been demonstrated in 
the  cardiovascular  system.    Catalase  transgenic  mice  were  generated  to 
investigate  the  role  of  H2O2  in  vascular  hypertrophy.    Angiotensin  II  induced 
aortic wall hypertrophy was attenuated by the increased expression and activity 
of  catalase  specifically  in  vascular  smooth  muscle  (114).    Over expression  of 
catalase in ApoE
 /  mice has also been shown to have protective properties by 
inhibiting the development of atherosclerosis and reducing markers of oxidative 
stress (115). 
 
1.4.3.4 Glutathione 
 
Glutathione is a small tripeptide molecule (γ glutamyl cysteinyl glycine) that is 
used by various detoxifying enzymes such as GPx and GST and plays an important 
role in antioxidant defence.  Glutathione exists in a reduced state and acts as an 
electron donor.  It can be oxidised to produce glutathione disulphide (GSSG) by 
various electrophilic substances including ROS leading to lower levels of reduced 
glutathione.    The  GSH:GSSG  ratio  is  often  used  as  an  indicator  of  cellular 
oxidative  stress  status.    Upon  stimulation  by  oxidative  stress  glutathione 
reductase is stimulated and converts glutathione back to its reduced form. 
 
The liver is a major producer of GSH, the most abundant low molecular weight 
thiol.  Glutathione is synthesised in a two step reaction in the presence of ATP 
by  two  cytosolic  enzymes;  γ glutamylcysteine  synthetase  (γGCS)  and  GSH 
synthetase, see Figure 1.10.     
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Figure 1.10 Glutathione synthesis 
Glutathione is synthesised in a 2 step reaction by GCS and GSH synthetase.  It 
can be oxidised to GSSG by various electrophilic substrates and reduced by GSH 
reductase. 
GSH:  glutathione,  GCS:  glutamyl cysteine  synthetase,  GSSG:  glutathione 
disulphide, GPx: glutathione peroxidase 
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Firstly, γ glutamyl cysteine is produced by γGCS which catalyses the reaction of 
the γ carboxyl of glutamate with the amino group of cysteine.  This first step is 
rate limiting for GSH synthesis as is the availability of L cysteine.  The second 
step involves the interaction of glycine with γ glutamyl cysteine to produce GSH 
which is catalysed by GSH synthetase. 
 
Glutathione  can  exert  its  antioxidant  effect  either  independently  or  through 
enzymatic  activity  such  as  GPx  or  GST.    Glutathione  can  non enzymatically 
interact  with  and  detoxify  OH
   and  can  also  detoxify  products  of  nitrosative 
stress such as peroxynitrite.    
 
1.4.3.5 Glutathione Peroxidase 
 
Glutathione  peroxidases  are able  to catalyse  the reduction of hydroperoxides 
including H2O2 by utilising glutathione as a reducing agent.  In mammals, there 
are 4 known selenocysteine containing isoforms of GPx.  GPx 1 and GPx 2 are 
both  tetrameric  proteins  and  share  similar  activities.    Each  is  capable  of 
metabolising H2O2 but cannot reduce phospholipid hydroperoxides.  GPx 1 was 
discovered first and is also known as classic or cytosolic GPx (cGPx).  GPx 2 is 
found predominantly in the epithelium of the gastrointestinal tract and is also 
known as GPx GI.  GPx 3 is a tetrameric glycoprotein that is present in plasma.  
The  main  source  of  this  enzyme  is  the  kidney,  with  mRNA  expression  found 
particularly in epithelial cells of the proximal tubules.  GPx 4 is a monomeric 
enzyme that is able to metabolise phospholipid hydroperoxides. 
 
The effect of adenosine mediated over expression of GPx 1 on human primary 
endothelial  cell  sensitivity  to  H2O2  was  assessed  by  Zhang  et  al.    Increased 
expression of GPx 1 reduced H2O2 cellular toxicity, confirming its protective role 
against oxidative stress (116).  GPx 1  deficiency in mice has been associated 
with endothelial dysfunction and structural abnormalities in the vasculature and 
has been shown to increase levels of isoprostanes, indicating increased oxidative 
stress in these animals (117).  
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1.4.3.6 Glutathione Transferases 
 
Glutathione S transferase mu type 1, identified as a positional and functional 
candidate gene for hypertension in the rat, is one of a large family of phase II 
detoxifying enzymes that play a role in the cellular defence against oxidative 
stress,  by  catalysing  the  conjugation  of  glutathione  to  various  electrophilic 
substrates  (118).    The  effectiveness  of  glutathione  transferases  (GST)  as 
antioxidant enzymes is limited by the enzymes responsible for GSH synthesis and 
those responsible for transporting  the GSH conjugates  out  of  the cell.  Once 
conjugated  to  GSH,  substrates  can  be  removed  from  the cell  by  various  ATP 
dependent  transport  mechanisms  including  multi drug  resistance  associated 
proteins (MRP) (119) and glutathione S conjugate export pumps (GS X) (120).  
 
The GSTs are dimeric enzymes and can exist as homodimers or heterodimers but 
can only be formed from subunits from the same class.  Members of the same 
class share greater than 40% identity and between classes share less than 25%.  
Each GST subunit is composed of two distinct domains.  The N terminal domain 1 
or  G  site  is  highly  conserved  between  classes  and  is  responsible  for  binding 
glutathione through its interaction with cysteine.  It is connected to domain 2 or 
the H site by a short linker sequence.  Domain 2 is less well conserved and is 
responsible  for  binding  hydrophobic  substrates.    The  diversity  in  the  H  site 
between classes may account for the broad substrate specificities of the various 
GSTs.  Once bound to the G site, GSH is activated and becomes deprotonated.  
By doing so, GSH becomes a strong nucleophile and facilitates its interaction 
with an electrophilic substrate (121). 
 
GSTs have been shown to detoxify the breakdown products of oxidative damage 
to protein, DNA and lipids such as base propenals and 4 hydroxyalkenals (118).  
Oxidative stress can lead to oxidation of nucleotides and DNA degradation and 
subsequently generate base propenals.  GSTs have been shown to protect cells 
against  cytotoxicity  mediated  by  adenine  and  thymine  propenal  generation, 
particularly Pi class GSTs (122).    Peroxynitrite induced protein nitrotyrosine 
production can be inhibited by incubation with GST, leading to denitration of 
proteins (123).  .   
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Alpha class GSTs also demonstrate glutathione peroxidase activity against lipid 
hydroperoxides  generated  from  damage  to  cell  membranes.    Although 
endogenous systems are in place to counteract ROS, if superoxide production is 
increased, these systems can be overwhelmed causing damage to DNA, proteins 
and lipids. 
 
In mammals there are at least seven classes of cytosolic GST including, alpha, 
mu, pi, theta, sigma, omega and zeta.  There are eight possible members of the 
mu class in the rat that have been reported to date.  The rat mu family includes, 
Gstm1, 2, 3, 4, 5 and 6.  A further 2 genes are designated Gstm6l (Gstm6 like) 
and Gstm7 (GSTM7 7 like).  All eight genes map to chromosome 2q34 and form a 
cluster in the order m7 m1 m2 m4 m6l m3 m6 followed by m5 (inverted).  There 
are  five  members  of  the  mu  class  in  humans  (GSTM1 5)  all  of  which  map  to 
chromosome 1p13.3 (124).  The genes are arranged in the following order: M4 
M2 M1 M5 and M3 (inverted).     
 
1.4.3.7 Glutathione S-Transferase Mu Type 1 
 
Polymorphisms  in  various  genes  encoding  glutathione  transferases  have  been 
implicated in carcinogenesis (125).  In humans, 50% of the population is GSTM1 
null and as such do not express GSTM1 protein.  The GSTM1 null allele has been 
associated with an increased risk of developing various cancers, particularly lung 
cancer (126).  At present, little work has been done to investigate the role of 
GSTM1 in cardiovascular disease.  A recent study aimed to assess the association 
between various GSTM variants and hypertension.  Individuals with and without 
hypertension were screened for SNPs in GSTM1, 2, 3, 4 and 5.  In the initial 
screen  a  SNP  in  the  3'  region  of  GSTM5  was  found  to  be  associated  with 
hypertension.  However this result was not replicated in a second cohort and 
suggests that GSTM gene variants are not associated with hypertension (127).   
Although an association between human GSTM1 and hypertension could not be 
confirmed, it is not yet known which human GSTM is the true orthologue of rat 
Gstm1. 
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The reduced expression of Gstm1 in 16 week old SHRSP kidneys was found in 
parallel with increased renal oxidative stress and blood pressure compared to 
the  2c*  and  WKY  strains  (69;77).    Expression  of  Gstm1  was  found  to  be 
significantly lower in 5 week old SHRSP before the onset of severe hypertension 
indicating that the differential expression of renal Gstm1 may be a contributing 
factor to the development of hypertension and is not an adaptive response to 
long  term  increased  blood  pressure  (77).    It  may  be  that  increased  renal 
oxidative stress in the SHRSP is contributing to the development of hypertension.  
Increased  renal  oxidative  stress  has  been  demonstrated  to  contribute  to 
hypertension in various rat models.  In Sprague Dawley rats, oxidative stress was 
induced  in  the  renal  medulla  by  infusion  of  the  CuZn SOD  inhibitor 
diethyldithiocarbamic  acid  (DETC).    Following  infusion  of  DETC,  increased 
superoxide  levels  were  found  in  the  renal  medulla  and  blood  pressure  was 
significantly  increased  (128).    The  addition  of  TEMPOL  prevented  the  DETC 
induced  increase  in  superoxide  but  did  not  prevent  the  DETC induced 
hypertension.    However,  when  catalase  was  co infused  with  TEMPOL,  DETC 
induced hypertension was blocked.  This suggested that removal of superoxide 
from the renal medulla alone was not sufficient to prevent the development of 
hypertension  but  by  limiting  TEMPOL  induced  H2O2  production,  hypertension 
could  be  prevented.  Direct  renal  infusion  of  H2O2  alone  was  also  found  to 
produce hypertension, possibly as a result of oxidative injury to renal medullary 
cells (129).  Hypertensive Dahl S rats on a high salt diet exhibited significantly 
lower  SOD  activity  levels  and  increased  excretion  of  urinary  isoprostanes  (a 
marker of lipid peroxidation), indicating increased oxidative stress in the kidneys 
of  these  rats  (130).    The  reduction  of  Gstm1  expression  in  kidney  tubular 
epithelium may result in reduced protection against the products of oxidative 
stress and subsequently lead to oxidative DNA, protein or lipid damage in these 
cells.  This is in turn may contribute to the development of hypertension due to 
an  impaired  ability  of  tubular  cells  to  properly  regulate  the  sodium fluid 
balance.  
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1.5 RNA Interference 
 
RNA interference (RNAi) is a naturally occurring mechanism that results in post 
transcriptional  gene  silencing  (PTGS)  in  response  to  double  stranded  RNA 
(dsRNA)  molecules  that  are  homologous  to  a  target  gene.  By  exploiting  this 
mechanism experimentally it is possible to reduce the expression of a particular 
gene of interest to further investigate its function.  Post transcriptional gene 
silencing was first observed by Napoli et al. during transgenic experiments in 
plants.  They found that introducing a chimeric chalcone synthase (CHS) gene 
(responsible  for  petunia  petal  pigmentation)  generated  white  flowers  lacking 
pigmentation resulting from suppression of both the endogenous and introduced 
CHS genes.  This unexpected effect was described as co suppression (131;132).  
Experiments carried out in Neurospora crassa identified a related mechanism for 
gene  inactivation,  termed  quelling  (133;134).    Both  of  these  mechanisms  are 
related  to  RNAi  which  was  first  described  in  C.elegans  by  Fire  et  al. 
Investigations  into  the  role  of  RNA  structure  in  genetic  silencing  found  that 
dsRNA mediates RNAi, as dsRNA directed against a luciferase reporter gene had a 
much stronger silencing effect than either sense or antisense strand alone (135).  
Tushl  and  colleagues  then  reported  that  the  strong  silencing  observed  in 
response  to  dsRNA  is  not  just  due  to  the  longer  half  life  of  dsRNA  as  single 
stranded RNA modified with a 7 methyl guanosine cap to increase stability is still 
unable to inhibit gene expression (136). 
 
1.5.1 RNA Interference: Mechanism  
  
The mechanism by which RNAi works has been elucidated through various studies 
with C.elegans and Drosophila (137).  This mechanism is outlined in Figure 1.11.  
RNA interference is induced by dsRNA sequences that are 21 22 nucleotides (nt) 
long  and  have  2nt  3’overhangs.    The  5’  end  of  the  sequence  contains  a 
phosphate group and the 3’ end contains a hydroxyl group (138).  These short 
interfering RNAs (siRNAs) are generated from long dsRNA molecules by Dicer, an 
ATP  dependent  RNase  III  like  enzyme  that  is  specific  for  dsRNA  (139).     56 
 
 
 
 
 
Figure 1.11 Mechanism of RNA interference  
Double stranded interfering RNA molecules (siRNA/shRNA) are introduced to the 
cell.    Duplex  RNA  dissociates  and  one  strand  is  incorporated  into  the  RNA 
induced silencing complex.  The target mRNA and siRNA strand anneal and the 
target is then degraded via nuclease activity.  Part of this RNAi pathway is also 
utilised by microRNAs.  
RISC: RNA induced silencing complex, siRNA: short interfering RNA, shRNA: short 
hairpin  RNA,  mRNA:  messenger  RNA,  miRNA:  microRNA,  pri miRNA:  primary 
miRNA, pre miRNA: precursor miRNA 
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Dicer is found in complex with R2D2, a dsRNA binding protein that facilitates 
siRNA binding.  Although R2D2 is involved in binding the siRNA duplex it is not 
required for production of siRNA as R2D2 mutant flies are no different to wild 
type in their ability to generate siRNAs (140).  However, R2D2 is necessary for 
siRNA incorporation into the RNA induced silencing complex (RISC), the effector 
complex responsible for sequence specific degradation of the mRNA (141;142).  
R2D2 has been found to bind to the more stable end of the siRNA duplex whereas 
Dicer binds to the less stable end; this binding of siRNA by Dicer/R2D2 produces 
the RISC loading complex (RLC) (143).  It is RISC that is responsible for mRNA 
cleavage and for this to take place; RISC must associate with the siRNA duplex 
and incorporate the guide strand.  Active RISC is composed of the Argonaute 
family of proteins and siRNA.  Argonaute proteins are composed of 4 domains: an 
N terminal,  PAZ  domain  (also  found  in  Dicer),  Mid  domain  and  PIWI  domain 
(144).  Prior to incorporation of siRNA, RISC is inactive and is termed holo RISC.  
To  become  active,  the  Argonaute  complex  interacts  with  the  RISC  loading 
complex allowing association with the siRNA duplex.  The duplex is cleaved by 
the Argonaute protein allowing it to unwind and the guide strand becomes part 
of  the  now  active  RISC  (145).    RISC  can  now  interact  with  the  target  mRNA 
through complementary base pairing with the siRNA.  The endonuclease activity 
provided by RISC results in cleavage of mRNA every 21 23 nucleotides, reflecting 
the size of the siRNA (146).   
 
1.5.2 MicroRNAs 
 
MicroRNAs  (miRNAs)  are  another  class  of  small  RNA  that  regulate  gene 
expression, in part, through the RNAi pathway (147).  Unlike siRNAs that are 
generated via viral replication or through introduction of chemically synthesised 
molecules  or  expression  vectors,  miRNAs  are  produced  from  endogenously 
expressed transcripts.  Genes encoding miRNAs generate primary miRNAs (pri 
miRNAs) that form long stem loop structures.  The hairpin region is then cut out 
by the RNase III family enzyme Drosha to generate a stem loop precursor miRNA 
(pre miRNA) of ~70nt long (148;149).  The pre miRNA is then exported from the 
nucleus to the cytoplasm where Dicer cleaves the stem loop structure to form 
the 21 25nt long mature miRNA (150;151).  The mature miRNA associates with   58 
RISC  and  binds  to  the  target  3'UTR  and  in  doing  so  results  in  translational 
repression. 
 
1.5.3 In Vitro RNAi 
 
Elbashir et al. were the first to demonstrate siRNA induced RNA interference in 
cultured mammalian cells.  They found that transfecting cells with 21nt siRNA 
duplexes  resulted  in  knock down  of  genes  expressed  endogenously  and  from 
reporter constructs (152).  To utilise RNAi for in vitro experimental purposes, 
double stranded RNA molecules first have to gain access to cells expressing the 
gene  of  interest.    This  can  be  achieved  in  a  variety  of  ways.    Chemically 
synthesised short interfering RNA (siRNA) molecules of 21 nucleotides in length 
can be incorporated into lipid or amine based complexes and introduced using 
various transfection methods.  As well as transfection, siRNA can be introduced 
via electroporation (153).  By using synthetically generated siRNA, the need for 
processing by Dicer is avoided.  As described previously, Dicer is responsible for 
cleaving  long  dsRNA  into  short  sequences  that  can  initiate  RNAi.    However, 
introduction of dsRNA molecules greater than 30nt can result in activation of the 
interferon response in mammalian cells (152).  Therefore, using short sequences, 
the possibility of adverse activation of interferon response genes can be limited.    
Alternatively,  plasmid  or  viral  vectors  can  be  used  that  are  engineered  to 
express short hairpin RNAs (shRNA) that are complementary to the target mRNA.  
Once in the cytoplasm, the siRNA/shRNA molecules can then associate with RISC.  
Once incorporated into RISC the siRNA associates with the target mRNA, leading 
to its degradation and subsequent knockdown of gene expression. 
 
1.5.4 In Vivo RNAi 
 
As  previously  mentioned,  RNAi  requires  the  introduction  of  dsRNA  molecules 
directly to those cells expressing the gene that is to be silenced.  This can be 
readily  achieved  in  vitro  (136;152)  however;  in  vivo  RNAi  poses  a  greater 
challenge. It is possible to introduce naked siRNA molecules in vivo.  McCaffrey 
et al was able to demonstrate luciferase reporter gene silencing in the livers of 
adult  mice  following  the  delivery  of  naked  siRNA  via  hydrodynamic  tail  vein   59 
injection (154).  Hydrodynamic delivery involves the rapid injection of nucleic 
acid in a large volume of fluid (155).  This method of delivery can elicit a quick 
silencing  response,  as  the  molecule  need  only  gain  access  to  the  cytoplasm 
where  it  can  interact  with  RISC  and  carry  out  its  function.    However,  the 
stability of these 21nt sequences within an in vivo environment is an issue, as 
well  as  factors  such  as  the  half life  of  the  target  protein  (156;157).    By 
introducing  siRNA  in  this  way  the  silencing  effect  would  be  short  lived  and 
although  introducing  large  concentrations  of  siRNA  may  help  to  prolong  the 
effect, excess siRNA could result in off target effects.  While siRNA is designed 
to be specific to a target mRNA, excess molecules could cause aberrant silencing 
of unintended genes (158).  High specificity will also help to ensure that no non 
specific binding occurs, thus helping to prevent off target effects. 
 
To  further  facilitate  in  vivo  delivery,  siRNA  molecules  can  be  introduced  in 
complex with cationic lipids.  A liposome based method was utilised by Sorensen 
et al, to induce gene silencing in adult mice (159).  More recently, Santel et al 
have demonstrated the use of lipoplexes for in vivo delivery of siRNA molecules 
targeted  against  genes  expressed  in  the  vascular  endothelium  of  mice.  
Following intravenous injection of the lipoplex (cationic lipid, helper lipid and 
siRNA),  reduced  expression  of  endothelial  specific  genes  was  observed  (160).   
This  method  of  liposomal  delivery  has  since  been  utilised  to  silence  gene 
expression in the liver of cynomolgus monkeys (161).  
 
Alternatively,  interfering  RNA  fragments  can  be  introduced  via  expression 
vectors, such as plasmids or viral vectors.  Viral vectors such as adeno associated 
viral (AAV) vectors can be manipulated to express short hairpin RNA molecules 
(shRNA), that can target host cell mRNA for destruction.  For this method to be 
effective the virus must gain entry to the nucleus, thus enabling the expression 
of the shRNA molecule and although this may take more time to produce an 
effect, the silencing obtained would be more stable.  Once expressed, the shRNA 
is processed and exported to the cytoplasm where it can associate with RISC, 
thereby  allowing  its  interaction  with  the  target  mRNA.  Wang  et  al  have 
demonstrated  gene  silencing  in  rats  following  intravenous  delivery  of  AAV 
vectors engineered to express shRNA (162). 
   60 
1.5.5 Therapeutic Potential 
 
RNA interference has more recently shown promise as a potential therapeutic for 
the treatment of disease.  Synthetically generated siRNAs have been shown to 
inhibit hepatitis C virus production in cultured cells (163).  Mice treated with 
siRNA targeted to the Fas receptor gene are shown to have greater resistance to 
liver  disease.    Following  intravenous  injection  of  siRNA,  hepatocytes  isolated 
from  treated  mice  were  resistant  to  apoptosis  (164).    DiFuglia  et  al 
demonstrated  the  potential  use  of  RNAi  as  a  treatment  for  the  neurological 
disorder Huntington’s disease (HD).  A virus mediated transgenic model of HD 
was utilised to test the efficacy of anti htt (HD gene) siRNA.  Striatal neurons in 
siRNA treated mice had a prolonged survival and presented fewer abnormalities 
that are associated with HD. 
 
RNA interference has also been evaluated as a potential antiviral therapy for 
respiratory syncytial virus (RSV) infection.  Bitko et al demonstrated inhibition of 
RSV following nasal administration of anti RSV siRNA in mice.  Antiviral effects 
were observed before and after RSV infection indicating the potential of siRNA 
as a therapy that can be delivered locally to combat RSV infection (165).  This 
siRNA has since gone on to be tested in a phase II clinical trial to evaluate its 
safety as an antiviral therapeutic.  The siRNA was delivered to the respiratory 
tract via a nasal spray and was found to be well tolerated with few side effects 
(166).    Another  disorder  where  clinical  trials  are  underway  for  a  therapeutic 
siRNA  is  age related  macular  degeneration  (AMD).    Studies  have  shown  that 
siRNAs  targeted  against  vascular  endothelial  growth  factor  (VEGF)  or  VEGF 
receptor 1 (VEGFR1) have beneficial effects in mouse models of AMD.  In these 
models,  reducing  expression  of  VEGF  or  VEGFR1  inhibited  choroidal 
neovascularisation (CNV), a common cause of vision loss in people suffering with 
AMD  (167;168).    Following  on  from  these  and  other  studies,  siRNA  targeting 
VEGFR1 (siRNA 027) has since been taken forward to phase II clinical trials (169).  
Another siRNA (REDD14NP) is also being evaluated for AMD in a phase I clinical 
trial (170).       
 
RNA interference provides an excellent tool for elucidating gene function both in 
vitro  and  in  vivo.    Using  various  means  of  delivery  it  is  possible  to  reduce   61 
expression in animal models of human disease and as such may prove beneficial 
in the identification of the function of glutathione S transferase mu type 1 in 
both  oxidative  stress  and  hypertension.    In  vivo  delivery  of  Gstm1  specific 
interfering RNA molecules would allow for a more accurate investigation into the 
role of Gstm1 in rat hypertension, with a view to finding similar blood pressure 
regulatory mechanisms in human.   62 
1.6 Hypothesis 
 
Due to the role of GSTs in defence against oxidative stress and the involvement 
of  oxidative  stress  in  the  development  of  hypertension,  we  hypothesise  that 
depleted  renal  expression  of  Gstm1  may  contribute  to  development  of 
hypertension  by  reducing  the  capacity  of  renal  cells  to  protect  themselves 
against the damaging products of oxidative stress.  In addition to the differential 
expression of Gstm1 observed between the parental and congenic strains, it may 
be  that  microRNAs  mapping  to  the  chromosome  2  congenic  region  are 
responsible for regulating the expression of genes which could contribute to the 
blood pressure phenotypes observed in these strains. 
 
  
1.6.1 Aims 
 
A combination of congenic breeding and microarray analysis has identified Gstm1 
as  a positional and functional candidate gene for  hypertension in the stroke 
prone spontaneously hypertensive rat (SHRSP).  This aims of this study are to 
investigate  the  role  of  Gstm1  using  an  RNAi  mediated  approach  and  develop 
molecular tools that could be used for targeted modulation of gene expression in 
vivo.  In addition to this, another aim is to investigate microRNAs that map to 
the chromosome 2 congenic regions. 
 
The specific aims of this study are: 
1.  To assess the ability to knock down Gstm1 expression specifically 
with siRNA and  develop tools for  in vivo  kidney targeted knock 
down 
2.  To assess the contribution of reduced Gstm1 expression to markers 
of oxidative stress  
3.  To investigate expression of microRNAs in kidney from parental and 
chromosome  2  congenic  strains  and  assess  expression  levels  of 
potential microRNAs targets 
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Chapter 2: Materials and Methods   64 
2.1 General Laboratory Practice 
 
This chapter outlines general materials and methods that are common to more 
than one chapter.  Where necessary, more details are given in the appropriate 
chapters.   
 
All laboratory equipment and reagents used throughout the project were of the 
highest available grades.  A laboratory coat and latex powder free gloves were 
worn during all procedures.  Handling of hazardous reagents was carried out in 
accordance with Control of Substances Hazardous to Health regulations. 
 
Laboratory glassware was cleaned in Decon 75 detergent, rinsed with distilled 
water and dried in a 37°C cabinet.  Sterile, disposable plastic ware was also 
used, including 0.5 ml, 1.5 ml and 2 ml microcentrifuge tubes (Greiner Bio One), 
15  ml  and  50  ml  Corning  centrifuge  tubes  and  5  ml  and  20  ml  Universal 
containers  (Sterilin).    Glass ware  and  reagents  requiring  sterilisation  were 
autoclaved in a Priorclave Tactrol 2. 
 
To weigh out reagents an Ohaus Portable Advanced balance (sensitive to 0.01 g) 
or  a  Mettler  HK160  balance  (sensitive  to  0.0001  g  was  used).    To  dispense 
volumes  from  0.1   l  to  1000   l,  Gilson  pipettes  were  used  (Gilson  Medical 
Instruments.  For larger volumes from 1 ml to 25 ml, sterile disposable pipettes 
(Corning)  were  used  with  a  Gilson  battery powered  pipetting  aid.    When 
preparing solutions, distilled water (dH20) was used unless otherwise stated and 
to aid dissolving and mixing a Jenway 1000 hotplate and stirrer was used.  The 
pH of solutions was determined using a Mettler Toledo digital pH meter.  The 
meter was calibrated before use with solutions of pH 4, 7 and 10 prepared from 
buffer  tablets  (Sigma Aldrich).    Vortexing  was  carried  out  using  an  FSA 
Laboratory Supplies WhirliMixer.  For experiments requiring incubations between 
37°C and 90°C, a Julabo TW8 water bath utilised and for temperatures up to 
100°C a Grant SBB14 boiling water bath was used.  For centrifugation of samples 
up  to  2  ml,  an  Eppendorf  4515  microcentrifuge  was  used.    Larger  volume 
samples were centrifuged in a Sigma 4K15, compatible with 15 ml and 50 ml 
centrifuge tubes, 20 ml Universal containers and carriers for standard reaction 
plates.    65 
 
For all experiments involving RNA, certified nuclease free reagents and plastic 
ware were used, including nuclease free water, 0.5 ml, 1.5 ml and 2 ml RNase 
free microcentrifuge tubes (Ambion) and nuclease free pipette tips for volumes 
between 0.2  l and 1 ml (RAININ).  Prior to beginning RNA work, all pipettes and 
bench space were wiped with RNaseZap (Ambion) and rinsed with nuclease free 
water.   
 
 
2.2 Cell Culture 
 
All  in  vitro  RNA  interference  experiments  were  carried  out  in  the  rat  renal 
tubular  epithelial  cell  line  NRK 52E.   Cells  were  obtained  from  the  European 
Collection  of  Cell  Culture  (ECACC).    The  details  of  other  cell  lines  used  are 
described in the methods section of the relevant chapters.  NRK 52E cells were 
grown  in  150  cm
2  flasks  containing  Dulbecco’s  modified  Eagle’s  medium  plus 
GlutaMAX  supplemented  with  10%  (v/v)  foetal  calf  serum  (FCS),  100  U/ml 
penicillin and 100 mg/ml streptomycin.  Cells were maintained at 37°C in a 5% 
CO2/95% air atmosphere incubator. 
 
2.2.1 Cell Passage 
 
Cell  culture  medium,  sterile  PBS  (Lonza)  and  1X  TE  (0.05%  trypsin;  0.2% 
ethylenediamine tetraacetic acid (EDTA)) were warmed to 37°C in a water bath.  
Culture medium was removed from the flask and cells were rinsed twice with 10 
ml sterile PBS.  To detach cells, 5 ml 1X TE was added to the flask and incubated 
at 37°C for 5 minutes.  Once cells had detached from the flask, 15 ml of culture 
medium containing 10% (v/v) FCS (to inactivate trypsin) was added and the cell 
mixture  was  transferred  to  a  50  ml  centrifuge  tube  (Corning).    Cells  were 
centrifuged  at  1500  rpm  for  5  minutes  to  pellet  cells.   The  supernatant  was 
removed  and  cells  were  re suspended  in  fresh  culture  medium.    Of  this 
suspension, 1/20 1/10 was transferred to a fresh 150 cm
2 flask containing 25 ml 
culture medium.  
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2.2.2 Cell Counting 
 
Cells  were  counted  using  a  haemocytometer  (Hausser  Scientific).    A  cell 
suspension was prepared by detaching cells with 1X TE as described in section 
2.3.  A cover slip was placed on the haemocytometer counting surface and 10  l 
of the cell suspension was applied to the grid under the coverslip.  The number 
of cells in a 1 mm
 square was determined by counting the number of cells in 
each  quadrant.    The  average  number  of  cells  in  each  1mm  square  was 
determined and multiplied by 10
4 to give the number of cells per ml.     
 
 
2.3 Transfection of NRK 52E Cells with siRNA  
 
Cells were cultured in 6 well plates until ~70% confluent and then transfected 
with  30  to  100nM  Silencer®  Pre designed  Gstm1  specific  siRNA  (Applied 
Biosystems).    Three  different  sequences  were  evaluated,  designated  A  (ID# 
200597),  B  (ID#  200598)  and  C  (ID#  200599).    The  siRNA  sequences  were  as 
follows: 
 
Sequence A: GCUCAUCAUGCUUUGUUACtt (sense) 
         GUAACAAAGCAUGAUGAGCtg (antisense)  
 
Sequence B:  CCUAUAUUUUCGAAGUUGGtt (sense) 
          CCAACUUCGAAAAUAUAGGtg (antisense) 
 
Sequence C:  CCUCACAGUCCUUUUCUGUtt (sense) 
      ACAGAAAAGGACUGUGAGGtt (antisense) 
 
Each sequence was 19nt long with 2nt 3’overhangs.  A Silencer® Cy™ 3 labelled 
control siRNA that has no known homology to any expressed genes was also used, 
allowing  for  an  assessment  of  transfection  efficiency  by  fluorescence 
microscopy.  In each experiment, three controls were used: untransfected cells 
(UTF),  cells  with  transfection  reagent  only  (TFC)  and  cells  transfected  with 
labelled control siRNA (siCTL).  RNase free micro centrifuge tubes and pipette 
tips were used throughout.  Each transfection was carried out in triplicate using   67 
siPORT™  Amine  transfection  reagent  (Applied  Biosystems)  according  to 
manufacturer’s instructions.  Briefly, 12  l of siPORT™ Amine was diluted to a 
final  volume  of  197   l  (per  well)  in  Opti MEM®  Reduced  Serum  Medium 
(Invitrogen) and incubated at room temperature for 15 minutes.  The volume of 
growth medium in each well was reduced to 800   l.   Chemically synthesised 
siRNA was added to the transfection reagent mix (to give a final concentration of 
30 or 100nM siRNA) and incubated at room temperature for 15 minutes.  The 
transfection reagent and siRNA complexes were added drop wise to each well.  
Plates were gently rocked back and forth to disperse the transfection complex 
and incubated at 37°C for 5 hours.  The medium in each well was then topped 
up with 2 ml of normal growth medium and incubated at 37°C for a further 48 
hours.  After 48 hours, cells or medium were collected for further analysis. 
2.4 Protein Extraction 
 
Protein  was  collected  from  cells  cultured  in  tissue  culture  plates.    Culture 
medium was removed and cells were rinsed twice with sterile PBS.  Adherent 
cells  were  made  permeable  with  0.2%  Triton  X 100/PBS  and  samples  were 
collected by scraping the cells with a pipette tip. Protein samples were then 
passed through a 25 gauge needle 5 times and briefly centrifuged to remove cell 
debris.  The supernatant containing protein was then transferred to a fresh 1.5 
ml centrifuge tube and stored at  20°C.  
 
2.4.1 Measuring Protein Concentration 
 
The  total  protein  concentration  of  each  lysate  was  determined  using  a 
bicinchoninic  acid  (BCA)  assay  kit  (Pierce)  according  to  the  manufacturer’s 
instructions.  A set of 9 albumin protein standards ranging from zero to 2000 
 g/ml were prepared by diluting each standard in PBS and used to generate a 
standard  curve.  The  BCA  working  reagent  (WR)  was  prepared  by  mixing  BCA 
Reagent A with BCA Reagent B at a ratio of 50:1 (A:B).  The total volume of 
working reagent required was calculated as follows: (no. of standards + no. of 
unknown  samples)  x  (no.  of  replicates)  x  (volume  of  WR  per  sample).    Each 
standard and sample (25  l) was assayed in duplicate in a 96 well plate and 200 
 l of the WR was added to each well.  The plate was then covered to protect   68 
from light and incubated at 37°C for 30 minutes.  Following incubation the plate 
was cooled to room temperature and the absorbance from each well was read at 
560nm  using  a  Wallac  Victor
2  plate  reader.    Each  standard  and  sample  was 
measured in duplicate and average readings were taken.  A standard curve was 
generated and the protein concentration in each sample was determined from 
the curve using ‘Work Out’ software (Wallac). 
 
2.5 Western Blot  
 
Western blotting was performed to assess levels of protein expression. 
 
2.5.1 Gel Electrophoresis 
 
Proteins were resolved by SDS PAGE (sodium dodecyl sulphate polyacrylamide 
gel electrophoresis) in a Hoefer SE 600 gel electrophoresis tank.  A 12% resolving 
gel was prepared and poured between 18 cm x 16 cm glass plates followed by a 
4% stacking gel poured on top.  The 12% resolving gel consisted of 40% (v/v) 
polyacrylamide  (30%)  (BIORAD),  0.375M  Tris  pH  8.8,  0.1%  (v/v)  SDS,  300   l 
ammonium  persulphate  (APS)  and  30   l  TEMED  (N,N,N',N' 
tetramethylethylenediamine).    The  4%  stacking  gel  consisted  of  13.3%  (v/v) 
polyacrylamide (30%), 0.125M Tris pH 8.8, 0.1% (v/v) SDS, 300  l APS and 30  l 
TEMED.   
 
Protein samples and controls were added to 2X Laemmli sample buffer (Sigma 
Aldrich) in a 1:1 ratio to a maximum volume of 60  l and heated to 100°C for 10 
minutes.    Amersham  low  range  rainbow  molecular  weight  markers  (GE 
Healthcare  Life  Sciences)  were  loaded  (15   l)  to  allow  for  determination  of 
protein size.  Samples were loaded into the wells of the gel and subjected to 
electrophoresis  at  100V  for  1  hour  in  running  buffer  (0.025M  Tris HCl,  0.2M 
glycine  and  0.001M  SDS).    Once  through  the  stacking  gel,  the  voltage  was 
increased  to  200V  for  approximately  3  hours  until  proteins  were  sufficiently 
resolved as determined by the separation of the rainbow markers.   
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After electrophoresis the gel and six sheets of Whatman 3 mm chromatography 
blotting paper were prepared for transfer by placing in transfer buffer (0.025 M 
Tris, 0.2 M glycine, 20% (v/v) methanol and 0.01% (v/v) SDS) for 20 minutes.  
Hybond™ P nitrocellulose membrane (Amersham) was prepared by wetting with 
methanol  for  5  seconds  and  then  soaking  in  distilled  water  for  5  minutes 
followed by 10 minutes in transfer buffer.  A transfer cassette was then set up 
(cathode to anode) as follows: 3 sheets of blotting paper, gel, membrane and 
another 3 sheets of blotting paper Resolved proteins were transferred onto the 
nitrocellulose membrane overnight at 90mA in transfer buffer in a Hoefer TE 50X 
transfer tank.  
 
2.5.2 Antibody Probing  
 
Following transfer, the membrane was blocked for at least 6 hours (with shaking) 
in a 10% (w/v) milk solution (blocking buffer) prepared in Tris buffered saline 
Tween buffer (TBS T) (0.025 M Tris pH7.4, 0.14 M NaCl, 0.0027 M KCl, 0.1% (v/v) 
Tween 20 (Sigma)).  After blocking, the membrane was incubated in primary 
antibody  solution  at  4°C  overnight,  with  shaking.    The  membrane  was  then 
washed 6 times for 5 minutes with TBS T and then incubated with a secondary 
antibody  conjugated  to  horseradish  peroxidase  (Dako)  for  1  hour  at  room 
temperature.    All  antibodies  were  diluted  to  the  required  concentration  in 
blocking buffer.  The membrane was washed again as described previously.   
 
2.5.3 Enhanced Chemiluminescence and Detection 
 
Bands  were  detected  using  Amersham  ECL  (enhanced  chemiluminescence) 
western blotting detection reagents (GE Healthcare).  Equal quantities of the 
two  reagents  were  mixed  and  poured  over  the  membrane,  ensuring  the 
membrane was completely covered.  After 3 minutes at room temperature, the 
membrane was removed from the ECL reagents and any excess was drained off.  
The  membrane  was  then  wrapped  in  Saran  wrap  and  placed  in  an 
autoradiography cassette.  Film exposure and development was carried out in a 
dark room.  Kodak general purpose medical X ray film was used and films were   70 
exposed for varying lengths of time from 5 seconds to overnight.  Films were 
developed in a Kodak X Omat 1000 developer. 
 
2.5.4 Densitometry 
 
To  ensure  that  any  change  in  protein  level  was  not  due  to  unequal  loading, 
membranes  were  stripped  and  re probed  for  β actin.    The  membrane  was 
incubated with stripping buffer (0.2 M glycine and 1% (v/v) SDS at pH 2.2) for 30 
minutes at room temperature then washed twice for 10 minutes in TBS T.  The 
membrane was blocked as before and incubated at 4°C overnight with a mouse 
β actin antibody (Abcam) used at a dilution of 1/1000.  Bands were detected on 
X ray film as before.   
 
To normalise each band, the X ray films were scanned using the BIORAD Fluor S 
Multi imager and bands were quantified using ‘Quantity One’ software (BIORAD).  
The intensity of each band  was  determined  by  the  software using the global 
background  subtraction  method  and  expressed  in  units  of  optical  density  per 
mm2 (ODU/mm
2).  The adjusted volume value for each band was divided by the 
equivalent value obtained for the β actin band to give a final value corrected for 
loading.  
 
2.6 RNA Extraction 
  
RNA  was  extracted  from  NRK 52E  cells  using  an  RNeasy  Mini  Kit  (Qiagen), 
according to the manufacturer’s guidelines.  Cell culture medium was removed 
and  cells  were  rinsed  twice  with  PBS.    Cells  were  lysed  by  scraping  with  a 
pipette tip in 350  l buffer RLT containing guanidine isothiocyanate with the 
addition β mercaptoethanol (10 l/ml).  The lysates were transferred to RNase 
free 1.5 ml centrifuge tubes and mixed with 350  l 70% ethanol by pipetting.  
The samples were transferred to RNeasy mini columns allowing RNA to bind to 
the  membrane  and  then  centrifuged  at  8000  g  for  15  seconds  and  the  flow 
through  discarded.    The  columns  were  washed  with  700   l  Buffer  RW1  and 
centrifuged at 8000 g for 15 seconds.  The columns were then washed with 500 
 l Buffer RPE and centrifuged at 8000 g for 15 seconds.  This wash step was   71 
repeated  but  centrifuged  at  8000  g  for  2  minutes.    The  flow through  was 
discarded and the column was centrifuged again for 1 minute at full speed to 
remove any residual buffer.  RNA was eluted in 40  l nuclease free water, put 
through the column twice and centrifuged at 8000 g for 1 minute.  RNA samples 
were stored at  80°C.  
2.6.1 DNase Treatment of Extracted RNA 
 
To  remove  any  contaminating  DNA  from  RNA  preparations,  samples  were 
subjected to TURBO DNA free DNase treatment (Applied Biosystems).  Samples 
were transferred to 0.5 ml RNase free centrifuge tubes.  To each sample, 0.1 
volumes of 10X TURBO DNase buffer and  1  l TURBO DNase  were  added and 
mixed  gently  followed  by  incubation  at  37°C  for  30  minutes.    Re suspended 
DNase inactivation reagent was then added to each sample (0.1 volumes) and 
incubated  for  2  minutes  at  room  temperature  with  occasional  mixing.    To 
remove the DNase inactivation reagent, samples were centrifuged at 10,000 g 
for  1.5  minutes.    This  step  pellets  the  DNase  inactivation  reagent  and  the 
supernatant containing the RNA can be transferred to a fresh RNase free tube.     
 
2.6.2 Nucleic Acid Quantification 
 
Total RNA or DNA concentrations were quantified using the NanoDrop ND 1000 
Spectrophotometer and ND 1000 v3.1.0 programme.  For each sample, 1.5  l of 
either  DNA  or  RNA  was  quantified.    An  absorbance  ratio  (260nm/280nm)  of 
approximately 2 for RNA and 1.8 for DNA indicated nucleic acid samples of high 
purity.   
 
 
2.7 Reverse Transcription   
 
TaqMan®  Reverse  Transcription  Reagents  (Applied  Biosystems)  were  used  to 
generate 1st strand cDNA from 1  g of total RNA using random hexamer primers.  
Nuclease free water was added to 1  g of total RNA to give a volume of 7.7  l.  
The reverse transcription reaction mix was prepared as follows:  
•  2  l 10X TaqMan RT buffer   72 
•  4.4  l 25mM magnesium chloride 
•  4  l deoxyNTPs mixture 
•  1  l random hexamer primers 
•  0.4  l RNase inhibitor 
•  0.5  l MultiScribe reverse transcriptase (50U/ l). 
 
This was added to the RNA sample to give a final reaction volume of 20  l.  Two 
control samples were also run; 1 blank (no RNA in sample) and 1 no RT control 
(nuclease  free  water  was  added  instead  of  reverse  transcriptase).    Reverse 
transcription was carried out using the following thermal cycling parameters:  
•  10 minutes at 25°C 
•  30 minutes at 48°C 
•  5 minutes at 95°C 
 
cDNA samples were stored at  20°C until ready for use. 
 
2.7.1 TaqMan® Quantitative Real Time Polymerase Chain Reaction  
 
Quantitative  real time  PCR  (qRT PCR)  was  performed  on  cDNA  using  Applied 
Biosystems Gene Expression Assays and the ABI PRISM 7900ht Sequence Detection 
System.    The  comparative  CT  method  (2
   Ct)(171)  was  used  to  determine 
expression of the gene of interest relative to a β actin house keeping control 
gene.  Efficiency tests were performed for each gene of interest to determine 
whether the assays for both the control gene (β actin) and gene of interest could 
be performed in the same well (duplex) or separate wells (simplex).  If the gene 
of interest amplified with equal efficiency to the control gene then both assays 
could be run in duplex, if not then they were run separately.  Serial dilutions of 
a cDNA template were prepared and set up in simplex and duplex reactions for 
each gene of interest and the β actin control gene.  Efficiencies were calculated 
according  to  the  manufacturer’s  instructions  (ABI  PRISM  7700  Sequence 
Detection  System  User  Bulletin  #2).    The  Ct  values  were  plotted  against  log 
(dilution) for the gene of interest and β actin and the gradient of each slope was 
compared.  If the absolute value of the slope was <0.1 then the efficiencies 
were considered to be equal.  
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For each gene of interest a 5 l duplex reaction was set up in a 384 well plate 
consisting of: 
•  0.25 l FAM labelled probe 
•  0.25 l VIC labelled probe 
•  2 l of template cDNA 
•  2.5 l of TaqMan® Universal PCR master mix 
 
The probes for the gene of interest were tagged to FAM labelled fluorescent dyes 
and  β actin  probes  were  tagged  to  VIC  labelled  fluorescent  dyes.    If  the 
efficiency  of  the  gene  of  interest  was  not  equal  to  β actin,  then  a  simplex 
reaction was prepared with nuclease free water added in place of the second 
probe.  All samples were assayed in duplicate or triplicate and subjected to the 
following temperature cycling: 
•  50°C for 2 minutes 
•  95°C for 10 minutes 
•  35 cycles of 95°C for 15 seconds followed by 60°C for 1 minute 
 
 
2.8 Production of Short Hairpin RNA Expressing Plasmids 
 
The pShuttle CMV vector (Stratagene) was used to generate Gstm1 targeting and 
control short hairpin RNA (shRNA) expressing vectors (pShuttle CMV shRNA), see 
Figure 2.1. 
 
2.8.1 pShuttle CMV Plasmid DNA Purification 
 
The  pShuttle CMV  vector  (Figure  2.1)  was  grown  from  a  glycerol  stock  by 
streaking  onto  Luria  agar  (Sigma)  plates  containing  kanamycin  at  50   g/ml.  
Plates  were  inverted  and  incubated  at  37°C  overnight.    A  single  colony  was 
picked and added to 10 ml Luria broth (LB) plus kanamycin and incubated with 
shaking  at  37°C  for  approximately  8  hours.    After  this  time,  cells  were 
transferred to 2 litre flasks containing 500 ml of LB and left to incubate at 37°C 
overnight with shaking. 
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The following day, the culture was transferred to sterile bug pots and bacteria 
were harvested by centrifugation at 6000 g for 15 minutes at 4°C in a Beckman 
Coulter Avanti J 26XP.  Plasmid DNA was extracted using  the  Qiagen  Plasmid 
Maxi Kit, according to kit instructions.  The bacteria pellet was re suspended in 
10 ml buffer P1 (lysis buffer) until no clumps were visible and 10 ml buffer P2 
was added.  The pot was inverted 4 6 times to mix and then 10 ml chilled buffer 
P3 was added.  The pot was inverted again and then kept on ice for 20 minutes.  
The lysates were then subjected to centrifugation at 20,000 g for 30 minutes at 
4°C.    The  supernatant  was  retained  and  transferred  to  equilibrated  columns 
(equilibrated  with  10  ml  buffer  QBT).    The  supernatant  was  allowed  to 
completely run through the column before the column was washed twice with 30 
ml buffer QC.  Plasmid DNA was eluted with 15 ml buffer QF into polypropylene 
centrifuge  tubes  and  DNA  was  precipitated  by  the  addition  of  10.5  ml 
isopropanol and centrifuged at 15,000 g for 30 minutes at 4°C. The supernatant 
was carefully poured off and the pellet was re suspended in 5 ml 70% ethanol 
and centrifuged at 15,000 g for 10 minutes at room temperature.  The ethanol 
was carefully removed by pipette and the DNA pellets were left to air dry for 
approximately  10  minutes  before  being  re suspended  in  200   l  nuclease  free 
water.  The plasmid DNA concentration was quantified as described in section 
2.5.2 and stored at  20°C 
 
2.8.2 Restriction Digest 
 
To  enable  cloning  of  the  shRNA  sequences  into  the  pShuttle CMV  backbone, 
plasmid DNA was digested with restriction enzymes.  A total of 3  g of DNA was 
digested in a reaction containing 4 CORE SYSTEM reaction buffer (Promega) and 
a  10 fold  excess  of  enzyme  over  DNA,  as  per  manufacturer’s  instructions.  
Typically a 20  l reaction was carried out, including 1.5  g plasmid DNA, 2  l 10X 
restriction buffer, 0.2  l BSA and 1.5  l of each restriction enzyme (10U/ l) so 
that there was a 10 fold excess of each enzyme per reaction.  The reagents were 
mixed gently, then centrifuged briefly and incubated in a water bath at 37°C 
overnight.   75 
 
  
 
Figure 2.1 pShuttle CMV vector and shRNA sequences 
A: Outline of the pShuttle CMV vector map used to generate shRNA expressing 
plasmids (172).  B: Oligonucleotides encoding each shRNA as shown above were 
cloned into the pShuttle CMV vector backbone. 
 
shRNA B  CCTATATTTTCGAAGTTG
GTGGATATAAAAGCTTCAAC
T 
T C A 
A 
G 
A  G 
A 
shRNA C  CCTCACAGTCCTTTTCTG
TTGGAGTGTCAGGAAAAGAC
T 
T C A 
A 
G 
A  G 
A 
shRNA SCR  ACTACCGTTGTTATAGGT
TTTGATGGCAACAATATCCA
T 
T C A 
A 
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A  G 
A 
A 
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2.8.3 Agarose Gel Purification 
 
The  digested  plasmid  DNA  fragments  were  separated  by  agarose  gel 
electrophoresis.  A 1% agarose gel (Eurogentec) was prepared in 1X Tris Borate 
EDTA (TBE) (Fisher Bioreagents) containing 1 l ethidium bromide (Sigma) per 100 
ml of molten agarose.  Loading dye (6X) (50% glycerol and 0.05% bromophenol 
blue) was added to the DNA sample and to a control sample (linearised pShuttle 
CMV DNA).  Samples and a 1kb DNA ladder were subjected to electrophoresis at 
6 volts per cm length of gel.  Gels were visualised by UV transillumination on a 
BIO RAD Fluor S Multi Imager.  Electrophoresis was stopped after clear resolution 
of bands was observed.  The band containing digested pShuttle CMV DNA was cut 
out of the gel and DNA was extracted using the Wizard SV gel and PCR clean up 
system  (Promega).    The  gel  band  was  weighed  and  stored  in  a  1.5  ml  tube.  
Membrane  binding  solution  was  then  added  (10   l  per  10  mg  of  gel)  and 
incubated  at  65°C  for  10  minutes  until  agarose  had  melted.    DNA  was  then 
extracted using the kit protocol provided and then eluted into 50  l of nuclease 
free water. 
 
2.8.4 Annealing and Ligation 
 
Oligonucleotides  encoding  shRNA  based  on  the  siRNA  sequences  already 
evaluated were designed to include ends that were compatible with restriction 
sites  present  in  the  multiple  cloning  site  of  pShuttle CMV  (Figure  2.1).    The 
oligonucleotide concentration required for annealing was 1  g/ l.  To achieve 
this, oligonucleotides were first diluted with nuclease free water to 2  g/ l and 
then diluted to 1  g/ l in 1X TE.  Oligonucleotides were annealed in a reaction 
containing  46   l  1X  DNA  Annealing  Solution  (Ambion)  and  2   l  of  each 
oligonucleotide (top and bottom).  The reaction was incubated at 90°C for 3 
minutes followed by 1 hour at 37°C.  Annealed oligonucleotides were stored at  
20°C. 
 
The NEB Quick Ligation kit was used to ligate the different Gstm1 shRNA inserts 
into the pShuttle CMV vector backbone.  A 100:1 insert to vector ratio was used   77 
with 100  ng  of  vector  in  each  ligation.   The  following  equation  was  used  to 
calculate how much insert to add to each ligation reaction: 
 
((ng of vector x kb size of insert) / kb size of vector) x (molar ratio of insert to 
vector) 
 
The  ligation  reaction  was  then  carried  out  according  to  the  manufacturer’s 
instructions.  A reaction mix was prepared containing 100 ng vector and a 100 
fold molar excess of insert adjusted to 10  l with water,  10  l 2X Quick Ligation 
Buffer and 1  l T4 DNA Ligase, this was mixed gently, centrifuged briefly and 
incubated at room temperature for 5 minutes.  After ligation, samples were kept 
on ice until required for transformation. 
 
2.8.5 Transformation of DH5α Cells 
 
MAX Efficiency DH5α competent cells (Invitrogen) were thawed gently on ice for 
approximately  5  minutes.    Once  thawed,  50   l  of  competent  cells  were 
transferred into pre chilled 1.5 ml tubes and kept on ice.  Ligation reactions 
were diluted 5 fold in 10 mM Tris HCL, 1 mM EDTA and then 1  l of the dilution 
was added to one 50  l aliquot of cells.  To determine transformation efficiency, 
a  control  transformation  was  carried  out  with  50  pg  of  control  plasmid  DNA 
(ampicillin resistant pUC19).  The cells were kept on ice for 30 minutes, heat 
shocked at 42°C for 45 seconds and then returned to ice for a further 2 minutes.  
Cells were removed from the ice and 0.9 ml of room temperature SOC media 
was added to each aliquot followed by 1 hour incubation at 37°C with shaking.  
The control plasmid transformation was diluted 1:100 and 100  l was plated onto 
an agar plate containing ampicillin.  For all other transformations, 200  l was 
spread onto agar plates with kanamycin (50  g/ml).  The plates were kept in a 
37°C incubator overnight. 
 
2.8.6 Polymerase Chain Reaction (PCR) 
   
After  overnight  incubation,  plates  were  removed  from  the  incubator  and  the 
number of colonies on each plate was determined.  Single colonies were picked   78 
and added to nuclease free water in a 96 well PCR plate.  A PCR master mix was 
then prepared containing:  
•  10X PCR buffer (plus 20mM MgCl2)  
•  2.5  l forward primer (2 M)  
•  2.5  l reverse primer (2 M)  
•  4  l dNTPs (1mM) 
•  0.2  l Taq (5U/ l). 
 
This was added  to each well to give a final reaction volume  of 20  l.  Each 
sample was then subjected to: 
•  4 minutes at 95°C  
•  34 cycles of 30 seconds at 94°C 
•  30 seconds at 58°C 
•  1 minute at 72°C  
•  7 minutes at 72°C.   
 
A 1.5% agarose gel was prepared in 1X TBE containing 2 l ethidium bromide.  
Loading  dye (6X)  was added to 10   l of  each  PCR reaction and subjected  to 
electrophoresis at 150V for 1½ hours alongside a 50bp DNA ladder (Promega).  
Reactions  that  generated  a  band  at  the  correct  size  were  purified  and 
sequenced. 
 
2.8.6.1 PCR Purification 
 
PCR  samples  were  purified  using  an  AMPure  PCR  purification  kit  (Agencourt) 
according to manufacturer’s instructions.  Briefly, 18  l of AMPure reagent was 
added  to  each  PCR  reaction  in  a  96  well  plate.    Reagents  were  mixed, 
centrifuged  at  1000  rpm  for  1  second  and  incubated  for  4  minutes  at  room 
temperature.  The plate was then placed on a SPRI magnet plate for 8 minutes.  
With the plate on the magnet, the plate was inverted and the cleared solution 
was discarded.  Fresh 70% ethanol was prepared and 200  l was added to each 
well  and  incubated  for  30  seconds.    The  plate  was  inverted  onto  tissue  and 
centrifuged at 600 rpm for 1 second then left to air dry for 20 minutes.  Once 
dry, 40  l of nuclease free water was added to each well, mixed and centrifuged   79 
at 1000 rpm for 1 second.  Cleaned products were then transferred to a 96 well 
plate and stored at  20°C until required for sequencing. 
 
2.8.7 Sequencing 
 
Forward  and  reverse  strand  sequencing  was  carried  out  on  each  PCR  sample 
using  the  BigDye  Terminator  v3.1  Cycle  Sequencing  Kit  (Applied  Biosystems).  
The  sequencing  reaction  was  carried  out  in  a  96  well  plate  and  prepared  as 
follows: 
•  10  l of each PCR sample 
•  1  l Ready Reaction Mix 
•  4 l of BigDye Terminator Sequencing Buffer (5X) 
•  2 l of forward or reverse primer (2 M) 
•  Nuclease free water to a final volume of 20  l   
 
Each reaction was then subjected to: 
•  25 cycles of 45 seconds at 96°C 
•  25 seconds at 50°C 
•  4 minutes at 60°C 
•  5 minutes at 12°C. 
 
 
2.8.7.1 Sequencing Clean-up 
 
Dye terminator removal was carried out on each sequencing reaction using the 
Agencourt  CleanSeq  Dye  Terminator  Removal  Kit.    Briefly,  10   l  of  room 
temperature CleanSeq was added to each sequencing reaction, followed by the 
addition of 62  l of 85% ethanol.  The reagents were mixed and centrifuged to 
1000 rpm for 1 second.  The plate was then placed on a SPRI magnet plate for 3 
minutes.  With the plate on the magnet, the plate was inverted and the cleared 
solution discarded.  Then 150  l of 85% ethanol was added to each well and 
incubated at room temperature for 30 seconds.  The plate was inverted on tissue 
paper, centrifuged to 600 rpm and then left to air dry for 20 minutes.  Once dry, 
40  l of nuclease free water was added to each well and centrifuged to 1000   80 
rpm.  The cleaned sequencing product (20  l) was then transferred to a bar 
coded 96 well plate and analysed with the Applied Biosystems 3730 DNA Analyzer 
and SeqScape v2.5 software.  
 
2.9 Immunohistochemistry 
 
2.9.1 Rat Tissue Preparation 
 
Tissues were rinsed in PBS and cut into sections.  Each section was fixed in 10% 
formalin solution at 4°C overnight.  After overnight fixing, the formalin solution 
was removed and replaced with PBS.  The fixed tissues were then embedded into 
paraffin.  Using a microtome, 3  m paraffin kidney sections were cut and baked 
onto microscope slides at 60°C for 3 hours followed by overnight incubation at 
40°C to ensure that the tissue section adhered to the slide. 
 
2.9.2 Deparaffinisation and Rehydration of Sections 
 
Slides were placed in racks then sections were deparaffinised and rehydrated 
through  an  alcohol  gradient  consisting  of  Histoclear,  twice  for  3  minutes, 
Histoclear and 100% ethanol (1:1 ratio) for 3 minutes, 100% ethanol, twice for 3 
minutes, 95% ethanol for 3 minutes, 70% ethanol for 3 minutes, 50% ethanol for 3 
minutes and a final rinse in running cold tap water. 
 
2.9.3 Primary Antibody  
 
Sections were washed twice for 5 minutes in TBS plus 0.025% Triton X 100.  The 
slides were then transferred onto humidified trays and a wax pen was used to 
draw around each section.  The sections were then blocked in 10% (v/v) normal 
goat serum in TBS for 2 hours at room temperature.  The blocking solution was 
drained  off  and  sections  were  incubated  with  primary  antibody  or  negative 
control IgG diluted in 1% goat serum in TBS overnight at room temperature.  
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2.9.4 Secondary Antibody 
 
Sections were washed twice for 5 minutes in TBS plus 0.025% Triton X 100, then 
incubated  for  30  minutes  in  0.03%  H2O2  diluted  in  methanol  to  quench 
endogenous peroxidase activity.  The slides were returned to humidified trays 
and  sections  were  incubated  with  biotinylated  secondary  antibody  from  the 
Vectastain ABC kit, for 30 minutes at room temperature.  Sections were washed 
with TBS, 3 times for 5 minutes and then ABC complex (pre incubated for 30 
minutes) was added to each section and incubated at room temperature for 30 
minutes (according to manufacturer’s instructions). 
 
2.9.5 Staining 
 
Sections  were  washed  3  times  for  5  minutes  in  TBS.    Sections  were  then 
incubated  with  DAB  chromogen  (3,  3’ diamionbenzidine,  Vector  Lab  DAB 
Substrate Kit) plus nickel solution to produce black staining, for 5 minutes at 
room temperature in humidified trays.  Sections were washed for 5 minutes in 
distilled water and counter stained with haematoxylin for 10 seconds followed 
by  5  minutes  in  running  tap  water.    The  sections  were  then  dehydrated  by 
putting through an alcohol gradient as described before, in reverse.  Sections 
were cover slip mounted using Histomount (National Diagnostics).  
 
2.10 Haematoxylin and Eosin Staining 
 
Following the removal of paraffin and rehydration of sections as described in 
section 2.9.2, sections were stained with haematoxylin for 2 minutes.  Slides 
were then washed in running tap water for 5 minutes and then transferred to 
eosin for 2 minutes.  Slides were washed again for 5 minutes in running tap 
water.  Sections were dehydrated through an alcohol gradient and cover slip 
mounted using Histomount.  
2.11 Statistical Analysis 
 
Analysis  of results for multiple groups  was performed by one  way analysis of 
variance  (ANOVA)  and  Dunnet’s  post hoc  test,  comparing  all  results  to  a 
designated control group.  For comparisons between two groups, 2 sample t   82 
tests were applied.  Statistical analysis was performed using Prism 4.0 Graph Pad 
Software.  Significance was determined as p<0.05.   
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Chapter 3: Development of Molecular Tools for Modulation of 
Gstm1 Expression   84 
3.1 Introduction 
 
Glutathione S transferase mu type 1 (Gstm1) has been identified as a positional 
and functional candidate gene for hypertension in the SHRSP (69).  At present 
there  are  no  selective  pharmacological  inhibitors  of  Gstm1  making  further 
investigation of its function difficult.  To overcome this, an approach involving 
RNA interference (RNAi) has been adopted.  RNA interference is an endogenous 
gene silencing mechanism that can be exploited to experimentally reduce the 
expression of a particular gene of interest (137).  In vitro knock down of gene 
expression has been successfully achieved through the introduction of chemically 
synthesised gene specific siRNA (152).  To assess siRNA mediated silencing of 
Gstm1 expression in vitro an appropriate cell line had to be chosen.  Previous 
work carried out by our group found that Gstm1 expression was localised to the 
tubular epithelium of the kidney, particularly the collecting ducts (77).  For this 
reason, in vitro RNAi experiments have been carried out in the rat cell line NRK 
52E, a renal tubular cell line.  
 
3.1.1 Adenoviral Vectors 
 
To utilise RNAi for in vivo gene knock down, adenoviral vectors have been used 
to  drive  the  expression  of  short  hairpin  RNA  molecules  that  mediate  gene 
silencing (173).  Recombinant  adenovirus  serotype 5 (Ad5) vectors have  been 
commonly used for delivery as they are able to infect both dividing and non 
dividing cells and have a broad cellular tropism.  However, Ad5 vectors have a 
high hepatic tropism so that when delivered systemically most vectors end up in 
the liver (174;175).  This characteristic means that Ad5 vectors are not practical 
for site specific delivery via systemic administration.  
 
The  adenoviral  capsid  is  composed  of  three  main  structural  proteins;  hexon, 
fiber and penton base.  The fiber is a major determinant of virus tropism and is 
composed of an N terminal tail, a central shaft and a C terminal knob domain 
(176).  The fiber knob domain interacts with the coxsackie virus and adenovirus 
receptor (CAR) to mediate cell binding and infection.  As mentioned previously, 
Ad5  vectors  have  a  high  hepatic  tropism  but  recent  studies  have  shown  that 
following intravascular administration, CAR is not involved in liver transduction.    85 
Following intravascular injection of mutant Ad5 vectors that are unable to bind 
CAR, liver transduction is the same as unmodified vectors that are able to bind 
CAR, indicating that another pathway is involved (177).  Ad5 vectors have been 
shown to bind blood coagulation factors and when mutations were introduced 
into  the  fiber  domain  to  ablate  blood  factor  binding,  reduced  liver  cell 
transduction was observed (178).  It has since been shown that the Ad5 hexon 
protein interacts with the vitamin K dependent coagulation factor X (FX) and in 
doing so mediates liver transduction (179 181).   
 
3.1.1.1 Adenoviral Vector Tropism 
 
High hepatic tropism  is problematic for site specific delivery but it has been 
shown that it is possible to modify tropism by pseudotyping Ad5 vectors with a 
fiber  from  another  serotype.    To  aid  the  re targeting  of  Ad5  gene  therapy 
vectors, a helper independent adenovirus vector expressing the β galactosidase 
reporter  gene  and  with  E1,  E3  and  fiber  genes  deleted  (Ad5.βgal. F)  was 
developed  (182).    This  vector  in  combination  with  packaging  cell  lines  that 
express the fiber gene of choice would allow for easier modification of virus 
tropism (183).   Previous work carried out by our group found that pseudotyping 
Ad5  with  the  fiber  from  serotype  Ad19p  (Ad5/19p)  reduced  hepatic  tropism 
(184).    The  ability  of  Ad5/19p  to  infect  cultured  rat,  mouse  and  human 
hepatocyte  cells  was  significantly  reduced  compared  to  unmodified  Ad5  and 
following systemic administration in vivo a similar reduction in liver transduction 
was observed (184).  This Ad5/19p pseudotyped vector was further developed to 
enable it to target the kidney specifically.  In vivo phage display was utilised to 
identify the peptides HTTHREP (HTT) and HITSLLS (HIT) both of which selectively 
target the kidneys in rats.  The Ad19p fiber gene was genetically modified to 
allow peptide insertion and oligonucleotides encoding HTT and HIT were cloned 
into modified fiber expressing plasmids.  The plasmids were used to generate 
peptide  modified  vectors  that  when  systemically  delivered  to  WKY  rats  were 
found  to  localise  to  kidney  tubular  epithelium  (Ad19p HTT)  and  glomeruli 
(Ad19p HIT) (185).  The use of such targeted vectors provides a powerful tool for 
site specific knock down of Gstm1.  It has previously been shown that Gstm1 
expression is localised to the tubular epithelium, specifically in the collecting 
ducts (77).  Therefore Ad19p HTT would be an appropriate choice of vector for   86 
expression of Gstm1 shRNA to allow for the role of Gstm1 to be investigated 
more fully in vivo.  
 
 
3.1.2 RNA Interference and Immune System Activation 
 
The use of targeted adenoviral vectors for knock down of gene expression may 
overcome the transduction issues associated with systemic delivery but there is 
still  the  possibility  that  delivery  of  dsRNA  could  activate  the  innate  immune 
response (186).  Double stranded RNA is recognized by cells as a by product of 
viral replication and so to counteract this, the interferon (IFN) system is induced 
and protein synthesis is inhibited.  Double stranded RNA longer than 30 bp has 
been found to stimulate the IFN response (152). 
 
3.1.2.1 Oligoadenylate Synthetase  
 
The  2' 5' oligoadenylate  synthetases  (2' 5'OAS)  have  been  characterised  as  IFN 
induced  enzymes  activated  by  dsRNA  molecules  longer  than  15bp  (187).  
Oligoadenylate synthetase 1 (OAS1) is one of four members of the mammalian 2' 
5'OAS  family  (186).    The  enzyme  is  composed  of  two  domains  that  when 
assembled form a dsRNA binding site and when bound by dsRNA result in enzyme 
activation (188).  Once activated, 2' 5'OAS uses ATP to form 2' 5' linked oligomers 
of adenosine (2' 5'oligoadenylates or 2 5A) which in turn bind and activate the 
endoribonuclease,  RNase  L.    This  leads  to  degradation  of  both  foreign  and 
cellular RNA and a subsequent reduction in protein synthesis (189).  
 
Early studies carried out to investigate in vitro silencing of gene expression by 
dsRNA found that the introduction of long dsRNA (>30 bp) to rabbit reticulocyte 
lysates caused substantial non specific mRNA degradation (136).  This was likely 
due to the activation of RNase L by the presence of long dsRNA as previously 
observed by Williams and colleagues (190).  However, it has been proposed that 
short dsRNAs would not activate 2' 5'OAS and it has been observed that dsRNA 
between 21 and 27 bp long are poor inducers of 2' 5'OAS in vitro (186;191). 
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3.2 Aims 
 
•  To evaluate 3 different siRNA sequences designed to be specific for Gstm1 
for  their  ability  to  knock down  Gstm1  expression  in  vitro  and  quantify 
expression at both mRNA and protein level 
 
•  To investigate non specific effects on other members of the Gstm family 
in response to Gstm1 specific siRNA  
 
•  To determine if introduction of Gstm1 specific siRNA into renal cells leads 
to induction of an interferon response  
 
•  To generate plasmids expressing Gstm1 specific and control shRNAs and 
evaluate their function 
 
•  To assess targeting of kidney tubules by modified adenoviral vectors 
 
•  To assess methods for local delivery of siRNA/shRNA to renal cells in vivo   
 
 
3.3 Methods 
 
3.3.1 Transfection of NRK 52E Cells with siRNA 
 
Short interfering RNA sequences targeted against Gstm1 were evaluated for their 
ability  to  knockdown  gene  expression  in  NRK 52E  cells.    Transfections  were 
carried out as described in section 2.3.  Transfected cells were incubated at 
37°C for 48 hours and then protein or RNA was extracted for analysis by western 
blot or quantitative real time PCR. 
 
3.3.2 Transfection of NRK 52E Cells with Plasmid DNA 
 
Each  transfection  experiment  was  performed  in  triplicate  and  included  an 
untransfected control (UTF) and a mock transfection control (cells treated with   88 
transfection  reagent  only)  (TFC).    In  experiments  involving  transfection  of 
pShuttle CMV shRNA vectors, a control vector (SCR) that expresses a scrambled 
shRNA sequence (based on the negative siRNA control used previously that has 
no known homology to any expressed genes) was also used. 
 
3.3.2.1 FuGENE® 6 Transfection 
 
FuGENE® 6 (Roche) is a proprietary mix of lipids in 80% ethanol that facilitates 
the transfer of plasmid DNA across cell membranes.  NRK 52E cells were cultured 
in 6 well tissue culture plates until 70% confluent.  Transfection complexes were 
prepared at a ratio of 6:3 ( l FuGENE® reagent :  g of plasmid DNA).  Per well, 6 
 l  FuGENE®  reagent  was  added  directly  to  94   l  OptiMEM®  Reduced  Serum 
Medium in a 1.5 ml tube, mixed gently and incubated at room temperature for 5 
minutes.  To the transfection reagent mix, 3  g of plasmid DNA was added and 
incubated for 25 minutes at room temperature.  The transfection reagent/DNA 
complex  was  added  drop wise  to  each  well  containing  2  ml  normal  growth 
medium.  Plates were gently rocked back and forth to disperse the transfection 
complex and then incubated at 37°C for 48 hours.  
 
3.3.2.2 Lipofectamine™ 2000 Transfection 
 
NRK 52E  cells  were  cultured  in  6  well  tissue  culture  plates  until  80% 90% 
confluent.    Lipofectamine™  2000  (Invitrogen)  is  a  proprietary  cationic  lipid 
formulation.    Transfection  complexes  were  prepared  at  a  ratio  of  3:1  ( l 
Lipofectamine™ 2000 :  g plasmid DNA).  Per well, 5  l Lipofectamine™ 2000 
reagent was added to 245  l OptiMEM® Reduced Serum Medium, mixed gently 
and incubated for 5 minutes at room temperature.  A volume of plasmid DNA (2 
 g) was diluted to 250  l with OptiMEM® Reduced Serum Medium.  The diluted 
DNA  was  then  combined  with  the  diluted  Lipofectamine™  2000  reagent  and 
incubated  for  20  minutes  at  room  temperature.    The  culture  medium  was 
removed from each well and cells were washed twice with 2 ml sterile PBS.  To 
each well, 500  l OptiMEM® Reduced Serum Medium was added followed by 500 
 l  of  the  Lipofectamine™  2000/DNA  complex,  added  drop wise.    Plates  were 
gently rocked back and forth to disperse the transfection complex and incubated   89 
for 5 hours at 37°C.  After this time, 2 ml of normal growth medium containing 
20% (v/v) FCS was added to each well.  Cells were incubated at 37° for a further 
48 hours. 
 
 
3.3.3 β galactosidase Expression Staining 
 
NRK 52E cells with transfected with the p Shuttle CMV LacZ vector (Stratagene) 
to assess transfection efficiency.  Following transfection, cell culture medium 
was removed from each well and cells were washed twice with 2 ml sterile PBS.  
To  fix  cells,  2  ml  2%  paraformaldehyde  in  0.1M  sodium  phosphate  (72  mM 
Na2HPO4, 23 mM NaH2PO4) was added to each well and cells were kept on ice for 
15 minutes.  The paraformaldehyde was removed and cells were washed again 
with  PBS.    To  each  well,  2  ml  X Gal  (5 bromo 4 chloro 3 indolyl  β D 
galactopyranoside)  stain  (77mM  Na2HPO4,  23mM  NaH2PO4,  1.3mM  MgCl2,  3mM 
K4Fe(CN)6, 0.05% (v/v) 20 mg/ml X Gal dissolved in dimethyl formamide) was 
added and cells were incubated at 37°C overnight.  After overnight incubation, 
cells were examined under a microscope for blue staining. 
 
 
3.3.4 Gstm1 Western Blot Analysis 
 
Protein samples were prepared and quantified as described in sections 2.4 and 
2.4.1.  Gel electrophoresis and blotting were carried out on these samples as 
described in section 2.5.1  Into each lane, 30 g of protein sample prepared in an 
equal volume of 2x sample reducing buffer was loaded and a low range rainbow 
marker was used to determine band size.  A rat GSTM1 purified protein standard 
(Yb1) was also loaded as a positive control (Oxford Biomedical).  For immuno 
detection the membrane was incubated at 4°C overnight with a rabbit anti rat 
GSTM1 polyclonal antibody (gift from Prof. John Hayes, University of Dundee) 
used  at  a  dilution  of  1/2000  followed  by  a  goat  anti rabbit  IgG  secondary 
antibody conjugated to horseradish peroxidase (Dako) at 1/2000 for one hour at 
room temperature.  Bands were visualised using enhanced chemiluminescence, 
as described in section 2.5.3.   90 
3.3.5 Gstm Family mRNA Expression 
 
RNA was extracted from NRK 52E cells and 1
st strand cDNA was generated as 
described in sections 2.6 and 2.7.  Quantitative RT PCR was performed on cDNA 
using TaqMan Gene Expression Assays (Applied Biosystems) for Gstm1 (Assay ID: 
Rn00755117_m1),  Gstm2  (Rn00598597_m1),  Gstm3  (Rn00579867_m1),  Gstm5 
(Rn00597012_m1) and Gstm7 (Rn00579867_m1)  (FAM labelled probes) in duplex 
with β actin (Assay ID: 4352340E) (VIC labelled probe).  Efficiency tests were 
carried  out  (section  2.7.1)  to  ensure  that  the  β actin  housekeeper  was 
compatible with each of the Gstm probes allowing each reaction to be carried 
out in duplex.  
 
3.3.6 OAS 1 mRNA Expression 
 
RNA and cDNA from transfected NRK 52E cells was prepared as before.  Samples 
were  assayed  separately  for  OAS 1  (Assay  ID:  Rn00594390_m1)  and  β actin 
expression.  A 5 l reaction was set up in a 384 well plate consisting of:  
•  0.25 l OAS 1 FAM labelled probe or 0.25 l β actin VIC labelled probe 
•  0.25 l nuclease free water 
•  2 l of template cDNA 
•  2.5 l of TaqMan Universal PCR master mix 
Each sample was analysed with the ABI PRISM 7900ht Sequence Detection System 
and results generated as before. 
 
 
3.3.7 Fiber modified Adenovirus Vector Production 
 
Vector production was carried out in human embryonic kidney 293T cells that 
express the adenovirus E1A gene necessary for viral replication.     91 
 
 
Figure 3.1 Ad19p HTT plasmid construct and genome structure of the 
Ad5.βgal. F vector 
A: The plasmid for the expression of the modified Ad19p HTT fiber protein (185).  
The plasmid contains the CMV promoter, Ad5 tripartite leader (to improve fiber 
gene  expression)  and  the  modified  Ad19p HTT  fiber  sequence  (for  renal 
selectivity). 
B: The genome structure of the Ad5.βgal. F vector.  This vector has E1, E3 and 
L5  (fiber  gene)  regions  deleted  with  a  β galacotsidase  reporter  gene  (LacZ) 
inserted  in  place  of  the  E1  region  (182).    Arrows  indicate  direction  of 
transcription.  Adapted from (192) 
TPL: tripartite leader, ITR: inverted terminal repeat, ψ: packaging signal, E1 E4: 
adenoviral early genes, L1 L5: adenoviral late genes 
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Cells  were  maintained  in  Eagle’s  modified  medium  (MEM)  supplemented  with 
10% (v/v) FCS, 2mM L Glutamine, 1mM sodium pyruvate, 100 U/ml penicillin and 
0.1  mg/ml  streptomycin.    To  passage  cells,  citric  saline  (0.13M  KCl,  0.017M 
sodium citrate in PBS) was used instead of trypsin.  Transfections were carried 
out in 70% confluent 293T cells cultured in 10cm
2 tissue culture plates (Nunc). 
 
293T cells were transfected with HTT modified fiber expressing plasmid (Figure 
3.1) using a calcium chloride (CaCl2) differential pH method.  Culture medium 
was removed from each plate and cells were washed twice in sterile PBS.  To 
each plate, 4.5 ml of low glucose (1000 mg/L) DMEM supplemented with 10% 
(v/v) FCS and 25mM HEPES, pH 7.9 was added.  A solution containing 960  l low 
glucose DMEM (supplemented with 25mM HEPES pH 7.1), 48  l CaCl2 and 21  g 
plasmid DNA was prepared and added drop wise to each plate and gently mixed.  
Cells were incubated at 37°C overnight. 
 
Following overnight incubation, cells were washed in sterile PBS and infected 
with Ad5.βgal. F (a fiber gene deleted vector that expresses the reporter gene 
LacZ,  see  Figure  3.1)  at  2000  virus  particles  per  cell.    The  volume  of  virus 
required was calculated and added to the standard 293T culture medium and 15 
ml  of  this  mix  was  added  to  each  plate.    After  the  cytopathic  effect  was 
observed (the majority of cells will have detached from the plate) cells were 
harvested  in  sterile  PBS  and  centrifuged  at  850  g  for  10  minutes.    The 
supernatant was discarded and the cell pellet was re suspended in 6 ml of sterile 
PBS.  Cells were lysed by freeze/thawing four times and cell debris was removed 
by  centrifugation  at  850  g  for  10  minutes.    The  adenovirus  containing 
supernatant  was stored  at  80°C  until purification  by caesium  chloride (CsCl) 
density gradient centrifugation. 
 
3.3.7.1 Adenovirus Purification   
 
Virus particles were purified by CsCl density gradient centrifugation.  Fourteen 
ml ultra clear centrifuge tubes (Beckman Coulter) were sterilised by rinsing with 
70% ethanol followed by  sterile water.  A CsCl gradient was  prepared in  the 
centrifuge  tube  by  adding  2  ml  1.45  g/cm
3  CsCl  followed  by  a layer  of  1.32   93 
g/cm
3 CsCl added drop wise then a layer of 2 ml 40% glycerol.  To the top of this 
gradient, the adenovirus supernatant was added and the rest of the tube was 
filled with sterile water.  The tube was loaded into a Sorvall Discovery 90 rotor 
container and centrifuged at 90000 g for 1.5 hours with maximum acceleration 
and free deceleration.  Following centrifugation a white band containing virus 
could  be  seen.    The  virus  was  removed  by  piercing  the  centrifuge  tube  just 
below  the  virus  layer  with  a  syringe  and  a  22  gauge  needle.    The  virus  was 
carefully drawn up into the syringe without disturbing any of the other layers.   
 
A  10000  molecular  weight  cut off  Slide A Lyzer  dialysis  cassette  (Pierce)  was 
prepared by soaking in 0.01M Tris pH 8, 0.001M EDTA (TE buffer) for 30 minutes.  
Extracted  virus  was  then  transferred  to  the  cassette  and  any  excess  air  was 
removed.  The virus was dialysed against 2 L 0.01M TE buffer pH 8 for 2 hours 
then the TE buffer was replaced and dialysis was continued overnight.  The next 
day, the TE buffer was changed and supplemented with 10% (v/v) glycerol and 
dialysis  was  continued  for  a  further  2  hours.    After  this  time,  the  virus  was 
carefully removed from the cassette and stored in 50  l aliquots at  80°C.  
 
3.3.7.2 Calculating Virus Particle Titres 
 
Virus particle titres were calculated using a Micro BCA assay kit (Pierce).  Eight 
BSA standards (from 0.5  g/ml to 200  g/ml) and PBS blanks were prepared and 
150  l of each was added, in duplicate, to a 96 well plate.  Three volumes of 
virus  preparation  (1   l,  3   l  and  5   l)  were  diluted  to  150   l  with  PBS  and 
assayed in duplicate.  The BCA working reagent was prepared by mixing 25 parts 
Solution A, 24 parts Solution B and 1 part Solution C and 150  l of the working 
reagent was added to each well.  The plate was covered to protect it from the 
light  and  incubated  at  37°C  for  2  hours.    The  absorbance  at  570nm  was 
measured for each standard and sample and duplicate readings were averaged 
and the blank measurements were subtracted.  A standard curve was generated 
and used to calculate the protein concentration in each virus sample.  The virus 
particle titre was then calculated using the formula: 1  g protein = 1 x 10
9 virus 
particles. 
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3.3.8 Animal Models 
 
Inbred colonies of SHRSP and WKY rat strains have been maintained by our group 
since  1991.    Animals  were  housed  in  a  temperature  and  humidity  controlled 
environment with 12 hour light/dark cycles.  Rats were fed standard rat chow 
and  water  provided  ad  libitum.    All  experimental  animal  procedures  were 
performed  in  accordance  with  the  UK  Home  Office  Animals  (Scientific 
Procedures) Act 1986 under the project licence number 60/3618. 
 
 
3.3.9 Local Delivery to a Single Kidney 
 
WKY rats were anaesthetised by inhalation of isofluorane.  A laparotomy was 
performed  and  the  intestines  were  exteriorised  and  wrapped  carefully  in 
moistened swabs. The left kidney and renal artery/vein were exposed by blunt 
dissection. Ties were placed on the renal artery and vein to control blood flow 
to and from the kidney. The artery was clamped briefly during administration 
(injection  into  artery)  of  Ad5/19p  virus  (1x10
11  virus  particles).    A  maximum 
volume of 500  l was infused over a maximum of 20 seconds.  The blood flow 
was re established and haemorrhage from the injection site was prevented by 
cauterisation.  The intestines were returned to the abdominal cavity and the 
laparotomy incision was closed.  Kidneys were removed and used for histological 
analysis.  
 
 
3.3.10 In Vivo Virus Administration 
 
To investigate targeting of Ad19pHTT 8 week old male SHRSP rats were infused 
with 3.5x10
11 virus particles per rat, via the femoral vein.  After 5 days rats were 
sacrificed and organs removed.  Expression of LacZ in the kidney was determined 
by IHC as described in section 2.9. 
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3.4 Results 
 
3.4.1 Transfection Efficiency of NRK 52E Cells 
 
In  order  to  carry  out  in  vitro  RNAi  experiments  in  NRK 52E  cells,  it  was 
important to  evaluate the  transfection  efficiency of these cells.  To  do  this, 
NRK 52E cells  were  transfected with a Cy3 labelled  scrambled siRNA control.  
This siRNA has no known homology to any expressed genes and as such should 
not generate a silencing effect.  Figure 3.2 shows a representative transfection 
experiment.  Panel C demonstrates that there was no background fluorescence 
generated  when  cells  were  subjected  to  a  mock  transfection  (treated  with 
transfection reagent only).  However when cells were transfected with 100nM 
Cy3  labelled  siRNA,  fluorescence  was  detectable  throughout  indicating 
successful transfection of these cells (panel B).  This control transfection was 
carried out in all subsequent Gstm1 RNAi experiments and in each experiment, 
greater than 70% transfection efficiency was achieved. 
 
3.4.2 Glutathione S Transferase Mu Type 1 mRNA Expression 
 
TaqMan quantitative real time PCR was carried out to investigate silencing of 
Gstm1  mRNA  expression  following  transfection  of  NRK 52E  cells  with  100nM 
siRNA.  The ability of each siRNA to knock down Gstm1 is shown in Figure 3.3.  
Figure 3.3 is representative of 8 individual experiments carried out in triplicate.  
All 3 siRNA sequences resulted in significantly reduced Gstm1 mRNA expression. 
At  100nM,  siRNA  A  produced  knock down  of  between  65  and  79%,  siRNA  B 
between  78  and  93%  and  siRNA  C  achieved  between  63  and  69%  knock down 
when compared to the scrambled siRNA control.  In each experiment, siRNA B 
appeared  to  be  the  most  effective  as  knock down  from  this  sequence  was 
consistently higher as illustrated in Figure 3.3 (85% knock down, p<0.01 v siCTL 
compared to 79% and 68% knock down with siRNA A and C respectively, p<0.01 v 
siCTL). 
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Figure 3.2 Transfection efficiency of NRK 52E cells with 100nM siRNA  
A: Transmitted light image of NRK 52E cells. B: Cells transfected with 100nM Cy3 
labelled siRNA.  Comparison with transmitted light image of the same field (A) 
suggests  high  transfection  efficiency.  C:  Mock  transfected  cells  showing  no 
background fluorescence.  Scale bar: 50 m 
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3.4.2.1 Glutathione S-Transferase Mu Family mRNA Expression 
 
The mu family of glutathione transferases is highly homologous and as such, a 
sequence designed to target Gstm1 may inadvertently have a non specific effect 
on other Gstm isoforms.  To check the specificity of each siRNA sequence, NRK 
52E cells were transfected as before and RNA extracted for TaqMan analysis of 
Gstm2, 3, 5 and 7.  The mRNA expression levels of each isoform following knock 
down  of  Gstm1  are  shown  in  Figure  3.4.    Figure  3.4  is  representative  of  6 
individual experiments carried out in triplicate.  Both siRNA A and C were found 
to be specific for Gstm1 as no significant effect on the mRNA levels of other 
isoforms  was  detected.  Table  3.1  shows  the  range  of  knock down  of  each 
isoform in response to each siRNA at 100nM.  However, siRNA B was found to be 
less specific, resulting in reduced expression of all four isoforms as shown in 
Figure 3.4.  Expression of Gstm2, 3, 5 and 7 was reduced by 63, 93, 31 and 49% 
in this example (Gstm2, 3 and 7, p<0.01 and Gstm5, p<0.05 when compared to 
siRNA control). 
 
To investigate if the non specific effect of siRNA B on the other Gstm family 
members  was  possibly  due  to  transfection  of  an  excess  of  siRNA  into  cells, 
transfections were repeated using a reduced concentration of siRNA.  Following 
transfection of NRK 52E cells with 30nM siRNA, RNA and protein were extracted 
for TaqMan and western analysis respectively.  Firstly Gstm1 expression levels 
were  evaluated  to  ensure  that  by  reducing  the  concentration  of  siRNA,  the 
silencing  potency  was  not  diminished.    Figure  3.5  is  representative  of  4 
individual experiments carried out in triplicate and shows that each siRNA, at 
30nM,  was  still  capable  of  significantly  reducing  Gstm1  expression.    In  the 
example shown in Figure 3.5, Gstm1 expression was reduced by 71% by siRNA A, 
61% by siRNA B and 66% by siRNA C when compared to control siRNA, p<0.05.  
Across  the  4  experiments,  levels  of  knock down  varied  between  56  and  71% 
(siRNA A), 61 and 76% (siRNA B) and 46 and 66% (siRNA C).  As before with siRNA 
used at 100nM, siRNAs A and C did not significantly knock down expression of 
Gstm2, 3, 5 and 7 and by reducing the concentration to 30nM, siRNA B no longer 
had a non specific effect on any other Gstm isoform (Figure 3.6). 
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Figure 3.3 Gstm1 mRNA expression following Gstm1 RNA interference in NRK 
52E cells 
NRK 52E  cells  were  transfected  with  100nM  control  (siCTL)  or Gstm1  specific 
siRNA (A, B or C).  TaqMan qRT PCR was performed to assess Gstm1 expression. 
In this example, 79% knock down was achieved by siRNA A, sequence B achieved 
85% and sequence C achieved 68% compared to siCTL (n=1 experiment performed 
in triplicate and is representative of 8 experiments in total) ** p<0.01 vs siCTL 
(ANOVA + Dunnett’s post hoc test). 
UTF:  untransfected  cells,  TFC:  mock  transfection,  siCTL:  siRNA  control 
transfected cells 
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Figure 3.4 Gstm family mRNA expression following Gstm1 RNA interference in 
NRK 52E cells 
NRK 52E  cells  were  transfected  with  100nM  control  (siCTL)  or Gstm1  specific 
siRNA (A, B or C).  TaqMan qRT PCR was performed to assess expression levels of 
Gstm2, 3, 5 & 7.  No significant knock down of any Gstm isoforms was observed 
with  siRNA  A  and  C.    However,  siRNA  B  significantly  reduced  each  of  the  4 
isoforms.    In  this  example,  Gstm2  and  Gstm3  were  reduced  by 63% and  93% 
respectively compared to siCTL (n=1 experiment performed in triplicate and is 
representative of 6 experiments in total), ** p<0.01 vs siCTL (ANOVA + Dunnett’s 
post hoc test).  Gstm5 and Gstm7 were reduced by 31% and 49% respectively 
compared to siCTL (n=1 experiment performed in triplicate and is representative 
of 6 experiments in total) *p<0.05 vs siCTL (ANOVA + Dunnett’s post hoc test).  
UTF:  untransfected  cells,  TFC:  mock  transfection,  siCTL:  siRNA  control 
transfected cells 
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Table 3.1 Percentage knock down of expression of Gstm isoforms in response to 
each siRNA at 100nM 
 
RANGE OF KNOCK DOWN (%) 
Gene  siRNA A  siRNA B  siRNA C 
Gstm2  1 to 30  48 to 87  7 to 42 
Gstm3  7 to 33  77 to 93  2 to 49 
Gstm5  3 to 36  31 to 56  7 to 43 
Gstm7  24  21 to 55  21 to 42   101 
3.4.3 Glutathione S Transferase Mu Type 1 Western Blot Analysis 
 
The sensitivity of the anti rat GSTM1 antibody was initially evaluated against a 
range of NRK 52E protein dilutions.  It was important that the antibody could 
detect  different  levels  of  GSTM1  protein  in  order  to  determine  if  effective 
knock down of GSTM1 had taken place.  Figure 3.7 indicates that the antibody 
was  sensitive  to  a  range  of  concentrations  of  GSTM1  (Panel  A).    Due  to  the 
homologous nature of GSTM1 and other members of the GSTM family, detecting 
GSTM1  selectively  can  be  problematic.  To  ensure  GSTM1  specificity,  the 
antibody was evaluated against GSTM1 (M1) and GSTM2 (M2) protein standards.  
The  antibody  was  found  to  be  specific  to  GSTM1  and  did  not  detect  GSTM2 
(Panel A in Figure 3.7). 
 
To  determine  whether  transfection  with  any  of  the  three  siRNA  sequences 
resulted in efficient knock down of GSTM1, western blot analysis was performed.  
A representative blot following transfection of NRK 52E cells with 100nM siRNA is 
shown in Figure 3.7 (Panel B).  Each band (~26kD) corresponds with the purified 
GSTM1  protein  standard.    Each  siRNA  sequence  caused  a  reduction  in GSTM1 
protein (bands A, B and C) when compared with the scrambled siRNA control 
(siCTL).  This was confirmed by normalising each band to the housekeeper β 
actin  by  densitometry.    A  representative  β actin  blot  and  the  corresponding 
densitometry results are shown in Figure 3.7 (Panels B and C).  The densitometry 
results show a 93% reduction in GSTM1 protein by siRNA A and knock down of 87 
and  88%  with  siRNA  B  and  C  respectively.    Western  blot  analysis  and 
densitometry was also performed to assess the ability of each siRNA to knock 
down  GSTM1  protein  levels  when  used  at  30nM,  as  shown  in  Figure  3.8.    As 
before, GSTM1  protein  was  lower  in  siRNA  treated  samples.    At  30nM  siRNA, 
protein expression was reduced by 60% with siRNA A and by 59 and 77% with 
siRNA B and C respectively.   102 
 
 
 
Figure  3.5  Knock down  of  Gstm1  expression  is  preserved  with  reduced 
concentrations of siRNA 
NRK 52E  cells  were  transfected  with  30nM  control  (siCTL)  or  Gstm1  specific 
siRNA (A, B or C).  TaqMan qRT PCR was performed to assess Gstm1 expression. 
In this example, 71% knock down was achieved by siRNA A, sequence B achieved 
61% and sequence C achieved 66% compared to siCTL (n=1 experiment performed 
in triplicate and is representative of 4 experiments in total) * p<0.05 vs siCTL 
(ANOVA + Dunnett’s post hoc test) 
UTF:  untransfected  cells,  TFC:  mock  transfection,  siCTL:  siRNA  control 
transfected cells 
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Figure  3.6  Gstm  family  mRNA  expression  is  unaffected  by  reduced 
concentrations of Gstm1 siRNA 
NRK 52E  cells  were  transfected  with  30nM  control  (siCTL)  or  Gstm1  specific 
siRNA  (A,  B  or  C).    TaqMan  qRT PCR  was  performed  to  assess  expression  of 
Gstm2, 3, 5 & 7. No significant reduction of mRNA expression was observed for 
any  of  the  other  Gstm  isoforms  following  transfection  with  30nM  siRNA  (n=1 
experiment  performed  in  triplicate  and  is  representative  of  4  experiments  in 
total).  
UTF:  untransfected  cells,  TFC:  mock  transfection,  siCTL:  siRNA  control 
transfected cells 
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Figure 3.7 Western blot analysis of GSTM1 protein expression  
A:  Total  protein  was  extracted  from  NRK 52E  cells  and  resolved  by  gel 
electrophoresis.  Western blotting confirmed the anti rat GSTM1 antibody was 
sensitive to a range of GSTM1 concentrations.  Anti rat GSTM1 was tested against 
GSTM1 (M1) and GSTM2 (M2) protein standards and was found to be specific for 
GSTM1.  B: NRK 52E cells were transfected with 100nM control (siCTL) or Gstm1 
specific siRNA (A, B or C).  Western blotting indicated GSTM1 protein levels were 
lower  in  cells  transfected  with  Gstm1  specific  siRNA  compared  to  siCTL.    C: 
Reduced GSTM1 was confirmed by densitometry with each band normalised to β 
actin  (n=1  experiment  performed  in  duplicate  and  is  representative  of  8 
experiments in total). 
UTF:  untransfected  cells,  TFC:  mock  transfection,  siCTL:  siRNA  control 
transfected cells 
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Figure 3.8 Western blot analysis of GSTM1 protein expression (30nM siRNA) 
A: NRK 52E cells were transfected with 30nM control (siCTL) or Gstm1 specific 
siRNA  (A,  B  or  C).    Total  protein  was  extracted  and  resolved  by  gel 
electrophoresis.  Western blotting was performed and bands indicated GSTM1 
protein  levels  were  lower  in  cells  transfected  with  Gstm1  specific  siRNA 
compared to siRNA control.  B: Reduced GSTM1 was confirmed by densitometry 
with each band normalised to β actin (n=1 experiment performed in duplicate 
and is representative of 3 experiments in total). 
UTF:  untransfected  cells,  TFC:  mock  transfection,  siCTL:  siRNA  control 
transfected cells 
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3.4.4 Interferon Response 
 
As well as the potential for non specific silencing of other genes by siRNAs, it 
was  also  possible  that  introduction  of  siRNA  to  cells  may  induce  off  target 
effects  through  induction  of  an  interferon  response.    To  investigate  the 
likelihood of each Gstm1 specific siRNA to induce an interferon response in NRK 
52E cells, the expression level of oligoadenylate synthetase 1 was quantified.  
Following  transfection  with  100nM  siRNA,  OAS 1  expression  was  significantly 
increased with the greatest increase observed in response to siRNA sequences A 
and B, as shown in the top panel of Figure 3.9.  In this example, siRNA A induced 
OAS 1 expression 245.8 fold when compared to siCTL and siRNA resulted in 489.5 
fold induction of OAS 1, p<0.01.  The induction of OAS 1 by siRNA C was much 
less,  with  only  a  4.6  fold  increase.    Expression  of  OAS 1  varied  between 
experiments; siRNA A caused a 17.5 to 245.8 fold increase, siRNA B caused a 
330.5 to 628.3 fold increase and siRNA C caused a 4.2 to 14.3 fold increase in 
OAS 1 expression.  This effect was diminished by reducing siRNA concentration 
to 30nM, as shown in the bottom panel of Figure 3.9.  When reduced to 30nM, no 
significant induction of OAS 1 expression was observed.  
 
3.4.5 Assessment of Local Delivery to Kidney 
 
Local delivery to the kidney was assessed by injecting modified Ad5/19p into the 
renal artery.  Haematoxylin and eosin staining was performed on kidney sections 
to  assess  what  effect  direct  administration  through  the  renal  artery  had  on 
kidney  structure.    Figure  3.10  shows  sections  from  infused  and  contralateral 
kidney.  Extensive damage was observed in kidney infused with virus.  In the 
contralateral kidney, the tubules can be observed as discrete structures but in 
the infused kidney, these defined structures are lost indicating tubular necrosis.   107 
   
Figure 3.9 Oligoadenylate synthetase expression levels 
Top panel: NRK 52E cells were transfected with 100nM control (siCTL) or Gstm1 
specific siRNA (A, B or C).  TaqMan qRT PCR was performed to assess expression 
levels  of  oligoadenylate  synthetase  (OAS 1).    A  large,  significant  increase  in 
oligoadenylate synthetase expression was observed in response to siRNA A and B 
(n=1 experiment performed in triplicate and is representative of 6 experiments 
in total) **p<0.01 vs siCTL.  Bottom panel: NRK 52E cells were transfected with 
30nM control (siCTL) or Gstm1 specific siRNA (A, B or C).  Induction of OAS 1 
expression  was  diminished  by  reducing  siRNA  concentration  to  30nM  (n=1 
experiment  performed  in  triplicate  and  is  representative  of  4  experiments  in 
total).  UTF: untransfected cells, TFC: mock transfection, siCTL: siRNA control 
transfected cells 
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3.4.6 Ad19pHTT Targeting in SHRSP Kidney 
 
The adenoviral vector Ad19pHTT has been shown to target the kidney tubular 
epithelium of WKY rats following peripheral intravenous injection.  To be able to 
use this vector for in vivo modulation of Gstm1 expression in the congenic 2c* 
(entirely SHRSP apart from region of chromosome 2 which is from WKY) targeting 
in SHRSP had to be determined.  Figure 3.11 shows representative images of the 
staining  observed  in  sections  of  the  same  kidney  region  treated  with  either 
negative  control  IgG  antibody  (right  panel)  or  β galactosidase  antibody  (left 
panel).    β galactosidase  staining  was  observed  specifically  in  tubules,  as  had 
been shown previously in WKY with little or no staining in control sections.  
 
3.4.7 Evaluation of shRNA Expressing Plasmids 
 
Gstm1  targeting  shRNA  expression  vectors  were  generated  by  cloning 
oligonucleotides  encoding  shRNA  into  the  multiple  cloning  site  (MCS)  of  the 
pShuttle CMV vector backbone.  The shRNA sequences used were based on the 
Gstm1  siRNA  and  scrambled  siRNA  control  sequences  tested  previously.    An 
outline  of  the  pShuttle CMV  vector  map  and  shRNA  sequences  are  shown  in 
Figure  2.1.    The  plasmid  region  encompassing  the  MCS  was  amplified  and 
subjected  to  gel  electrophoresis  to  check  if  the  shRNA  insert  was  present.  
Plasmid vector containing insert generated a band of ~200 bp and vector without 
insert generated a band of ~150 bp.  Samples that generated a band at 200 bp 
were then sequenced to check that the orientation and sequence of the shRNA 
insert was correct.  An example gel and sequencing results are shown in Figure 
3.12. 
 
To assess the transfection efficiency of NRK 52E cells for transfection of plasmid 
DNA, cells were transfected with a pShuttle CMV vector that expresses the β 
galactosidase reporter gene, LacZ (pShuttle CMV LacZ).     109 
 
 
Figure 3.10 Haematoxylin and eosin staining of WKY kidney sections 
Top panel: Ad5/19p virus (1 x 10
11 virus particles) was administered directly to 
male  WKY  rat  kidney  via  the  renal  artery.    Renal  artery  infusion  leads  to 
significant kidney damage.  Bottom panel: Undamaged contralateral kidney with 
normal appearance. Scale bar = 100 m. 
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Figure 3.11 Analysis of kidney targeting in SHRSP  
Eight week old male SHRSP were infused with Ad19pHTT (3.5x10
11 virus particles 
per  rat)  via  the  femoral  vein.    Immunohistochemistry  performed  on  kidney 
sections  confirmed  β galactosidase  expression  (grey black  staining)  in  the 
tubules  with  no  non specific  staining  in  the  control  sections  treated  with  a 
negative control IgG antibody. Sections were counter stained with haematoxylin 
to stain nuclei blue.  Representative sections are shown (n=3).  Scale bar = 100 
 m (x10 magnification).  Scale bar = 50  m (x20 magnification). 
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Plasmid  DNA  transfection  of  NRK 52E  cells  was  optimised  using  two  different 
transfection reagents and by altering the ratio of DNA to transfection reagent 
used.  Using 2  g of plasmid DNA was found to be most effective in combination 
with 5  l of transfection reagent (Lipofectamine™ 2000).  However, transfection 
of NRK 52E cells with plasmid DNA was very low as shown by the low level of 
blue  stained  cells  (Figure  3.12).   Approximately  5 10%  transfection  efficiency 
was achieved.   
 
The ability of the pShuttle CMV shRNA plasmids to knock down Gstm1 expression 
in vitro was assessed by transfecting the plasmids into NRK 52E cells.  TaqMan 
RT PCR was carried out to assess changes in expression.  The top panel in Figure 
3.13 indicates that Gstm1 mRNA expression is reduced in cells transfected with a 
plasmid expressing Gstm1 shRNA.  When compared to cells transfected with a 
scrambled  control  shRNA  (SCR),  Gstm1  expression  was  58%  lower,  p<0.05.  
However this result was not reproducible, of 8 experiments only 1 demonstrated 
successful knock down of Gstm1.  The remaining 7 experiments did not show any 
significant knock down as demonstrated in the bottom panel of Figure 3.13.     112 
 
 
 
 
Figure  3.12  Transfection  efficiency  of  NRK 52E  cells  and  shRNA  vector 
sequencing analysis 
A: NRK 52E cells were transfected with pShuttle CMV at Lipofectamine:DNA ratio 
of  5:2  ( l: g).    β galactosidase  staining  demonstrated  5 10%  transfection 
efficiency.  Scale bar = 100 m.  B: PCR gel of amplified vector to check for 
insert.  Samples that generated a band at ~200bp were selected for sequencing 
(circled  in  yellow).  C:  DNA  sequencing  electropherogram  showing  correct 
insertion of each shRNA sequence.  
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Figure 3.13 Gstm1 mRNA expression levels in cells transfected with Gstm1 
shRNA expressing vector 
TaqMan qRT PCR analysis of Gstm1 mRNA expression following transfection of 
NRK 52E cells with Gstm1 shRNA expressing pShuttle CMV.  Top panel: Gstm1 
mRNA  expression  was  reduced  by  58%  in  cells  transfected  with  Gstm1  shRNA 
compared  to  scrambled  shRNA  control  (SCR)  (n=1  experiment  performed  in 
triplicate) *p<0.05 vs SCR (ANOVA + Dunnett’s post hoc test).  Bottom panel: no 
change  in  Gstm1  expression  was  observed  in  shRNA  treated  cells  (n=1 
experiment  performed  in  triplicate  and  is  representative  of  7  experiments  in 
total). 
UTF: untransfected, TFC: mock transfection, SCR: control vector transfection  
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3.5 Discussion 
 
The  in  vitro  experiments  described  so  far  indicate  that  NRK 52E  cells  are 
amenable  to  transfection  with  siRNA  allowing  for  accurate  measurement  of 
reduced gene expression.  Using available RNA interference technology, three 
siRNA  sequences  have  been  identified  that  can  successfully  and  reproducibly 
knock down Gstm1 expression in vitro.  The level of knock down achievable can 
be quantified at both protein and mRNA expression level by western blot and 
quantitative real time PCR analysis respectively.  Although significant silencing 
could be achieved with each siRNA, sequence B was consistently more effective 
at  reducing  Gstm1  mRNA  expression  than  either  siRNA  A  or  C.    As  well  as 
measuring Gstm1 expression, levels of Gstm2, 3, 5 and 7 were also quantified to 
ensure that no non specific silencing occurred.  The genes that encode the Gstm 
family  are  all  highly  homologous  and  because  of  this,  a  sequence  targeted 
against Gstm1 may result in non specific knock down of other members of the 
family,  especially  at  high  siRNA  concentrations.   Gstm1  shares  84%  homology 
with Gstm2, 85% with Gstm3, 71% with Gstm5 and 82% homology with Gstm7.  At 
100nM siRNA, all isoforms were affected by siRNA B but not siRNA A or siRNA C.  
To  minimise  this  effect,  the  concentration  of  siRNA  was  reduced  to  30nM.  
Lowering the concentration of siRNA used from 100nM to 30nM still resulted in 
significant  reduction  of  Gstm1  expression  but  the  level  of  knock down 
achievable from  each  siRNA  was  slightly reduced.    At  30nM,  the  non specific 
effect on other  Gstm  isoforms was lost.  This demonstrates that  by reducing 
siRNA concentration the selectivity of the siRNA for Gstm1 can be increased.    
 
This  is  also  the  case  when  trying  to  limit  the  risk  of  inducing  an  interferon 
response following the introduction of double stranded RNA (dsRNA) molecules.  
Double  stranded  RNA  of  greater  than  30bp  has  been  shown  to  induce  an 
interferon response in mammalian cells (152).  By using shorter RNA molecules it 
is thought that this effect can be avoided as it has been suggested that at least 
40 to 60 bp of dsRNA are required for the activation of 2' 5'OAS (191). However, 
OAS 1  expression  was  significantly  increased  in  NRK 52E  cells  following  the 
introduction of short (21 nt) siRNA molecules against Gstm1.  This effect was 
removed by lowering the siRNA concentration from 100nM to 30nM, indicating 
that as well as dsRNA length, concentration is also important.  This was found to   115 
be the case in studies with IFN treated HeLa cells, where higher concentrations 
of dsRNA were able to activate 2' 5'OAS more effectively (193).  Therefore, to 
achieve  successful  and  specific  RNA  interference,  the  lowest  effective 
concentration of siRNA should be used to limit off target effects. 
 
To be able to take investigation of the function of Gstm1 into an in vivo setting, 
local delivery to the kidney was evaluated as a potential means of introducing 
Gstm1 targeting siRNA directly to the kidney.  Direct administration of siRNA 
would maintain a high concentration of siRNA at the target site without having 
to deliver a large dose and so would also help to limit systemic side effects.  
Local delivery of siRNA has proved successful for delivery to the eye in mouse 
models  of  ocular  neovascularisation  (167;168).    However,  delivery  of  siRNA 
throughout  the  kidney  has  been  found  to  be  more  difficult  (194).    Various 
methods have been employed to deliver siRNA/shRNA to the kidney.  An adeno 
associated virus vector expressing shRNA targeted against the mineralocorticoid 
receptor  (MR)  was  introduced  to  Sprague  Dawley  rats  by  IV  injection  to  the 
jugular vein.  Renal MR expression was reduced and cold induced hypertension 
and renal damage were subsequently inhibited (162).  The jugular vein was also 
used as a delivery route for a liposomal siRNA complex targeting V2 receptors in 
mouse kidney (195).  The method investigated in this study for potential in vivo 
knock down of Gstm1 involved direct delivery to the kidney via the renal artery.  
However, following injection of Ad5/19p to the kidney, extensive damage was 
observed.    Successful  kidney  delivery  via  renal  artery  injection  has  been 
described  previously.    Renal  artery  injection  of  a  shRNA  expression  plasmid 
effectively inhibited TGF β1 expression in mouse kidney (196).  Direct delivery 
to  rat  kidney  has  also  been  shown  using  an  electroporation  mediated  gene 
transfer system (197).  Synthetic siRNA was introduced to the kidney by injection 
via  the  renal  artery,  the  renal  vein  was  then  clamped  and  the  kidney  was 
subjected to electrical pulses.  This method resulted in efficient transduction of 
glomeruli and significant silencing of gene expression (198).  The silencing effect 
was restricted to the glomeruli with limited transduction of tubules observed.  
This method would not be appropriate for investigation of Gstm1 silencing as 
expression of Gstm1 has been found in kidney tubular epithelium.  Neither study 
mentioned kidney damage sustained as a result of renal artery infusion. 
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To overcome the damage induced by direct kidney injection, a kidney targeting 
adenoviral  vector  that  can  be  delivered  systemically  was  evaluated.    Kidney 
targeted  Ad5  vectors  have  been  generated  as  described  previously  (185)  and 
targeting  was  evaluated  in  SHRSP.    This  testing  in  SHRSP  was  necessary  as 
previous work had been carried out in WKY animals.  The 2c* congenic strain is 
entirely SHRSP apart from a region of chromosome 2 encompassing Gstm1 which 
has been transferred from WKY.  The 2c* was found to have a greater level of 
Gstm1 expression than SHRSP.  Knocking down expression of Gstm1 in the kidney 
of 2c* may re establish the SHRSP phenotype and a greater understanding of the 
role of reduced expression observed in the SHRSP would be gained.  Selective 
staining of the tubules has been shown which is important for in vivo Gstm1 
studies as differential expression of Gstm1 was previously localised to kidney 
tubular epithelium (77).   
 
Plasmid vectors that express short hairpin forms of the siRNA sequences already 
tested in vitro have been generated and could be incorporated into the kidney 
targeted Ad5 vector  system.  However, when assessing  the activity of  Gstm1 
shRNA in vitro, knock down of Gstm1 expression could not be achieved.  Various 
studies have investigated optimal shRNA design for efficient knock down of gene 
expression.  In a study performed by Siolas et al, shRNAs with a 29 nt long stem 
and 3' nt overhang were found to be more efficient inducers of RNAi than shRNAs 
with  19  nt  long  stems.    It  has  been  suggested  that  Dicer  substrates  are 
incorporated into RISC more effectively.  The 29 mer shRNAs with 3' overhangs 
were efficiently converted to 22 nt products (mediators of RNAi) by incubation 
with Dicer however, this was not the case for 19 mer shRNAs suggesting that 
Dicer requires a minimum stem length for successful cleavage.  The presence of 
3' overhangs was also found to be important for Dicer activity as 29 mer shRNAs 
without the overhang generated very little 22 nt product.  Both 29 mer and 19 
mer stems were connected by a 4 nt loop in this study (199).  This would suggest 
that for efficient Dicer activity and subsequent incorporation into RISC, shRNAs 
should  be  designed  with  29 mer  stems  and  a  3'  nt  overhang.    The  shRNAs 
designed for knock down of Gstm1 in this study are composed of 19 nt stems 
with a 3' nt overhang and a 9 nt loop sequence.   However, experiments carried 
out by Li and colleagues found that only when a 4 nt loop was incorporated into 
the shRNA design were 29 mer stem shRNAs more effective than 19 mer shRNA.    117 
When combined with a 9 nt loop, shRNA with 19 mer stems were more efficient 
than 29 mer shRNA (200).  They also found that 19 nt stems with a 9 nt loop 
provide an appropriate substrate for Dicer.  This would suggest that the shRNA 
design  used  in  our  study  should  be  processed  by  Dicer  and  result  in  the 
production of small RNAs capable of knocking down Gstm1.   
 
Another factor that could affect the production of shRNA is the promoter used to 
drive  shRNA  expression.    The  p Shuttle  vector  used  to  generate  the  Gstm1 
specific shRNA in this study utilises a CMV promoter.  Many viral vectors use CMV 
to drive shRNA expression and a recent study involving plasmid generated shRNA 
found no significant differences in the silencing response generated from H1, U6 
and  CMV  promoters  (201).   However,  another  group  found  that  CMV  was  not 
suitable for expression of shRNA and that CMV driven shRNA constructs were far 
less efficient than other promoter driven constructs (200).  It may be that the 
pShuttle CMV vector is not suitable for efficient production of shRNA and that 
perhaps another vector should be used in the future.  As well as the various 
hairpin RNA design and expression considerations, a major factor contributing to 
in vitro gene silencing is transfection efficiency.  It seems most likely that the 
reason  the  pShuttle CMV shRNA  constructs  failed  to  successfully  knock down 
Gstm1 was due to the poor transfection efficiency of NRK 52E cells with plasmid 
DNA.    At  most,  20%  of  cells  were  successfully  transfected  with  the  Gstm1 
pShuttle CMV shRNA expression vectors as determined by LacZ expression.  NRK 
52E  cells  have  proved  to  be  very  difficult  to  transfect  with  plasmid  DNA  as 
observed in this study and by other colleagues in the laboratory.  Even if the 
cells that have taken up the shRNA constructs can generate a complete knockout 
of Gstm1 expression, still only 20% knock down would be observed for the entire 
cell  population.    Thus,  the  pShuttle CMV shRNA  construct  may  generate 
effective Gstm1 targeting shRNA but to fully evaluate their potency, a cell line 
more amenable to plasmid  transfection would need to be used in any future 
studies. 
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Chapter 4: Investigating the Impact of Altered Gstm1 Expression 
on Markers of Oxidative Stress  119 
4.1. Introduction 
 
As described in detail in Chapter 1, Gstm1 is part of a large family of antioxidant 
enzymes  involved  in  the  detoxification  of  the  by products  of  oxidative  stress 
such as the break down products of lipid peroxidation and oxidative DNA damage 
(118).  The results of Chapter 3 demonstrated that expression of Gstm1 can be 
successfully and consistently knocked down at both protein and mRNA level by 
siRNA mediated RNA interference.  The effect of reduced Gstm1 expression on 
markers of oxidative stress was investigated to assess the antioxidant role of 
Gstm1. 
 
4.1.1. Lipid Peroxidation 
 
Lipid  peroxidation  is  a  common  feature  of  free  radical  induced  damage  to 
membranes (202).  Cell membranes containing polyunsaturated fatty acids are 
highly  susceptible  to  peroxidation  and  the  lipid  radicals  produced  lead  to 
propagation  of  free  radical  reactions,  further  contributing  to  lipid  damage.  
Increased lipid peroxidation has been described as a significant contributor to 
the development of atherosclerosis (203).  The production of lipid radicals and 
their intermediates can affect cell function, lead to inflammation and vascular 
damage and may contribute to endothelial dysfunction (204). 
 
Isoprostanes  are  commonly  used  markers  of  lipid  peroxidation  and  oxidative 
stress.  The prostaglandin like F2 isoprostanes are derived from the peroxidation 
of  arachidonic  acid  and  can  be  measured  in  blood  and  urine  to  assess  lipid 
peroxidation  in  vivo  (204;205).    The  most  commonly  used  biomarker  of  lipid 
peroxidation is 8 isoprostane (204).  Levels of 8 isoprostane have been shown to 
be higher in subjects with cardiovascular risk factors than in healthy subjects 
and  were  also  found  to  be  elevated  in  smokers  (206;207).    Studies  in 
hypertensive individuals have shown that plasma 8 isoprostane concentration is 
higher in salt sensitive subjects during salt loading (208) and that angiotensin II 
infusion also leads to increased 8 isoprostane in plasma of hypertensive subjects 
with  high  salt  intake  (209).    Measurement  of  8 isoprostane  has  also  been 
performed in vitro (210) and was used as an indicator of oxidative stress in NRK 
52E cells (211).    120 
4.1.2. DNA Damage 
 
Increased  levels  of  oxidative  stress  can  also  lead  to  DNA  modification  and 
damage.    Free  radicals,  such  as  the  hydroxyl  radical  can  cause  DNA  base 
oxidation (212).  8 hydroxy 2 deoxyguanosine (8 OH dG) is a product of such free 
radical induced damage resulting from hydroxylation of the guanosine base.  It is 
frequently measured as an indicator of oxidative stress in vivo (213).  Studies 
measuring  8 OH dG  have  shown  that  increased  DNA  damage  is  present  in 
patients  with  type  2  diabetes  compared  to  non diabetic  subjects  (214)  and 
plasma  levels  of  8 OH dG  are  higher  in  hypertensive  patients  compared  to 
normotensive subjects (215).  
 
The comet assay or single cell gel electrophoresis is commonly used to assess 
levels of DNA damage in response to oxidative stress (216).  It is frequently used 
to measure and analyse DNA breakage in individual cells and is sensitive to low 
levels  of  DNA  damage  (217).    Damaged  DNA  when  subjected  to  an  electric 
current, following unwinding under alkaline conditions, will migrate out of the 
nucleoid and when stained can be visualised as a comet (218).  The length of the 
comet tail generated is proportional to the level of damage, so that a longer 
comet tail indicates greater damage to DNA.  The comet assay has been used to 
investigate  the  protective  effects  of  antioxidant  treatment  in  various 
intervention studies and to assess oxidative stress both in vitro and in vivo (219).      
      
 
4.2 Aims  
 
•  To assess GST activity following modification of Gstm1 expression 
 
•  To  measure  levels  of  reduced  glutathione,  by  high  performance  liquid 
chromatography (HPLC) 
 
•  To  assess  the  contribution  of  Gstm1  to  oxidative  stress,  using  8 
isoprostane and 8 OH dG assays and the comet assay  
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4.3 Methods 
 
4.3.1 Transfection of NRK52E Cells with siRNA 
 
NRK 52E cells were transfected with anti Gstm1 siRNA (30 to 100nM) as outlined 
in section 2.3. 
 
4.3.2 Cell Culture 
 
HeLa cells were cultured in Eagle’s minimum essential medium supplemented 
with 10% FCS, 100 I.U/ml of penicillin and 100  g/ml of streptomycin.  A10 and 
H9C2 cells were cultured in Dulbecco’s modified Eagle’s medium plus GlutaMAX 
supplemented  with  10%  FCS,  100  I.U/ml  of  penicillin  and  100   g/ml  of 
streptomycin.  All cells were maintained in a 5% CO2 atmosphere at 37°C. 
  
4.3.3 HeLa Cell Infection 
 
To examine the effect of over expression of Gstm1 on GST activity, HeLa cells 
were  infected  with  an  adenovirus  engineered  to  express  the  WKY  version  of 
Gstm1 (RAd WKY Gstm1) (220).  As a negative control, cells were also infected 
with  a  non expressing  vector  (RAd60).    Twenty  four  hours  prior  to  infection, 
HeLa cells were plated out in 6 well plates and infected once approximately 90% 
confluent.  The number of cells in each well was determined by collecting and 
counting the cells from a control well as described in section 2.2.  The number 
of cells/well was then used to calculate the number of virus particles required 
for a multiplicity of infection (MOI) of 10, 50 and 100 and the volume of virus 
required per well was determined by virus titre.  The virus stocks were diluted in 
sterile PBS and added to cell culture medium in each well.  Following overnight 
incubation at 37°C, the virus containing medium was removed and replaced with 
fresh medium.  Forty eight hours after infection, protein was harvested from 
cells as described in section 2.4.  
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4.3.4 Total GST Activity 
 
Total  GST  activity  was  determined  by  the  rate  at  which  glutathione  is 
conjugated  to  1 Chloro 2,4 Dinitrobenzene  (CDNB)  by  glutathione  transferases 
present in each sample (GST Activity kit from Sigma).  Protein samples were 
prepared as described in section 2.4.  Assays were carried out in 96 well plates 
as  per  manufacturer  instructions.    The  substrate  solution  was  prepared  as 
follows: 2 l of 100mM CDNB, 2 l of 200mM reduced GSH and 196 l of DPBS (per 
well).  Control GST was diluted to a final concentration of 25 g/ml.  20 l of 
each sample and 4 l of diluted control GST was added to substrate solution to a 
final volume of 200 l per well and run in duplicate.  Immediately after preparing 
reaction samples, the absorbance from each well was read at 340nm and then at 
1  minute  intervals  until  10  readings  had  been  obtained.    The  increase  in 
absorbance  is  directly  proportional  to  total  GST  activity  in  the  sample.    The 
change in absorbance per minute was used to calculate specific GST activity. 
 
4.3.5 Glutathione Measurement 
 
High performance liquid chromatography (HPLC) (221) was utilised to measure 
levels  of  reduced  GSH  in  NRK 52E  cells  following  knock down  of  Gstm1 
expression. 
 
4.3.5.1 Cell Culture 
 
NRK 52E  cells  were  cultured  in  100mm  plates  until  70%  confluent  and  then 
transfected with 30nM siRNA, as described before. 
4.3.5.2 Sample Preparation 
 
Culture medium was removed from each plate and cells were rinsed twice with 
PBS.  To  detach cells, 3ml of 1X Trypsin EDTA was added  to  each plate  and 
incubated at 37°C for 5 minutes.  Once detached, 10ml of medium containing 
10% FCS was added to inactivate trypsin and cells were transferred to a 50ml 
falcon tube.  Cells were centrifuged at 1000rpm for 5 minutes to pellet cells and 
medium was removed.  200 l of cold 10% metaphosphoric acid was added to   123 
each  NRK 52E  sample  and  incubated  for  10  minutes  at  4°C.    Samples  were 
transferred to 1.5ml centrifuge tubes and centrifuged at 16,000g for 25 minutes 
at  4°C.    The  supernatants  were  transferred  into  fresh  1.5ml  tubes  and 
immediately stored at  80°C. 
 
4.3.5.3 Derivatisation of GSH 
 
To 50 l of each sample, 1ml of 0.1% EDTA in 0.1M sodium hydrogenphosphate 
(pH 8.0) was added.  After mixing well, a 20 l aliquot was removed and to this, 
300 l of 0.1% EDTA in 0.1M sodium hydrogenphosphate and 20 l of 0.1% ortho 
phthalaldehyde (OPA) in methanol was added.  Each sample was briefly vortexed 
to  mix  and  incubated,  in  the  dark,  for  25  minutes  at  25°C.    Glutathione 
standards were prepared in the same way and used to generate a calibration 
curve. 
 
4.3.5.4 Chromatography 
  
Following derivatisation of GSH with OPA, chromatography was performed using 
a Shimadzu LC 10AT HPLC pump with a SIL 9A auto injector and a reverse phase 
column.    The  mobile  phase  consisted  of  12%  methanol  in  25mM  sodium 
hydrogenphosphate,  pH  6.0  and  the  flow  rate  was  held  at  a  constant 
0.8ml/minute.  Fluorescence  was  detected  using the  Perkin  Elmer Series  200 
fluorescence detector and excitation and emission wavelengths were set to 350 
and 420nm respectively.  Data was collected and analysed using the JCL6000 for 
Windows 2.0 Chromatography Data System.  The concentration of GSH in each 
sample was determined from the calibration curve. 
 
4.3.6 Lipid Peroxidation: 8 Isoprostane Assay 
 
Levels of 8 isoprostane in the culture medium of cells transfected with Gstm1 
specific  siRNA  were  measured  using  an  8 isoprostane  ELISA  kit  according  to 
manufacturer’s instructions (Cayman Chemical).   
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4.3.6.1 Sample Preparation 
 
Culture medium samples were collected from cells 48 hours post transfection 
with siRNA (as described before) and assayed immediately.  Each sample was run 
in duplicate alongside 8 isoprostane standards in a 96 well plate.  All standard 
dilutions were  prepared with fresh culture medium.   All assay  reagents  were 
prepared with UltraPure water (Cayman Chemical).  The EIA buffer used in the 
assay was diluted by adding 90ml of UltraPure water to the buffer concentrate 
supplied  with  the  kit.    The  8 isoprostane  tracer  and  8 isoprostane  antiserum 
were reconstituted with 6ml EIA buffer.  Wash buffer was prepared by diluting 
the Wash Buffer concentrate 1:400 and adding Tween 20 (0.5 ml/litre of wash 
buffer).   
 
4.3.6.2 8-isoprostane Assay 
 
Each 96 well plate was set up to include 2 blanks, 2 non specific binding (NSB) 
wells, 2 maximum binding (Bmax) wells and an 8 point standard curve run in 
duplicate.  To each NSB well, 50 l of culture medium, 50 l EIA buffer and 50 l 
of tracer was added.  To each Bmax well, 50 l of culture medium, 50 l of tracer 
and 50 l of antiserum was added.  Antiserum and tracer (50 l) was also added to 
each well containing standard or sample (50 l).  Once all reagents were added, 
the plate was covered with plastic film and incubated for 18 hours at 4°C.  To 
develop  the  plate,  Ellman’s  reagent  was  reconstituted  with  20ml  UltraPure 
water and kept in the dark until ready to use.  Each well was emptied and rinsed 
5 times with wash buffer then 200 l of Ellman’s reagent was added to each well.  
The plate was left in the dark on a shaker for at least 90 minutes to allow the 
plate to develop.  The absorbance was measured at 405nm and readings were 
taken when the Bmax wells reached 0.3 A.U. after the blank wells had been 
subtracted.   
 
4.3.6.3 Analysis 
 
Each absorbance reading was blank corrected and then the average reading from 
the NSB wells was subtracted from the average reading from the Bmax wells to   125 
give  the  corrected  maximum  binding.    The  %  sample  or  standard  bound  / 
maximum  bound  (%B/Bmax)  was  calculated  by  subtracting  the  average  NSB 
absorbance from the average standard or sample absorbance and dividing this by 
the corrected Bmax absorbance. This was then multiplied by 100 to give the 
%B/Bmax.  A standard curve was generated by plotting the %B/Bmax of each of 
the  standards  against  8 isoprostane  concentration  and  used  to  calculate  the 
concentration of 8 isoprostane in each sample. 
 
4.3.7 DNA Damage: Comet Assay  
 
The Trevigen comet assay kit was used to assess damage to DNA following knock 
down  of  Gstm1  expression.    This  assay  works  on  the  basis  of  single  cell  gel 
electrophoresis on a pre treated slide provided with the kit.  
 
4.3.7.1 Cell Preparation 
 
NRK52E  cells  were  transfected  with  100nM  siRNA  as  before  and  cells  were 
examined for DNA damage.  As a control, cells were treated with 100 M H2O2 in 
normal cell culture medium for 20 minutes at 4°C.  Cells were collected using a 
cell scraper and centrifuged at 1500 rpm for 5 minutes to form a pellet.  The 
cell pellet was washed in ice cold PBS, centrifuged again and then re suspended 
in ice cold PBS to 1 x 10
5 cells/ml. 
 
4.3.7.2 Single Cell Gel Electrophoresis 
 
The electrophoresis step was carried out according to kit instructions.  Briefly, 
50 l of each cell suspension was combined with 500 l agarose (pre warmed to 
37°C) and spread evenly over the CometSlide™ area.  Slides were kept in the 
dark  at  4°C  for  10  minutes  and  then  placed  in  lysis  solution  at  4°C  for  40 
minutes.  The slides were then placed in alkaline solution and incubated in the 
dark  at  room  temperature  for  40  minutes.    Slides  were  washed  twice  for  5 
minutes in 1X TBE buffer and then placed in the middle an electrophoresis tank 
containing  1X  TBE,  so  that  the  slides  were  just  covered  with  buffer.  
Electrophoresis  was  carried  out  at  14  volts  for  10  minutes.    After   126 
electrophoresis, slides were removed from the tank and placed in 70% ethanol 
for 5 minutes.  The samples were then left to air dry.    
 
4.3.7.3 Staining 
 
To visualise the DNA, samples were stained with 50 l of diluted SYBR® Green I 
nucleic  acid  gel  stain  (supplied  with  comet  assay  kit)  and  examined under  a 
fluorescence  microscope.    To  evaluate  DNA  damage,  comet  tail  length  was 
measured.  For each slide, up to 60 measurements were taken resulting in a 
maximum of 180 measurements per triplicate group. 
  
4.3.8 DNA Damage: 8 hydroxy 2 deoxy Guanosine Assay 
 
Levels  of  8 hydroxy 2 deoxy  guanosine  (8 OH dG)  were  measured  in  NRK 52E 
cells following transfection with Gstm1 specific siRNA using an 8 OH dG ELISA kit 
(Cayman Chemical) according to the manufacturer’s instructions.  
 
4.3.8.1 Sample Preparation 
 
NRK 52E cells were cultured and transfected using serum free medium as foetal 
calf  serum.    Cell  culture  medium  was  collected  from  NRK 52E  cells 48  hours 
after transfection with siRNA (as described before) and immediately stored at  
80°C until ready to be assayed.  All assay reagents were prepared in UltraPure 
water  (Cayman  Chemical).    The  EIA  Buffer  was  prepared  by  adding  90ml  of 
UltraPure water to the buffer concentrate supplied.  The 8 OH dG tracer and 
antiserum  were  reconstituted  with  6ml  EIA  buffer.    The  wash  buffer  was 
prepared by diluting the Wash Buffer concentrate 1:400 and adding Tween 20 
(0.5ml/litre  of  wash  buffer).    All  standard  dilutions  were  prepared  in  fresh, 
serum free culture medium. 
 
4.3.8.2 8-hydroxy-2-deoxy Guanosine Assay 
 
Each  sample  was  run  in  duplicate  alongside  8 OH dG  standards  in  a  96  well 
plate.  Each plate also contained 2 NSB wells and 2 Bmax wells.  The plate was   127 
set  up  and  assayed  as  described  in  section  4.3.5.2  using  8 OH dG  tracer  and 
antiserum.  The  8 OH 2dG  concentration  was  calculated  as  described  for  8 
isoprostane in section 4.3.5.3.  
 
 
4.4 Results 
 
4.4.1 GST Activity Assay 
 
Prior to investigating the effect of Gstm1 silencing in NRK 52E cells on total GST 
activity,  protein  samples  were  extracted  from  3  different  rat  cell  lines  and 
tested for their basal levels of GST activity.  The following cell lines were used: 
A10 cells (aortic smooth muscle) H9C2 cells (cardiomyocytes) and NRK 52E cells 
(renal  tubular).    Figure  4.1  demonstrates  that  a  measureable  level  of  GST 
activity was present in NRK 52E cells (n=1 experiment performed in duplicate 
and is representative of 3 experiments in total).  In this example, the highest 
level of total GST activity was measured in NRK 52E cells. 
 
Following confirmation that total GST activity was readily detectable in NRK 52E 
cells, the assay was repeated with protein from cells transfected with 100nM 
siRNA to knock down Gstm1.  From the initial experiment carried out it seemed 
that lowering Gstm1 expression resulted in reduced total GST activity as shown 
in  the  top  panel  of  Figure  4.2.    In  this  experiment,  total  GST  activity  was 
reduced by 53% in siRNA A treated cells when compared to control siRNA treated 
cells (siCTL) (p<0.05).  In cells transfected with siRNA B, activity was reduced by 
72% compared to siCTL (p<0.05) but no significant change was observed in siRNA 
C  treated  cells.    However,  this  result  was  not  reproducible.    Instead,  upon 
repeated  experiments  (n=6),  total  GST  activity  levels  were  unaffected  by 
reduced  Gstm1  expression,  with  no  significant  difference  between  cells 
transfected with Gstm1 siRNA and those transfected with control siRNA as shown 
in the bottom panel of Figure 4.2.     128 
 
Figure 4.1 Total GST activity in rat cell lines 
Top panel: GST activity increases over time.  Bottom panel: Total GST activity 
observed in 3 rat cell lines.  Basal  activity was highest in NRK 52E cells  and 
lowest  in  H9C2  cells  (n=1  experiment  performed  in  duplicate  and  is 
representative of 3 experiments in total).  
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Figure 4.2 GST activity following Gstm1 RNAi 
NRK 52E  cells  were  transfected  with  100nM  control  (siCTL)  or Gstm1  specific 
siRNA (A, B or C).  Total protein was extracted and GST activity was measured.  
Top panel: Reduced GST activity was observed in response to siRNA A and B (n=1 
experiment performed in triplicate) *p<0.05 vs siCTL (ANOVA + Dunnett’s post 
hoc  test).    Bottom  panel:  No  change  in  GST  activity  was  observed  following 
knock down of Gstm1 in NRK 52E cells (n=1 experiment performed in triplicate 
and is representative of 6 experiments in total). 
UTF:  untransfected  cells,  TFC:  mock  transfection,  siCTL:  control  siRNA 
transfected cells 
 
 
0 
0.005 
0.01 
0.015 
0.02 
0.025 
UTF  TFC  siCTL  A  B  C 
0 
0.002 
0.004 
0.006 
0.008 
0.01 
0.012 
0.014 
0.016 
0.018 
0.02 
UTF  TFC  siCTL  A  B  C 
* 
* 
A
c
t
i
v
i
t
y
 
 
m
o
l
/
n
g
/
m
i
n
A
c
t
i
v
i
t
y
 
 
m
o
l
/
n
g
/
m
i
n  130 
As total activity could not be modulated by reducing Gstm1 expression, it was 
then investigated if over expression of  Gstm1 could alter GST activity levels.  
For the purposes of this experiment, HeLa cells were used instead of NRK 52E 
cells.  Previous experiments carried out in the laboratory found that NRK 52E 
cells  were  not  amenable  to  infection  with  a  recombinant  adenoviral  vector 
engineered to express Gstm1.  HeLa cells were infected with the empty vector 
RAd60  as  a  negative  control  and  a  recombinant  Ad  vector  expressing  Gstm1 
(RAd_Gstm1) at MOI  of 10, 50 and 100.    Figure 4.3  shows  a  dose  dependent 
increase in total GST activity following the over expression of Gstm1, compared 
to cells infected with an empty vector (n=3).  The RAd60 control vector had no 
significant effect on GST activity.  No significant increase in GST activity was 
observed between RAd_Gstm1 infected cells and RAd60 infected cells at MOI 10.  
At MOI 50, a significant 30% increase in activity was observed between control 
cells  and  Gstm1  over expressing  cells,  p<0.05  and  at  MOI  100,  activity  in 
RAd_Gstm1 infected cells was 63% higher than control cells, p<0.01. 
 
4.4.2 Glutathione Measurement  
 
High  performance  liquid  chromatography  (HPLC)  was  performed  to  measure 
reduced  glutathione  concentration  in  NRK 52E  cells  to  assess  whether  levels 
were affected by reduced Gstm1 expression.  A representative trace is shown in 
Figure 4.4.  The top panel is a representative HPLC chromatogram generated 
from the samples assayed and the bottom panel is a blank control chromatogram 
where only 10% metaphosphoric acid was assayed.  The top panel shows a peak 
representing GSH at a retention time of 2.36 minutes and this was the same for 
all  samples,  no  peak  was  observed  in  the  blank  trace  (bottom  panel).    A 
calibration curve was generated using GSH standards from 2 to 10  M (Figure 
4.5, top panel).  The relative fluorescence generated from each standard was 
plotted against concentration and this was used to calculate the concentration 
of GSH in each unknown sample.  The bottom panel in Figure 4.5 shows the GSH 
concentration measured in each NRK 52E sample.  No significant difference in 
GSH concentration was observed between control and siRNA treated groups.  The 
concentration of glutathione was found to be similar in all groups; 13.36 M in 
the untransfected group, 9.98 M in the mock transfected group, 11.98 M in the 
control siRNA group and 13.68 M in the siRNA B treated group.     131 
 
 
 
Figure 4.3 Total GST activity following over expression of Gstm1 in HeLa cells 
Total GST activity in uninfected (UI) HeLa cells and following infection with a 
non expressing vector (RAd60) or vector expressing Gstm1 (AdGstm1) at MOI of 
10, 50 and 100.  GST activity shows a dose dependent increase in response to 
over expression of Gstm1 compared to RAd 60 infected cells at equivalent MOI 
(n=1 experiment performed in triplicate and is representative of 3 experiments 
in total) *p<0.05 vs Rad60, **p<0.01 vs Rad60 (ANOVA + Dunnett’s post hoc test).  
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Figure 4.4 HPLC analysis of glutathione  
Top panel: Representative HPLC chromatogram of glutathione present in NRK 
52E  cells.    Bottom  panel:  Blank  control  HPLC  chromatogram  with  no  peak 
detected. 
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Figure 4.5 Glutathione measurement 
Top panel: Glutathione calibration curve showing linear relationship in low  M 
range.  Bottom panel: Glutathione concentration in NRK 52E cells transfected 
with 30 nM control (siCTL) or Gstm1 specific siRNA (B).  No difference in GSH 
concentration  was  observed  in  cells  transfected  with  Gstm1  specific  siRNA  B 
when compared to control groups (n=1 experiment performed in triplicate). 
UTF:  untransfected  cells,  TFC:  mock  transfection,  siCTL:  control  siRNA 
transfected cells 
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4.4.3 Lipid Peroxidation 
 
In an attempt to examine what affect reducing Gstm1 expression would have on 
oxidative stress, an ELISA based assay that measures levels of 8 isoprostane was 
used.  Initially the assay was tested on the culture medium from NRK 52E cells 
treated with H2O2 to ensure that a change in 8 isoprostane could be detected 
following induction of oxidative stress.  As indicated in Figure 4.6 (Panel B), 8 
isoprostane levels show a dose and time dependent increase in response to H2O2 
(n=1 experiment performed in duplicate and is representative of 3 experiments 
in  total).    This  indicates  that  8 isprostane  can  be  measured  in  the  culture 
medium from NRK 52E cells. 
 
The  assay  was  then  performed  with  culture  medium  from  NRK 52E  cells 
transfected  with  each  of  the  Gstm1  specific  siRNA  sequences.  In  the  initial 
experiment, 8 isoprostane concentration appeared to be significantly increased 
in response to knock down of Gstm1 as shown in the bottom panel of Figure 4.6.  
In  this  experiment,  treatment  of  NRK 52E  cells  with  siRNA  A  and  C  had  no 
significant  effect  on  8 isoprostane  concentration  but  transfection  of  NRK 52E 
cells with siRNA B resulted in a 96% increase in 8 isoprostane concentration and 
was significant, p<0.05.  However, no significant change in 8 isoprostane was 
observed  following  knock down  of  Gstm1  in  any  other  experiments  (n=6)  as 
shown in Figure 4.7.  Western blot analysis was performed to ensure that GSTM1 
was still being effectively knocked down in each experiment and this is shown in 
a representative blot in Figure 4.7.  Each band was normalised to β actin and the 
densitometry  results  indicated  that  GSTM1 was  successfully  knocked  down  by 
65%,  79%  and  40%  by  siRNA  A,  B  and  C  respectively  when  compared  to  the 
scrambled siRNA control bands. 
 
   135 
 
Figure 4.6 8 Isoprostane measurement 
A: 8 isoprostane standard curve.  B: 8 isoprostane concentration in NRK 52E cells 
following  treatment  with  H2O2.    8 isoprostane  concentration  is  increased  in 
response  to  increasing  concentrations  of  H2O2  (n=1  experiment  performed  in 
duplicate  and  is  representative  of  3  experiments  in  total).    C: NRK 52E  cells 
were transfected with 30nM control (siCTL) or Gstm1 specific siRNA (A, B or C).  
8 isoprostane  concentration  was  significantly  increased  in  NRK 52E  cells 
transfected  with  siRNA  B  compared  to  control  siRNA  transfected  cells  (n=1 
experiment performed in triplicate) *p<0.05 vs siCTL (ANOVA + Dunnett’s post 
hoc test). 
UTF:  untransfected  cells,  TFC:  mock  transfection,  siCTL:  control  siRNA 
transfected cells 
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Figure 4.7 8 Isoprostane measurement and Gstm1 western blot analysis 
NRK 52E  cells  were  transfected  with  30nM  control  (siCTL)  or  Gstm1  specific 
siRNA (A, B or C).  A: No significant change in 8 isoprostane concentration was 
observed  in  cells  transfected  any  Gstm1  specific  siRNA  (n=1  experiment 
performed  in  triplicate  and  is  representative  of  6  experiments  in  total).    B: 
GSTM1  and  β actin  western  blots  indicating  that  GSTM1  protein  levels  were 
reduced in cells transfected with Gstm1 siRNA.  C: Reduced GSTM1 protein was 
confirmed  by  densitometry  with  each  band  normalised  to  β actin  (n=1 
experiment performed in duplicate). 
UTF:  untransfected  cells,  TFC:  mock  transfection,  siCTL:  control  siRNA 
transfected cells 
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4.4.4 DNA Damage 
 
To  examine  whether  reduced  Gstm1  contributes  to  increased  DNA  damage, 
single cell gel electrophoresis was carried out using a comet assay kit.   
 
To  ensure  that  comet  tails  could  be  easily  detected  using  our  available 
resources, NRK 52E cells were treated with increasing concentrations of H2O2 to 
induce  oxidative  stress  before  being  assessed.    Representative  images  of  the 
cells examined are shown in Figure 4.8.  As shown in the top panel of Figure 4.8 
no visible tail was detected in untreated control cells or those that had been 
treated  with  10 M  H2O2.      However,  when  the  concentration  of  H2O2  was 
increased  to  100 M,  a  pronounced  tail  was  clearly  visible  indicating  that  an 
increased level of DNA damage was present in this cell.  At 300 M, a similar 
level of DNA damage was observed. 
 
Following  knock down  of  Gstm1,  a  significant  increase  in  tail  length  was 
observed in cells transfected with either siRNA B or C indicating increased DNA 
damage in these cells (n=3).  Tail length measurements are shown in the chart in 
Figure 4.8.  In this example, when compared to cells transfected with control 
siRNA, tail length increased by 20% in response to siRNA B and 33% in response to 
siRNA C, p<0.05.  No significant increase in tail length was observed in response 
to siRNA A in this example.  Representative comet images obtained from each of 
the  groups  are  shown  in  Figure  4.9.    As  demonstrated  in  this  Figure,  no 
substantial  comet  tails  were  detected  in  any  of  the  control  groups  when 
compared to the H2O2 induced tails as a reference.  In each of the siRNA treated 
groups, comet tails were readily detectable but with variation in length between 
cells and groups. 
 
4.4.5. 8 Hydroxy 2 Deoxyguanosine Measurement 
 
Levels  of  8 OH dG  were  measured  in  the  culture  medium  of  NRK 52E  cells 
following knock down of Gstm1 expression.  Figure 4.10 is representative of 4 
experiments.    As  shown  in  Figure  4.10,  no  significant  difference  in  8 OH dG 
concentration was observed between NRK 52E cells treated with Gstm1 specific 
siRNA B and control siRNA.     138 
 
 
Figure 4.8 Analysis of DNA damage by comet assay  
Top  panel:  Representative  comet  images  from  NRK 52E  cells  stimulated  with 
increasing  concentrations  of  H2O2.    Bottom  panel:  NRK 52E  cells  were 
transfected  with  30nM  control  (siCTL)  or  Gstm1  specific  siRNA  (A,  B  or  C).  
Following knock down of Gstm1 expression by RNAi, increased comet tail length 
was observed compared to the siRNA control indicating increased damage to DNA 
(n=1 experiment performed in triplicate and is representative of 3 experiments 
in total) **p<0.01 vs siCTL (ANOVA + Dunnett’s post hoc test). 
UTF:  untransfected  cells,  TFC:  mock  transfection,  siCTL:  control  siRNA 
transfected cells 
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Figure 4.9 Comet assay analysis 
Representative  images  obtained  from  NRK 52E  cells  transfected  with  30nM 
control (siRNA CONTROL) or Gstm1 specific siRNA (A, B or C).  No clearly visible 
tails were present in any of the control groups (top 3 panels).  Comet tails of 
varying lengths were observed in cells treated with Gstm1 specific siRNA.  
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Figure 4.10 Measurement of 8 hydroxy 2 deoxyguanosine  
8 OH dG was measured in NRK 52E cells following transfection with 30nM control 
(siCTL)  or  Gstm1  specific  siRNA  (B  and  C).    No  significant  change  in 
concentration was observed in response to knock down of Gstm1 expression (n=1 
experiment  performed  in  triplicate  and  is  representative  of  4  experiments  in 
total). 
UTF:  untransfected  cells,  TFC:  mock  transfection,  siCTL:  control  siRNA 
transfected cells 
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4.5 Discussion 
 
The  results  of  the  previous  chapter  show  that  Gstm1  expression  can  be 
selectively knocked down using RNA interference.  In an attempt to translate the 
expression data into a change in Gstm1 activity, a GST assay kit was evaluated.  
At present, there are no selective substrates for Gstm1; instead the kit used 
measures  total  GST  activity  by  measuring  the  rate  at  which  glutathione  is 
conjugated to CDNB, a substrate for a broad range of GST isozymes.  After a 
number of attempts, no significant change in GST activity could be measured in 
response to reduced Gstm1 expression.  Therefore, one obvious conclusion from 
these  experiments  is  that  a  kit  measuring  total  GST  activity  is  not  sensitive 
enough to detect changes when only one member of a large class of enzymes is 
reduced, as reduction of Gstm1 enzyme activity may be masked by other GSTs in 
the sample.  In contrast, total GST activity was increased when Gstm1 was over 
expressed.  This suggests that total GST activity can indeed be modulated when 
a single GST (Gstm1 in this case) is over expressed to a high enough level.  
 
Glutathione transferases detoxify the products of oxidative stress by catalysing 
the  conjugation  of  reduced  glutathione  (GSH)  to  such  products.    Therefore, 
lower  levels  of  GST  expression  may  lead  to  increased  levels  of  GSH.    The 
concentration  of  GSH  in  NRK 52E  cells  with  lower  expression  of  Gstm1  was 
evaluated but no difference in GSH concentration was found.  Again, this is likely 
due to the presence and activity of other GST in the sample.  It is unlikely that 
total GSH levels would be greatly affected by the reduction of one GST when 
other GST isozymes and other enzyme systems such as glutathione peroxidase 
utilise glutathione as a substrate.   
 
As previously mentioned, oxidative stress has been implicated in development of 
hypertension.    Following  knock down  of  Gstm1  by  RNA  interference,  DNA 
damage  and  lipid  peroxidation  were  investigated  as  both  are  markers  of 
oxidative  stress.    Lipid  peroxidation  showed  no  change  in  any  of  the  siRNA 
treated cells demonstrated by the levels of 8 isoprostane in the culture medium.  
This  data  suggests  that  Gstm1  does  not  play  a  role  in  protection  from  lipid 
peroxides; however, it could be that other members of the GST super family are 
compensating for reduced Gstm1 expression.  Treatment of primary cultured rat   142 
cerebral cortical cells with valproate (a mood  stabilising  drug)  inhibited lipid 
peroxidation and also increased Gstm1 and Gsta4 levels (222;223).  This may 
suggest a role for Gstm1 in lipid peroxidation protection.  Previous studies have 
shown a role for alpha class GSTs in reduction  of lipid hydroperoxides (224).  
Therefore,  the  increase  in  Gsta4  may  have  contributed  more  to  lipid 
peroxidation inhibition.  Although 8 isoprostane is a commonly used biomarker 
for lipid peroxidation in vivo, it may not be the best way to assess oxidative 
stress as such products are quite often only minor end products of peroxidation 
and may not give a reliable indication of oxidative stress status (225).   
 
As  well  as  lipid  peroxidation,  DNA  damage  was  investigated  using  the  comet 
assay and by assessing levels of the oxidative DNA damage marker 8 OH dG.  The 
data collected from comet assay analysis show that reduced Gstm1 expression 
was  associated  with  a  small  but  significant  increase  in  comet  tail  length, 
suggesting greater DNA damage in these cells compared to cells transfected with 
control siRNA.  However, this result did not correlate with the results from the 
8 OH dG assay.  No change in 8 OH dG concentration was observed when Gstm1 
expression  was  reduced,  suggesting  that  lowering  Gstm1  expression  does  not 
contribute to oxidative stress mediated DNA damage.  The comet assay detects 
strand  breaks  and  as  such  may  not  represent  damage  resulting  solely  from 
oxidative stress.  In order to enhance evaluation of oxidative DNA damage in 
NRK 52E  cells,  the  comet  assay  could  be  used  in  combination  with 
formamidopyrimidine  DNA  glycosylase  (FPG).    This  enzyme  recognizes  and 
removes oxidative DNA base modifications including 8 OH dG and generates a 
strand  break.    By  measuring  comet  tails  after  incubation  with  FPG  and  then 
subtracting  the  score  obtained  from  cells  without  enzyme  an  indication  of 
oxidative damage could be obtained (216;226).  However, it has been suggested 
that 8 OH dG may not be a particularly reliable marker of oxidative damage to 
DNA.  The initial products generated from free radical attack on DNA bases are 
converted into end products such as 8 OH dG and relative amounts will depend 
on various reaction rates and conditions leading to variation between samples 
(213).    This  may  be  important  when  measuring  8 OH dG  in  vivo  but  in  the 
current study, all assays were performed in medium from cultured cells where 
sample to sample variation is less likely.  It has also been suggested that it is   143 
unreliable  to  measure  one  single  reaction  product  and  use  this  alone  as  an 
indicator of oxidative stress (227).   
 
The current study has assessed various markers of oxidative stress and results 
demonstrated  that  reduction  of  Gstm1  alone  was  not  sufficient  to  cause 
increased oxidative damage.  It may be that expression of other GSTs in NRK 52E 
cells  compensate  for  reduced  Gstm1  expression  and  in  doing  so,  mask  any 
functional significance resulting from Gstm1 knock down.  However, it could be 
the case that Gstm1 is not important for protection against oxidative stress in 
NRK 52E cells.  Previous studies have shown that Gstm1 expression is localised to 
kidney  tubular  epithelium,  particularly  the  collecting  ducts  (77).    Perhaps 
investigating Gstm1 in primary cells isolated from the collecting ducts of SHRSP 
and WKY rats would provide a better model for assessment of the role of Gstm1 
in oxidative stress.  However, it may be that the only way to actually assess the 
function of Gstm1 is to modulate expression in specific cells of interest in vivo.    
   144 
Chapter 5: MicroRNA Analysis in Rat Congenic Strains   145 
5.1 Introduction 
 
The  previous  chapters have  demonstrated  knock down  of  gene  expression  via 
siRNA mediated RNAi.  Analogous to siRNA, microRNAs (miRNA) are a class of 
endogenous  short  RNA  that  drive  post transcriptional  inhibition  of  gene 
expression.  These short regulatory RNAs were first described in C.elegans with 
the  discovery  of  lin 4  and  let 7,  short  transcripts  that  were  found  to  be 
complementary to regions in the 3' UTR of genes involved in larval development 
(228;229).    MicroRNA  induced  gene  silencing  can  result  from  translational 
repression  like  that  observed  in  studies  with  C.elegans  or  from  mRNA 
degradation (230;231).  Unlike siRNAs, miRNAs are generated from endogenous 
transcripts  that  produce  long  hairpin  structures.    These  hairpins  are  further 
processed to generate 21 22 nt mature miRNAs (147 149).  For efficient siRNA 
mediated  gene  knock down,  near  perfect  complementary  base  pairing  is 
required  between  the  siRNA  and  target  mRNA.    However  for  efficient  miRNA 
activity,  it  has  been  suggested  that  complementary  base  pairing  is  most 
important between the miRNA seed region (6 7nt consecutive nucleotides at 5' 
end of miRNA) and the 3' UTR of the target gene, with binding at multiple sites 
(232;233). 
 
 
5.1.1 MicroRNA Target Prediction 
 
Various computational programs have been developed to improve miRNA target 
gene identification, including TargetScan, MiRanda and PicTar.  Each program 
uses  specific  base  pairing  rules  to  identify  miRNA  targets  and  also  take  into 
account cross species conservation of the target site (234).  Target sites can be 
classified according to miRNA interaction.  Those target sites that have perfect 
complementarity with at least the miRNA seed region and substantial pairing at 
the 3' end can be described as 5' dominant canonical sites.  Where perfect base 
pairing is limited to the 5' seed region, target sites are described as 5' dominant 
seed  only.    Targets  where  there  is  imperfect  pairing  to  the  seed  region  but 
considerable pairing to the 3' end of the miRNA are described as 3' compensatory 
target sites (234;235).  Following on from target identification it is important 
then to try and validate the miRNA/mRNA target pair (236).   146 
5.1.2 Microarray Analysis of Gene Expression     
   
It may be possible to further enhance miRNA target identification by combining 
the  computational  systems  described  with  microarray  analysis  of  gene 
expression.  Microarray analysis of rat parental and congenic strains was utilised 
previously by our group, leading to the identification of Gstm1 as a positional 
and potentially functional target in blood pressure regulation (69).  This work 
was performed in 16 week old animals, since then microarrays have been carried 
out in kidney tissue from SHRSP, WKY and congenic animals at 5 weeks and 21 
weeks of age, allowing for examination of changes in gene expression over time.   
 
As well as the 2c* congenic strain, other chromosome 2 congenic strains have 
been generated.  The SP.WKYGla2a (2a) strain is of SHRSP background with a 
region of chromosome 2 incorporating 2 BP QTLs transferred from WKY (70).  The 
SP.WKYGla2k  (2k)  strain  is  of  SHRSP  background  with  a  10  cM  region  of 
chromosome 2 transferred from WKY (237).  The 2a congenic encompasses both 
2c* and 2k congenic regions and the 2c* and 2k regions partially overlap as shown 
in Figure 5.1.  The 2a and 2k strains demonstrate significantly lower baseline and 
salt loaded blood pressure, however the 2c* retains salt sensitivity (237).  Thus 
the region that differs between the 2c* and 2k likely contains genes responsible 
for salt sensitivity. The genes encoding miR 9 1 (rno miR 9 1) and miR 137 (rno 
miR 137) map to the 2c* and 2k congenic regions respectively and may play a 
role  in  baseline  blood  pressure  regulation  (miR 9 1)  and  salt sensitive 
hypertension (miR 137).   
 
Ingenuity  Pathway  Analysis  (IPA)  is  a  web based  data  analysis  tool  and 
knowledge database that can be used to investigate relationships between gene 
expression data generated from microarray and other high throughput analyses.    147 
 
 
 
Figure 5.1 Rat chromosome 2 congenic sub strains 
Chromosome 2 congenic strains were generated by transferring chromosomal 
regions from WKY onto the SHRSP background.  Yellow bars represent regions of 
WKY homozygosity.  Blue bars represent regions of SHRSP homozygosity. 
 
Adapted from (237). 
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Ingenuity Pathway Analysis was combined with microarray analysis of salt loaded 
21 week SHRSP, WKY and 2a strains to identify genes involved in salt sensitivity 
(237).    Using  IPA,  microarray  data  can  potentially  be  integrated  with  results 
from  miRNA  target  prediction  to  identify  genes  which  may  be  differentially 
expressed as a result of miRNA targeting.   
 
 
5.2 Aims 
 
•  To  investigate  the  expression  of  miR 9 1  and  miR 137  in  kidneys  from 
SHRSP, WKY and congenic rat strains at 5 weeks (post weaning), 16 weeks 
(adult) and 21 weeks (post salt challenge) 
 
•  To  identify  potential  miRNA  gene  targets  and  assess  differential 
expression  of  these  targets  in  the  microarray  datasets  previously 
generated 
 
•  To  evaluate  the  ability  of  precursor  miRNA  molecules  and  miRNA 
inhibitors to drive up and knock down miRNA expression in NRK 52E cells  
 
•  To assess expression of predicted miRNA gene targets in rat kidney tissue 
and in NRK 52E cells following modulation of miRNA expression 
 
 
5.3 Materials and Methods 
 
5.3.1 Transfection of NRK 52E Cells 
 
NRK 52E cells were transfected with Pre miR™ miRNA precursors and Anti miR™ 
miRNA inhibitors for rno miR 9 and rno miR 137 (Applied Biosystems) using the 
siPORT™  Amine  transfection  protocol  outlined  in  section  2.3.    All  reagent 
volumes and incubation times were the same as those described in section 2.3, 
replacing  siRNA  with  30nM  to  50nM  of  Pre miR™  or  Anti miR™.    To  assess 
transfection efficiency, cells were transfected with Cy™3 dye labelled Pre miR™   149 
or Anti miR™ negative control sequences and transfection levels were assessed 
by fluorescence microscopy.   All transfection  experiments were performed in 
triplicate and included the following controls: untransfected cells (UTF), cells 
treated with transfection reagent only (TFC) and cells treated with either Pre 
miR™ negative control (Pre CTL) or Anti miR™ negative control (Anti CTL).  
 
 
5.3.2 MicroRNA Extraction 
 
The  miRNeasy  Mini  Kit  (Qiagen)  was  used  for  the  purification  of  total  RNA 
(including miRNA) from NRK 52E cells and frozen rat kidney tissue.  Cultured 
cells and tissues were first homogenized in QIAzol® lysis reagent (phenol and 
guanidine thiocyanate solution).  Each frozen kidney section was transferred into 
5 ml of cold QIAzol® lysis reagent and homogenised with a Polytron 2100 rotor 
homogeniser  at  full  speed.    The  homogenate  was  split  into  700   l  aliquots.   
NRK 52E cells (cultured in 6 well plates) were rinsed twice with PBS and then 
700  l QIAzol® lysis reagent was added to each well.  Cells were homogenized by 
scraping with a pipette tip, transferred to a 1.5 ml centrifuge tube and vortexed 
briefly. 
 
Cell/tissue  homogenates  were  incubated  at  room  temperature  for  5  minutes, 
followed by the addition of 140  l chloroform to each sample.  Samples were 
mixed by shaking vigorously for 15 seconds and incubated at room temperature 
for 2 3 minutes.  This was followed by centrifugation at 12000 g for 15 minutes 
at 4°C to separate the homogenate into aqueous and organic phases.  The upper 
aqueous layer was transferred to a fresh 1.5 ml centrifuge tube and 1.5 volumes 
of 100% ethanol was added and mixed by pipetting.  A maximum of 700  l was 
then applied to the RNeasy Mini spin column and centrifuged at 8000 g for 15 
seconds.  The flow through was discarded and the remaining sample was applied 
to the column and centrifuged as before.  The column was washed with 700  l 
buffer  RWT,  centrifuged  at  8000  g  for  15  seconds  and  the  flow through 
discarded.  The column was then washed with 500  l buffer RPE and centrifuged 
at 8000 g for 15 seconds.  This wash step was repeated but with centrifugation 
at 8000 g for 2 minutes.  The flow through was discarded and columns were 
centrifuged again for 1 minute to dry the column membrane.     150 
To elute RNA, nuclease free water was added to the column membrane.  For 
tissue  RNA  samples,  40   l  of  nuclease free  water  was  added  to  the  column 
membrane  and  centrifuged  for  1  minute  at  8000  g.    This  elution  step  was 
repeated with 40  l nuclease free water and centrifuged again at 8000 g for 1 
minute.   For cell RNA samples, 40  l of nuclease free water was added to the 
column membrane and centrifuged at 8000 g for 1 minute.  The flow through 
(containing RNA) was applied to the column membrane again and centrifuged at 
8000 g for 1 minute.  All RNA samples were subjected to DNase treatment as 
described in section 2.6.1 and quantified as described in section 2.6.2. 
 
 
5.3.3 MicroRNA Reverse Transcription  
 
The TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems) was used 
to generate cDNA for analysis of miRNA expression with miRNA specific primers 
and TaqMan® MicroRNA Assays.  Each RNA sample was diluted in nuclease free 
water to 2 ng/ l and 5  l of this was used in each reverse transcription reaction.  
The reverse transcription reaction mix was prepared as follows: 
•  1.5  l 10X RT Buffer 
•  0.15  l dNTP mix 
•  1  l MultiScribe reverse transcriptase (50 U/ l) 
•  0.19  l RNase inhibitor (20 U/ l) 
•  4.16  l nuclease free water 
 
This was added to 5  l of the diluted RNA sample and 3  l of the specific miRNA 
primer (supplied with the TaqMan® MicroRNA Assay, Applied Biosystems) to give 
a final reaction volume of 15  l.  Reverse transcription was carried out in a 96 
well plate using the following thermal cycling parameters: 
•  30 minutes at 16°C 
•  30 minutes at 42°C 
•  5 minutes at 85°C 
 
cDNA samples were stored at  20°C. 
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5.3.3.1 TaqMan® MicroRNA Assays 
 
Quantitative  real time  PCR  was  performed  using  TaqMan®  MicroRNA  Assays 
(Applied Biosystems) for quantification of rat miR 9 1 (Assay ID: 000583, hsa 
miR 9) and rat miR 137 (Assay ID: 001129, mmu miR 137).  Expression of each 
miRNA was normalised to U87 (control miRNA, Assay ID: 001712) and expression 
levels were determined using the comparative CT method (2
   Ct) (171).  For each 
miRNA assay, a 20  l simplex reaction was prepared in a 96 well plate as follows: 
•  10  l 2X TaqMan® Universal PCR master mix 
•  1  l 20X TaqMan® MicroRNA Assay 
•  7.6  l nuclease free water 
•  1.2  l RT product 
 
Each reaction was performed in duplicate and subjected to the thermal cycling 
parameters described in section 2.7.1. 
 
 
5.3.4 miR 9 Target Genes: mRNA Expression 
 
Quantitative  RT PCR  was  performed  on  cDNA  using  TaqMan  Gene  Expression 
Assays (Applied Biosystems) for the following genes:   
 
 
Gene ID  Gene Name  Assay ID 
Adamts1  ADAM metallopeptidase with 
thrombospondin type 1 motif, 1  Rn01646120_m1 
Comt  Catechol O methyltransferase  Rn00561037_m1 
Ctsb  Cathepsin B  Rn00575030_m1 
Igfbp3  Insulin like growth factor binding protein 3  Rn01401281_m1 
Igsf11  Immunoglobulin superfamily, member 11  Rn01439426_m1 
Scly  Selenocysteine lyase  Rn01427211_m1 
Trim35  Tripartite motif containing 35  Rn01534954_m1   152 
 
The expression of each gene of interest was normalised to β actin expression 
and all assays were performed in simplex as described in section 2.7.1. 
 
 
5.4 Results 
 
5.4.1 Rat Kidney Expression of miR 9 1 and miR 137 
 
The expression levels of miR 9 1 and miR 137 were examined in kidney tissue 
from SHRSP, WKY and congenic strains at various time points to assess whether 
miRNA expression differs between strains.  Figure 5.2 shows the levels of miR 9 
expression in SHRSP, 2c* and WKY kidney at 5, 16 and 21 weeks of age (n=4).  No 
significant  change  in  miR 9  levels  was  observed  at  any  time point  in  SHRSP.  
However, a significant decrease in miR 9 expression was observed between 5 
and 16 weeks of age in 2c* and WKY animals, p<0.05.  Figure 5.3 shows the 
levels of miR 137 expression in SHRSP, WKY and 2k kidney at 5, 16 and 21 weeks 
of  age  and  at  21  weeks  with  salt  (n=4).    No  significant  change  in  miR 137 
expression was observed in 2k or WKY strains regardless of time point or salt 
loading.  However, a significant increase in miR 137 expression was observed in 
21 week old salt loaded SHRSP compared to 21 week old SHRSP animals without 
salt, p<0.05. 
   153 
 
Figure 5.2 Kidney miR 9 1 expression levels 
TaqMan®  qRT PCR  analysis  of  miR 9 1  expression  in  rat  kidney  shows  that 
expression of miR 9 1 was unchanged across all time points in SHRSP.  Expression 
of miR 9 1 was significantly reduced in 16 week 2c* and WKY kidney compared to 
5 week, n=4, *p<0.05. 
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Figure 5.3 Kidney miR 137 expression levels 
TaqMan®  qRT PCR  analysis  of  miR 137  expression  in  rat  kidney  shows  that 
expression  of  miR 137  was  unchanged  across  all  time points  in  2k  and  WKY 
kidney.  Expression of miR 137 was significantly increased in 21 week salt loaded 
SHRSP compared to 21 week SHRSP without salt, n=4, *p<0.05. 
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5.4.2 In Vitro Modulation of miR 9 1 and miR 137 Expression 
 
To  modulate  expression  of  miR 9 1  and  miR 137  in  vitro,  Pre miR™  miRNA 
precursors or Anti miR™ miRNA inhibitors were used.  The transfection efficiency 
of  NRK 52E  cells  for  transfection  of  Pre miR™  and  Anti miR™  molecules  was 
assessed  using  Cy™3  labelled  control  versions  of  both.    Figure  5.4  shows  a 
representative Cy™3 labelled control Pre miR™ transfection experiment.  Panel B 
demonstrates  that  no  fluorescence  is  generated  when  NRK 52E  cells  are 
subjected  to  a  mock  transfection  (treated  with  transfection  reagent  only).  
However,  when  cells  are  treated  with  30nM  Cy™3  labelled  control  Pre miR™, 
fluorescence  is  detected  throughout  (panel  C).    The  level  of  fluorescence 
observed  indicates  that  at  least  70%  transfection  efficiency  was  achieved.  
Figure 5.5 shows a representative Cy™3 labelled control Anti miR™ transfection 
experiment.  As before, cells subjected to a mock transfection do not generate 
fluorescence (Figure  5.5, panel B).  Initial experiments  performed with 30nM 
Cy™3  labelled  control  Anti miR™  did  not  achieve  the  levels  of  transfection 
observed with the Pre miR™.  However, when increased to 50nM, similar levels 
of transfection efficiency were achieved, as shown in Figure 5.5, panel C. 
 
Following  confirmation  of  efficient  transfection  of  NRK 52E  cells  with  control 
Pre miR™ and Anti miR™, transfections were repeated with miR 9 1 and miR 137 
Pre miR™ and Anti miR™ molecules.  The ability to over express each miRNA was 
evaluated  first.    Figure  5.6  is  representative  of  4  individual  experiments 
performed in triplicate.  The top panel of Figure 5.6 shows the results obtained 
from  transfection  of  NRK 52E  cells  with  30nM  Pre miR 9.    In  this  example, 
transfection  with  Pre miR 9  resulted  in  a  1928  fold  increase  in  miR 9 1 
expression  compared  to  cells  transfected  with  control  Pre miR  (Pre CTL), 
p<0.0001.  Across the 4 experiments, expression of miR 9 was increased up to 
2629  fold.    The  bottom  panel  of  Figure  5.6  shows  the  results  obtained  from 
transfection of NRK 52E cells with 30nM Pre miR 137.  In this example, miR 137 
expression  was  increased  2278  fold  in  cells  transfected  with  Pre miR 137 
compared to Pre CTL cells, p<0.0001.   156 
 
 
 
Figure 5.4 Pre miR transfection efficiency of NRK 52E cells 
Panel A: Transmitted light image of NRK 52E cells.  B: Mock transfected cells 
showing  no  background  fluorescence.    C:  Cells  transfected  with  30nM  Cy™3 
labelled Pre miR.  Comparison with transmitted light image of the same field (A) 
suggests high transfection efficiency.  Scale bar: 50 m  
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Figure 5.5 Anti miR transfection efficiency of NRK 52E cells 
Panel A: Transmitted light image of NRK 52E cells.  B: Mock transfected cells 
showing  no  background  fluorescence.    C:  Cells  transfected  with  50nM  Cy™3 
labelled Anti miR.  Comparison with transmitted light image of the same field 
(A) suggests high transfection efficiency.  Scale bar: 50 m 
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The  ability  to  inhibit  miR 9 1  and  miR 137  expression  was  then  assessed  by 
transfecting  NRK 52E  cells  with  50nM  of  each  miRNA  inhibitor.    Figure  5.7  is 
representative  of  4  individual  experiments  performed  in  triplicate.    The  top 
panel  indicates  that  miR 9 1  expression  was  not  reduced  in  cells  transfected 
with  Anti miR 9  as  no  significant  change  in  expression  was  detected.    The 
bottom panel of Figure 5.7 shows the results obtained from transfection of NRK 
52E cells with Anti miR 137.  Expression of miR 137 was not inhibited although 
expression levels were found to be highly variable. 
 
 
5.4.3 Target Identification and Ingenuity Pathway Analysis 
 
Target genes were identified by searching for perfect complementarity between 
miR seed regions (miR 9 1 and miR 137) and the 3' UTR of genes represented on 
the  microarray  chips  used  previously.    The  seed  region  was  designated  as  a 
consecutive stretch of 6 nucleotides starting from the second nucleotide at the 
5' end of the mature miRNA.   
 
 
The sequence marked in red was used to search through 3' UTRs for regions that 
would base pair with each miRNA.  A list of predicted gene targets for miR 9 1 
and miR 137 was generated (see Table A1 and A2 in the appendix for full list of 
genes)  and  uploaded  to  the  Ingenuity  Pathway  Analysis  (IPA)  website.
5' CCAAAG 3' 
3' AGUAUGUCGAUCUAUUGGUUUCU 5' miR 9 1 
3' GAUGCGCAUAAGAAUUCGUUAUU 5' 
5' GCAATA 3' 
miR 137   159 
 
 
Figure 5.6 Over expression of microRNAs in NRK 52E cells 
TaqMan®  qRT PCR  analysis  of  miRNA  expression  in  NRK 52E  cells  following 
transfection with Pre MiR.  Top panel: Following transfection of cells with 30nM 
Pre miR 9, miR 9 1 expression was significantly increased (~1900 fold) compared 
to Pre CTL (n=1 experiment performed in triplicate and is representative of 4 
experiments in total) *p<0.0001 vs Pre CTL (ANOVA + Dunnett’s post hoc test).  
Bottom panel: Following transfection of cells with 30nM Pre miR 137, miR 137 
expression was  significantly increased (~2000 fold)  compared  to Pre CTL (n=1 
experiment  performed  in  triplicate  and  is  representative  of  4  experiments  in 
total) *p<0.0001 vs Pre CTL (ANOVA + Dunnett’s post hoc test). 
UTF: untransfected cells, TFC: mock transfected cells, Pre CTL: Control Pre miR 
transfected cells 
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Figure 5.7 Effect of Anti miR transfection on miRNA expression in NRK52E 
cells 
TaqMan®  qRT PCR  analysis  of  miRNA  expression  in  NRK 52E  cells  following 
transfection with Anti miR.  Top panel: Following transfection of cells with 50nM 
Anti miR 9, no significant change in miR 9 1 expression was observed compared 
to Anti CTL (n=1 experiment performed in triplicate and is representative of 4 
experiments in total).  Bottom panel: Following transfection of cells with 50nM 
Anti miR 137,  no  significant  change  in  miR 137  expression  was  observed 
compared  to  Anti CTL  (n=1  experiment  performed  in  triplicate  and  is 
representative of 4 experiments in total). 
UTF: untransfected cells, TFC: mock transfected cells, Anti CTL: Control Anti 
miR transfected cells 
 
0 
0.5 
1 
1.5 
2 
2.5 
3 
UTF  TFC  Anti CTL  Anti miR 9 
0 
2 
4 
6 
8 
10 
12 
UTF  TFC  Anti CTL  Anti miR 137 
RQ 
RQ   161 
Using  IPA,  the  list  of  targets  was  combined  with  gene  expression  datasets 
generated  from  5  week,  16  week,  21  week  and  21  week  plus  salt  kidney 
microarray analysis carried out previously.  The predicted targets identified for 
miR 9 1 were combined with SHRSP, WKY and congenic microarray datasets (16 
week  versus  5  week)  to  identify  genes  that  were  up regulated  in  both  the 
congenic  and  WKY  datasets  but  not  in  the  SHRSP  dataset  (as  kidney  miR 9 1 
expression  was  lower  in  16  week  WKY  and  congenic  but  was  unchanged  in 
SHRSP).    The  predicted  targets  identified  for  miR 137  were  combined  with 
SHRSP,  WKY  and  congenic  microarray  datasets  (21  week  versus  21  week plus 
salt) to identify genes that were down regulated in the SHRSP comparison but 
were unchanged in both WKY and congenic datasets (as SHRSP kidney miR 137 
expression was greater in 21 week old animals with salt than in 21 week old 
animals  without  but  was  unchanged  in  the  congenic  and  WKY).    Table  5.1 
contains information regarding miR 9 1 seed/target interactions of gene targets 
identified by IPA.  Of the list of targets uploaded, 7 were found that were up 
regulated  and  common  to  both  the  congenic  and  WKY  (Figure  5.8)  but  were 
unchanged in the SHRSP (Figure 5.9).  The following genes were identified: ADAM 
metallopeptidase with thrombospondin type 1 motif, 1 (Adamts1), Cathepsin B 
(Ctsb), Catechol O methyltransferase (Comt), Insulin like growth factor binding 
protein  3  (Igfbp3),  Immunoglobulin  superfamily,  member  11  (Igsf11), 
Selenocysteine lyase (Scly) and Tripartite motif containing 35 (Trim35). Table 
5.2 outlines the miR 9 1 gene targets identified by IPA.  However, analysis of the 
miR 137 targets failed to find any genes that were down regulated in the SHRSP 
21  week/21  week  salt  dataset  and  unchanged  in  both  congenic  and  WKY 
datasets.  
 
 
5.4.4 Expression of miR 9 1 Target Genes 
 
The mRNA expression levels of the gene targets identified by IPA were examined 
in kidney tissue from SHRSP, WKY and congenic strains at 5 weeks and 16 weeks 
of age (n=4 for each target gene) and in NRK 52E cells transfected with Pre miR 
9 1  (each  figure  is  representative  of  4  individual  experiments  performed  in 
triplicate).    162 
 
 
 
 
 
 
 
 
Table 5.1 Seed site information for predicted miR 9 1 targets  
A1: nucleotide at first position downstream of the seed match, M8: nucleotide at 
first position upstream of the seed match  
 
RefSeq  Gene  No. of 
Seeds 
Position in 3' 
UTR  A1  M8 
NM_024400  Adamts1  1  230  T  C 
NM_012531  Comt  1  212  G  G 
NM_022597  Ctsb  1  337  G  T 
NM_012588  Igfbp3  1  209  T  G 
NM_001013120  Igsf11  1  1197  A  C 
NM_001007755  Scly  2  601  T  G 
                 756  G  G 
NM_001025142  Trim35  1  106  T  C   163
 
Congenic (16wk V 5wk)  WKY (16wk V 5wk)  SHRSP (16wk V 5wk) 
RefSeq  Gene  Location 
Mean 
Difference  p value  Mean 
Difference  p value  Mean 
Difference  p value 
NM_024400  Adamts1  11q11  1.031  0.0125  1.106  0.0054  1.695  0.2055 
NM_012531  Comt  11q23  1.141  0.0025  1.907  5.74E
 6  1.056  0.0992 
NM_022597  Ctsb  15p12  1.823  0.0173  1.591  4.13E
 6  1.474  0.1278 
NM_012588  Igfbp3  14q21  1.310  0.0515  3.002  7.63E
 6  1.066  0.4538 
NM_001013120  Igsf11  11q21  1.037  0.0218  1.802  5.40E
 6  0.751  0.2495 
NM_001007755  Scly  9q36  0.775  0.0124  1.107  2.10E
 4  0.281  0.7195 
NM_001025142  Trim35  15p12  1.552  0.0090  2.172  0.0011  1.893  0.0803 
 
 
 
 
Table 5.2 Microarray expression data: predicted miR 9 1 targets 
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Figure 5.8 Ingenuity Pathway Analysis of congenic and WKY microarray 
datasets 
Data output from Ingenuity Pathway Analysis of predicted miR 9 1 target genes.  
Seven targets were identified that were up regulated in 16 week versus 5 week 
datasets and common to both congenic and WKY strains.  Red represents up 
regulation  of  genes  and  colour  intensity  represents  the  significance  of  up 
regulation. 
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Figure 5.9 Ingenuity Pathway Analysis of SHRSP microarray datasets 
Data output from Ingenuity Pathway Analysis of predicted miR 9 1 target genes.  
Data shows that predicted miR 9 1 targets are not differentially expressed in 16 
week versus 5 week SHRSP microarray dataset. 
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As miR 9 1 expression was found to be down regulated in 16 week compared to 5 
week old 2c* and WKY strains, it would be expected that miR 9 1 target genes 
would  be  up regulated  in  these  strains  at  16  weeks  compared  to  5  weeks.  
Conversely, target gene expression would be expected to go down in NRK 52E 
cells where miR 9 1 has been over expressed.  The functions of each gene target 
are summarised in Table 5.3.    
 
 
5.4.4.1 Adamts1 
 
Kidney mRNA expression of Adamts1 showed no change between 5 and 16 week 
old  2c*  but  was  significantly  up regulated  by  6.5  fold  in  16  week  old  WKY 
compared to 5 week, p<0.05 (Figure 5.10, top panel).  No significant change in 
expression was observed between 5 and 16 week old SHRSP.  The bottom panel 
of  Figure  5.10  shows  Adamts1  expression  in  NRK 52E  cells  following  over 
expression  of  miR 9 1.    No  significant  change  in  Adamts1  expression  was 
observed in NRK 52E cells treated with Pre miR 9. 
 
5.4.4.2 Comt 
 
No significant difference in Comt expression was observed between 5 week and 
16  week  time points  in  SHRSP  and  WKY  strains  (Figure  5.11,  top  panel).  
However a significant 1.3 fold increase in expression was detected in 16 week 
2c* compared to 5 week, p<0.05.  Over expression of miR 9 1 in NRK 52E cells 
had no significant effect on Comt expression (Figure 5.11, bottom panel). 
 
5.4.4.3 Ctsb 
 
No significant difference in Ctsb mRNA expression was observed between 5 and 
16 week time points in any of the strains (Figure 5.12, top panel).  Expression of 
Ctsb  in  NRK 52E  cells  showed  no  significant  difference  following  transfection 
with Pre miR 9 (Figure 5.12, bottom panel).   
 
 
 
Table 5.3 Functional information of each miR 9 1 predicted target gene identified by 
IPA 
 
Gene  Function  Refs 
Adamts1 
Binds VEGF and inhibits VEGFR2 phosphorylation.  Inhibits 
endothelial cell proliferation.  Inhibits tumour growth and 
has anti angiogenic function. 
(238 240) 
Comt 
Catalyses the methylation and inactivation of catecholamine 
neurotransmitters.  Possible role in BP regulation in SHR and 
Dahl S rats.  Decreased levels have been shown to associate 
with pre eclampsia 
(241 243) 
Ctsb  Role in cell proliferation, tumour development and tumour 
progression.  Possible target for cancer therapy.  (244;245) 
Igfbp3  Role in growth, proliferation and apoptosis.  Shown to have 
anti proliferative and pro apoptotic functions  (246) 
Igsf11  Preferentially expressed in brain and testes.  Regulates cell 
growth and is elevated in various cancers.  (247;248) 
Scly  Metabolism of L selenocysteine  (249) 
Trim35  Member of the tripartite motif containing family with roles 
in cell growth, proliferation and apoptosis  (250;251)   168 
 
 
 
Figure 5.10 Adamts1 mRNA expression 
TaqMan® qRT PCR analysis of Adamts1 mRNA expression.  Top panel: Expression 
of  Adamts1  in  kidney  of  SHRSP, congenic  and  WKY  strains  at  different  time 
points.  No significant change in expression was observed in SHRSP or congenic 
but  was  significantly  increased  in  16  week  WKY  compared  to  5  week  (n=4) 
*p<0.05  vs  5wk  WKY  (2  sample  t test).    Bottom  panel:  Adamts1  expression 
following  transfection  of NRK 52E  cells  with  30nM  control  (Pre CTL)  or  miR 9 
precursor (Pre miR 9).  No significant change in expression was observed (n=1 
experiment  performed  in  triplicate  and  is  representative  of  4  experiments  in 
total). 
UTF: untransfected cells, TFC: mock transfected cells, Pre CTL: Control Pre miR 
transfected cells 
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Figure 5.11 Comt mRNA expression 
TaqMan® qRT PCR analysis of Comt mRNA expression.  Top panel: Expression of 
Comt in kidney of SHRSP, congenic and WKY strains at different time points.  No 
significant  change  in  expression  was  observed  in  SHRSP  or  WKY  but  was 
significantly increased in 16 week congenic compared to 5 week (n=4) *p<0.05 vs 
5wk 2c* (2 sample t test).  Bottom panel: Comt expression following transfection 
of NRK 52E cells with 30nM control (Pre CTL) or miR 9 precursor (Pre miR 9).  No 
significant  change  in  expression  was  observed  (n=1  experiment  performed  in 
triplicate and is representative of 4 experiments in total). 
UTF: untransfected cells, TFC: mock transfected cells, Pre CTL: Control Pre miR 
transfected cells  
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Figure 5.12 Ctsb mRNA expression 
TaqMan® qRT PCR analysis of Ctsb mRNA expression.  Top panel: Expression of 
Ctsb in kidney of SHRSP, congenic and WKY strains at different time points.  No 
significant change in expression was observed in any of the strains, regardless of 
time point (n=4).  Bottom panel: Ctsb expression following transfection of NRK 
52E  cells  with  30nM  control  (Pre CTL)  or  miR 9  precursor  (Pre miR 9).    No 
significant  change  in  expression  was  observed  (n=1  experiment  performed  in 
triplicate and is representative of 4 experiments in total). 
UTF: untransfected cells, TFC: mock transfected cells, Pre CTL: Control Pre miR 
transfected cells 
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5.4.4.4 Igfbp3 
 
No significant difference in Igfbp3 expression was observed between 5 and 16 
week time points in any of the strains (Figure 5.13, top panel).  No significant 
change in Igfbp3 expression was observed in Pre miR 9 transfected NRK 52E cells 
when  compared  to  Pre CTL  transfected  cells.    However,  expression  was 
markedly  reduced,  by  approximately  10  fold  in  all  cell  groups  treated  with 
transfection  reagent  compared  to  untransfected  cells,  p<0.05  (Figure  5.13, 
bottom panel). 
 
5.4.4.5 Igsf11 
 
No significant change in expression of Igsf11 was observed in SP or WKY between 
5  week  and  16  week.    A  significant  decrease  in  Igsf11  expression  of 
approximately 2 fold was observed in 16 week 2c* compared to 5 week, p<0.05 
(Figure 5.14).  No detectable level of Igsf11 expression was found in NRK 52E 
cells. 
 
5.4.4.6 Scly 
 
No significant difference in Scly expression was observed between 5 and 16 week 
time points  in  any  of  the  strains  (Figure  5.15,  top  panel).    No  change  in 
expression was observed in NRK 52E cells transfected with Pre miR 9 compared 
to Pre CTL transfected cells (Figure 5.15, bottom panel). 
 
5.4.4.7 Trim35 
 
No significant change in Trim35 expression was observed between 5 and 16 week 
time points  in  any  of  the  strains.  (Figure  5.16,  top  panel).  172 
 
 
Figure 5.13 Igfbp3 mRNA expression 
TaqMan® qRT PCR analysis of Igfbp3 mRNA expression.  Top panel: Expression of 
Igfbp3 in kidney of SHRSP, congenic and WKY strains at different time points.  
No significant change in expression was observed in any of the strains, regardless 
of time point (n=4).  Bottom panel: Igfbp3 expression following transfection of 
NRK 52E cells with 30nM control (Pre CTL) or miR 9 precursor (Pre miR 9).  No 
significant change in  expression was observed compared to  Pre CTL, however 
when  compared  to  UTF  all  other  groups  were  significantly  reduced  (n=1 
experiment  performed  in  triplicate  and  is  representative  of  4  experiments  in 
total) *p<0.05 vs UTF (ANOVA + Dunnett’s post hoc test). 
UTF: untransfected cells, TFC: mock transfected cells, Pre CTL: Control Pre miR 
transfected cells 
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Figure 5.14 Igsf11 mRNA expression 
TaqMan®  qRT PCR  analysis  of  Igsf11  mRNA  expression  in  kidney  of  SHRSP, 
congenic  and  WKY  strains  at  different  time points.    No  significant  change  in 
expression was observed in SHRSP or WKY between 5 week and 16 week time 
points.    Igsf11  expression  was  significantly  decreased  in  16  week  congenic 
compared to 5 week (n=4) *p<0.05 vs 16 wk 2c* (2 sample t test).    
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Figure 5.15 Scly mRNA expression 
TaqMan® qRT PCR analysis of Scly mRNA expression. Top panel: Expression of 
Scly in kidney of SHRSP, congenic and WKY strains at different time points.  No 
significant change in expression was observed in any of the strains, regardless of 
time point (n=4).  Bottom panel: Scly expression following transfection of NRK 
52E  cells  with  30nM  control  (Pre CTL)  or  miR 9  precursor  (Pre miR 9).    No 
significant  change  in  expression  was  observed  (n=1  experiment  performed  in 
triplicate and is representative of 4 experiments in total). 
UTF: untransfected cells, TFC: mock transfected cells, Pre CTL: Control Pre miR 
transfected cells 
0 
0.5 
1 
1.5 
2 
2.5 
3 
UTF  TFC  Pre CTL  Pre miR 9 
RQ 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
1.6 
SHRSP   2c*  WKY 
RQ 
5wk 
16wk   175 
 
 
 
Figure 5.16 Trim35 mRNA expression 
TaqMan® qRT PCR analysis of Trim35 mRNA expression. Top panel: Expression of 
Trim35 in kidney of SHRSP, congenic and WKY strains at different time points.  
No significant change in expression was observed in any of the strains, regardless 
of time point (n=4).  Bottom panel: Trim35 expression following transfection of 
NRK 52E cells with 30nM control (Pre CTL) or miR 9 precursor (Pre miR 9).  No 
significant  change  in  expression  was  observed  (n=1  experiment  performed  in 
triplicate and is representative of 4 experiments performed in triplicate). 
UTF: untransfected cells, TFC: mock transfected cells, Pre CTL: Control Pre miR 
transfected cells 
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No change in Trim35 expression was observed in NRK 52E cells following over 
expression of miR 9 (Figure 5.16, bottom panel).      
 
 
5.5 Discussion 
 
As  previously  mentioned,  miR 9 1  and  miR 137  map  within  the  2c*  and  2k 
congenic  regions.    Using  commercially  available  TaqMan®  probes  designed  to 
detect  and  quantify  mature  miRNAs,  it  has  been  possible  to  investigate 
expression of miR 9 1 and miR 137 in kidney tissue from SHRSP, congenic and 
WKY animals.  As the mature miRNA is the active species responsible for binding 
to  the  3'  UTR  of  target  mRNA  and  subsequent  inhibition  of  gene  expression, 
quantification of mature miRNA is preferred (252).  Kidney expression of mature 
miR 9 1 was found to be higher in 5 week old than 16 week old congenic and 
WKY  strains.    However,  expression  of  miR 9 1  in  SHRSP  was  unchanged  over 
time.    Kidney  expression  of  mature  miR 137  was  found  to  be  higher  in  salt 
loaded 21 week old SHRSP than in 21 week old SHRSP without salt loading.  No 
significant change in miR 137 expression was observed in kidney from congenic 
and  WKY strains  at any  time point.   This  suggests  that miR 137 and its gene 
targets may be play a role in salt sensitivity in the SHRSP.   
 
To aid in the validation of miRNA/mRNA target pairs, ‘gain of function’ and/or 
‘loss  of  function’  experiments  can  be  performed  (236).    If  a  predicted 
miRNA/mRNA is valid then over expression of a miRNA mimic (gain of function) 
would result in reduced target expression and inhibition of a miRNA by antisense 
oligonucleotides (loss of function) would result in increased target expression.  
NRK 52E cells were transfected with miRNA precursor and inhibitor molecules for 
miR 9 1 and miR 137 and the ability of each miRNA to be up regulated or down 
regulated was assessed.  Using precursor miRNA molecules (designed to mimic 
mature  miRNAs);  expression  of  miR 137  and  miR 9 1  was  significantly  up 
regulated.    However,  when  NRK 52E  cells  were  transfected  with  miRNA 
inhibitors,  no  down regulation  of  either  miRNA  was  observed.    Anti miRNA 
antisense  oligonucleotides  (ASO)  have  been  used  previously  in  attempts  to 
modulate  miRNA  expression  to  improve  target  validation.    Antisense 
oligonucleotides  are  chemically  modified  single  stranded  RNA  molecules  and   177 
have been used to target and inhibit mature miRNA (253).  However, measuring 
the  level  of  miRNA  inhibition  can  be  difficult.    Neither  miR 9 1  nor  miR 137 
inhibition was detectable by qRT PCR.  Other studies investigating the efficacy 
of  miRNA  inhibition  by  ASO  have  utilised  reporter  constructs  to  demonstrate 
reduced  miRNA  activity.    Cheng  and  colleagues  used  a  luciferase  reporter 
construct  engineered  so  that  the  3'  UTR  contained  miRNA  target  sites.    The 
reporter  constructs  and  miRNA  inhibitors  were  then  co transfected  into  HeLa 
cells.    In  those  cells  treated  with  miRNA  inhibitor,  luciferase  activity  was 
increased  due  to  the  inhibition  of  endogenous  miRNA  thus  preventing  miRNA 
mediated repression of reporter gene expression (254).  A luciferase reporter 
system  was  also  used  to  assess  the  effect  of  different  ASO  chemical 
modifications on ASO activity after attempts to measure target expression by RT 
PCR were not sensitive enough to detect subtle changes following ASO treatment 
(255). An EGFP reporter construct containing a miR 21 complementary sequence 
in the 3' UTR was used to evaluate anti miR 21 activity in HeLa cells.  Expression 
of EGFP was restored when cells were transfected with anti miR 21 (256).  The 
expression  data  generated  from  TaqMan®  analysis  of  miR 9 1  and  miR 37 
suggests that expression is quite low in NRK 52E cells and may explain why it was 
not  possible  to  detect  reduced  miRNA  expression  by  qRT PCR.    In  future 
experiments involving analysis of miRNA activity a reporter construct method 
could be used in conjunction with qRT PCR of mature miRNA to further enhance 
miRNA expression analysis. 
 
It has been shown that over expression of miR 9 1 and miR 137 can be readily 
achieved  in  NRK 52E  cells.    This  over expression  was  then  used  to  try  and 
validate  predicted  miRNA  targets.    Target  validation  has  proved  to  be 
problematic.    The  targets  of  interest  were  identified  using  a  computational 
method  to  find  3'  UTR  sequences  complementary  to  the  miRNA  seed  region 
combined  with  bioinformatic  analysis  to  identify  which  targets  were 
differentially expressed.  Analysis found 7 predicted target genes for miR 9 1 but 
none for miR 137.  The mRNA expression levels of each predicted target were 
assessed in kidney tissue and in NRK 52E cells over expressing miR 9 1.  None of 
the  predicted  targets  followed  the  pattern  of  expression  expected  in  kidney 
tissue and no significant changes in target expression were observed in NRK 52E 
cells following over expression of miR 9 1.     178 
 
The lack of miR 9 1 induced changes to gene expression may be because binding 
of just one miRNA to the 3' UTR of these targets is not sufficient and that binding 
of  multiple  miRNAs  may  be  required  before  a  reduction  in  expression  is 
observed.  Different miRNAs can affect the regulation of a single transcript by 
co operative binding to the 3' UTR and binding of multiple identical miRNAs can 
also  enhance  down regulation  (257).    Each  of  the  targets  investigated  were 
chosen  according  to  complementarity  between  the  3'  UTR  and  miRNA  seed 
region.  All targets were found to contain only one seed apart from Scly which 
contained  two.    The  greater  the  number  of  seed  regions  in  the  3'  UTR  that 
miRNA can bind to, the greater the miRNA activity (258;259).  Another factor 
contributing  to  miRNA  ability  to  down regulate  expression  is  the  distance 
between miRNA seed sites in 3' UTR.  It has been suggested that optimal activity 
of miRNAs occurs when 2 seed sites are separated between 13 and 35 nt (260).  
Our data shows a lack of seed sites in the 3' UTR of each predicted target and 
when more than one seed site was detected, the distance between sites was 
much larger than suggested for optimal activity.  MicroRNA specificity may also 
be affected by the nucleotide present in the A1 position of the seed site.  This 
corresponds to the first nucleotide of the miRNA, which is usually a uracil (this is 
the case for miR 9 1) such that an adenine in the position next to the seed site 
(3') may improve specificity (261).  However, Table 5.1 shows the nucleotide 
present at the A1 position for each predicted target; none contained an adenine 
at  this  position.    This  may  have  contributed  to  reduced  miRNA  binding 
specificity.    The  target  identification  method  used  here  relied  solely  on 
complementarity between the 3' UTR and the miRNA seed region.  However, it 
has  been  suggested  that  complementarity  to  the  seed  region  is  not  the  only 
factor important for target recognition (230).  
 
Various  computational  approaches  have  been  used  to  identify  miRNA  targets.  
These  approaches  also  use  seed  binding  as  an  indicator  of  potential  targets.  
TargetScan requires perfect complementary base pairing with the miRNA seed 
(261) but other resources, such as MiRanda, consider seed binding as important 
but do not require perfect complementarity (234;262).  However, as a second 
criterion  for  target  prediction,  these  programs  also  require  cross  species 
conservation.  Both TargetScan and PicTar require that the portion of the 3' UTR   179 
that interacts with the miRNA seed be conserved between at least five species.  
MiRanda also requires cross species conservation but only between human and 
rodent  (234).    In  order  to  improve  miRNA  target  prediction  in  future 
experiments, it may be better to assess cross species conservation and to also 
consider genes that have multiple predicted sites even if complementarity to the 
seed is not perfect.  Target sites could also be 3' compensatory so the ability to 
detect targets may be reduced by focusing solely on the seed region (5' dominant 
sites). 
 
MicroRNA mediated down regulation of gene expression can result from either 
translational  repression  or  mRNA  degradation  (262).    Potentially,  the  lack  of 
target validation at mRNA observed in the present study may be a reflection of 
translational repression occurring further downstream.  It has been suggested 
that if the miRNA is sufficiently complementary to the mRNA target then mRNA 
cleavage would be the outcome; otherwise the miRNA would induce translational 
repression (263;264).  It may have been more appropriate to try and validate 
each  target  at  the  protein  level,  as  it  could  be  the  case  that  target  mRNA 
expression was unaffected by miR 9 1 over expression and that miRNA activity 
was mediated through repression of translation. 
 
A recent study demonstrated successful identification and validation of hsa miR 
193b and its target urokinase type plasminogen activator (uPA).  Using anti miR 
193b  in  human  breast  cancer  cells  lines  resulted  in  increased  uPA  protein 
expression and increased cell invasion.  However, over expression of miR 193b 
reduced  protein  expression  and  also  reduced  cell  invasion  (265).    The  work 
performed here highlights the difficulties involved when trying to identify and 
validate predicted miRNA/mRNA target pairs.  The approach used in the present 
study attempted to increase the likelihood of identifying a valid miRNA/mRNA 
target  pair  by  combining  target  identification  methods  with  gene  expression 
data from microarray analysis.  By looking at genes that were down regulated in 
kidney tissue at time points when miRNA expression was up regulated and vice 
versa, it was hoped that a valid target would be found.  This was not the case in 
this study but the same strategy could be applied to miRNAs of interest in the 
future.    The  application  of  proteomics  could  further  enhance  miRNA  studies.  
Strategies such as pulsed SILAC (stable isotope labelling with amino acids in cell   180 
culture) labelling of proteins allow for genome wide quantification of protein 
synthesis  (258;266).    This  method  was  utilised  by  Selbach  and  colleagues  to 
measure  changes  in  protein  production  in  HeLa  cells  following  modulation  of 
miRNA  expression.    By  pulse  labelling  miRNA  transfected  cells  and  control 
transfected cells with different heavy stable isotopes it was possible to measure 
differences in protein production between the two samples.  This study found 
that  a  single  miRNA  could  down regulate  production  of  hundreds  of  proteins 
(258).  By combining such methods for analysis of protein expression with mRNA 
expression analysis, the ability to detect and validate miRNA targets could be 
vastly improved. 
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Chapter 6: General Discussion   182 
A combination of congenic breeding and microarray analysis to assess changes in 
gene expression led to the identification of Gstm1 as a positional and functional 
candidate gene for hypertension in the SHRSP (69).  As Gstm1 is part of a large 
family of antioxidant enzymes, it was proposed that depleted renal Gstm1 levels 
in the SHRSP may contribute to the development of hypertension by increasing 
the susceptibility of kidney tubular cells to the damaging effects of oxidative 
stress.  This in turn could impair the ability of the kidney to regulate the sodium 
and fluid balance and subsequently alter blood pressure.  This study has aimed 
to  investigate  the  role  of  Gstm1  using  an  RNAi  mediated  approach  and  to 
develop  molecular  tools  that  could  be  used  for  targeted  modulation  of  gene 
expression  in  vivo.    In  addition  to  this,  two  microRNAs  that  mapped  to  the 
congenic  region  were  investigated  to  assess  their  potential  contribution  to 
differences in gene expression observed between the SHRSP, WKY and congenic 
rat strains. 
   
The findings from chapter 3 indicate that expression of Gstm1 can be effectively 
and reproducibly knocked down in response to siRNA and can be quantified at 
both mRNA and protein level.  It has also been shown that by modulating the 
concentration of siRNA used any non specific effects on the expression of other 
Gstm family members can be prevented and interferon response gene activation 
can be avoided.  To be able to take investigation of the function of Gstm1 into 
an in vivo setting the possibility of using local delivery to the kidney for in vivo 
gene knock down was assessed but was found to be inappropriate as it resulted 
in significant renal damage.  However, successful targeting of renal tubules in 
SHRSP  following  systemic  delivery  was  demonstrated  using  a  previously 
identified  kidney  targeting  modified  adenoviral  vector  (185).    Furthermore, 
over expression and RNAi sequences could be incorporated into these targeted 
adenoviral vectors allowing both approaches to be delivered to specific cells of 
interest.  Short hairpin RNA expressing vectors have been generated and were 
evaluated in NRK 52E cells, however knock down of Gstm1 was not confirmed in 
this  cell  line.    The  integration  of  targeted  vectors  and  modulation  of  Gstm1 
expression would allow the role of Gstm1 to be investigated more fully in vivo.   
 
Following on from the optimisation of Gstm1 knock down performed in chapter 
3,  the  experiments  carried  out  in  chapter  4  sought  to  investigate  the   183 
contribution of reduced Gstm1 expression to oxidative stress.  Reduced Gstm1 
expression  was  not  sufficient  to  cause  a  change  in  glutathione  levels  and 
reduced  activity  could  not  be  detected  using  a  total  GST  activity  kit.    Lipid 
peroxidation  (as  determined  by  8 isoprostane  level)  and  DNA  damage  (as 
determined by 8 OH 2OG level) were unaffected by reducing Gstm1 expression.  
However,  when  DNA  damage  was  assessed  by  comet  assay,  a  small  but 
significant  increase  in  tail  length  was  observed  in  cells  with  reduced  Gstm1 
expression, suggesting increased damage in these cells.  The results generated 
tend  to  suggest  that  Gstm1  alone  is  not  responsible  for  cellular  protection 
against products of oxidative stress such as lipid radicals, as suggested in the 
hypothesis of this study.  Rather Gstm1 may function as part of a larger pathway 
in the protection against oxidative stress.   
 
Two miRNAs (miR 9 1 and miR 137) were identified that map to the chromosome 
2 congenic region.  It was proposed that miRNA within this region may target 
genes expressed in the kidney and contribute to differential gene expression in 
parental and congenic strains.  Expression analysis of miR 9 1 and miR 137 found 
expression of miR 9 1 was lower in 16 week old congenic and WKY strains than in 
5  week  animals  of  the  same  strain  but  was  unchanged  in  SHRSP  and  that 
expression of miR 137 was unchanged across all time points in congenic and WKY 
strains but was significantly higher in 21 week old, salt loaded SHRSP than in 21 
week  old  SHRSP  without  salt.   By  combining  previously  generated  microarray 
data with predicted miRNA targets using IPA, 7 predicted targets for miR 9 1 
were identified.  However, none of the predicted targets were validated by qRT 
PCR in kidney tissue or in NRK 52E cells transfected with pre miR 9.  Although no 
targets  were  validated  in  this  instance,  miR 9 1  may  still  have  a  role  in 
contributing to the changes in gene expression observed in kidney from congenic 
and WKY strains. 
 
The combined congenic breeding and microarray strategy used to identify Gstm1 
has been used previously and led to the identification and confirmation of Cd36 
as a candidate gene for insulin resistance in the SHR (65;267).  This strategy was 
also used to identify Vcam1 and Edg1 as candidate genes for salt sensitivity in 
the SHRSP (237).  This study utilised IPA to generate a molecular network linking 
each  gene  and  demonstrated  how  Edg1  could  regulate  Vcam1  expression.    184 
Following on from identification of Gstm1 as a candidate gene for hypertension 
in  SHRSP,  this  study  sought  to  further  investigate  its  function  and  role  in 
oxidative stress.  Increased renal oxidative stress was identified in SHRSP (77).  
However, using RNAi to knock down Gstm1 expression in a rat kidney cell line 
did not lead to identification of a specific role for Gstm1 in protection against 
products of oxidative stress.  This would suggest that the decreased expression 
of Gstm1 alone, as observed in SHRSP, is not responsible for reduced oxidative 
stress protection but instead may act as part of an oxidative stress pathway.  As 
described  previously,  Gstm1  is  part  of  a  large,  highly  homologous  family  of 
antioxidant enzymes.  A recent study observed a small reduction (less than 2 
fold) in expression of other Gstm isoforms in kidney from the SHRSP (268) but it 
may  be  that  many  small  changes  in  the  expression  of  genes  participating  in 
oxidative stress defence contribute to the overall phenotype observed.  Indeed it 
would seem that for analysis of complex traits, instead of investigating singular 
candidate  genes,  it  would  be  more  informative  to  assess candidate  pathways 
encompassing such genes (269).   
 
This study has investigated the effects of reduced Gstm1 expression; conversely, 
a transgenic SHRSP expressing Gstm1 may provide greater information regarding 
a  direct  link  between  Gstm1  and  blood  pressure.    Our  group  has  recently 
completed the generation of a Gstm1 transgenic rat and studies are underway to 
investigate  the effect of  Gstm1  over expression on blood pressure.  If Gstm1 
does indeed have a significant contribution to blood pressure regulation then it 
would be expected that over expression in the SHRSP would cause a reduction in 
blood pressure. 
 
RNA  interference  is  now  a  commonly  used  method  for  knock down  of  gene 
expression  allowing  for  subsequent  functional  analysis  and,  as  described  in 
section 1.5.5, is a potential therapeutic for various human disorders.  Various 
routes  of  administration  have  been  evaluated  for  in  vivo  delivery  of  siRNA 
(270;271).  Delivery vectors have also been used to drive expression of shRNA in 
vivo,  such  as  adenoviral  vectors  (272),  lentiviral  vectors  (273)  and  adeno 
associated viral vectors (AAV) (162;274).  However, in vivo expression of siRNA 
or shRNA can be problematic due to immune system activation (275;276).  Not 
only can immune system activation be detrimental but a study that used AAV   185 
mediated shRNA expression in mice found that shRNA expression caused liver 
damage and in some cases was fatal.  They then discovered that this was due to 
saturation  of  the  endogenous  miRNA  pathway  machinery.    However,  after 
careful  optimisation  of  AAV  vector  dose  and  selection  of  shRNA  with  lower 
expression, the study was able to demonstrate efficient and persistent silencing 
of hepatitis B virus in mice (277;278).  Due to technical difficulties encountered 
by colleagues working on virus development it was not possible to generate the 
Gstm1  shRNA  expressing  targeted  adenoviral  vectors.    Given  more  time  and 
optimisation, the completion of these vectors would provide an excellent tool 
for thorough in vivo investigation of Gstm1 function.  This system could also be 
applied to evaluate future renal expressed candidate genes in hypertension and 
oxidative stress.   
 
MicroRNAs are an endogenous class of short RNA that regulate gene expression 
by binding the 3’ UTR of target genes resulting in mRNA degradation (like siRNA) 
or translational repression.  MicroRNAs represent another level of complexity in 
the control of gene expression, as one miRNA can target many genes and one 
gene can be targeted by many miRNAs (279).  Genome wide profiling of miRNA 
expression in human heart disease found that in specific types of heart disease 
there was a distinct miRNA expression profile (280).  This also supports the idea 
that a single miRNA is not responsible for gene expression changes contributing 
to  phenotype, instead many miRNAs together regulate gene expression.  This 
may  account  for  the  lack  of  significant  change  in  predicted  target  gene 
expression following over expression of miR 9 1 and also why targets for miR 137 
were not identified in this study.  As hypertension is a complex trait, it may be 
that  many  miRNAs  regulate  the  expression  of  many  genes,  with  each  gene 
imparting a small effect and contributing to overall phenotype.  Our group is 
currently analysing data generated from miRNA microarrays performed on kidney 
from SHRSP, WKY and congenic strains at the various time points described in 
chapter  5.    It  is  hoped  that  this  in  combination  with  IPA  and  molecular 
techniques to assess predicted targets will further elucidate the potential role of 
miRNAs  in  hypertension  in  the  rat.    In  chapter  5,  IPA  was  employed  to 
interrogate  microarray  data  and  combined  with  miRNA  target  prediction.  
Although the targets identified were not validated in this study, the combination 
of miRNA and microarray analysis of congenic and parental strains may further   186 
contribute  to  identification  of  candidate  genes  and  also  provide  important 
information on how such genes are regulated.  Ingenuity pathway analysis has 
been used to probe miRNA target lists and compare to genes known to have a 
role in cancer.  This allowed a large list of targets to be stratified according to a 
reported role in a specific type of cancer (281).  More recently, IPA has been 
used to build signalling networks using the predicted targets of 8 miRNAs found 
to be differentially expressed in heart failure (282). 
 
It is hoped that by combining strategies to identify candidate genes with in vitro 
and in vivo functional analysis using techniques such as RNAi will lead to a better 
understanding of genes involved in oxidative stress and hypertension.  Although 
the experiments performed here have not identified a specific role for Gstm1, 
the  same  approach  could  be  used  to  evaluate  future  candidates.    MicroRNA 
expression profiling adds another level of complexity and may provide important 
information regarding the differential expression of genes.  The utilisation of 
microarray analysis of mRNA and miRNA expression may lead to identification of 
candidate miRNA that contribute to regulation of functionally important genes.  
The integration of such data using Ingenuity Pathway Analysis would allow for 
specific  targets  to  be  identified  depending  on  whether  they  are  part  of  a 
pathway of interest.  Using such technologies may lead to the identification of 
pathways that directly contribute to oxidative stress or blood pressure regulation 
in the rat.  It may then be possible to find similar regulatory mechanisms in 
human  that  could  be  translated  to  generate  therapeutic  measures  for  the 
treatment of essential hypertension.  
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RefSeq  Gene ID  RefSeq  Gene ID  RefSeq  Gene ID  RefSeq  Gene ID 
NM_001001508  Prg1  NM_001017376  Phyhip  NM_017162  Gif  NM_053584  Gosr1 
NM_001002016  Lmna  NM_001017377  Paqr4  NM_017164  Capza3  NM_053598  Nudt4 
NM_001003401  Enc1  NM_001017382  Frs3  NM_017214  Rgs4  NM_053603  Clic5 
NM_001003404  Il22ra2  NM_001017386  Tmem10  NM_017224  Slc22a6  NM_053605  Smpd3 
NM_001003957  Dnmt3a  NM_001017445  Ubxd8  NM_017226  Padi2  NM_053610  Prdx5 
NM_001004084  RT1 Bb  NM_001017446  RGD1310199  NM_017230  Padi3  NM_053621  Magi2 
NM_001004090  Tspan5  NM_001017451  RGD1309228  NM_017238  Vipr2  NM_053622  Pom121 
NM_001004107  Tacc1  NM_001017453  RGD1311203  NM_017244  Crabp2  NM_053623  Acsl4 
NM_001004210  Xbp1  NM_001017454  RGD1307799  NM_017249  Mbc2  NM_053624  Pitx1 
NM_001004222  Arfip2  NM_001017482  LOC498033  NM_017255  P2ry2  NM_053635  St14 
NM_001004266  RGD1303144  NM_001017499  LOC498353  NM_017259  Btg2  NM_053638  Idh3a 
NM_001004269  Jam3  NM_001017504  LOC498425  NM_017261  Gria2  NM_053667  Lepre1 
NM_001004271  Ugt2b4  NM_001017508  LOC498664  NM_017265  Hsd3b6  NM_053670  Crcp 
NM_001004274  Igfbp4  NM_001017988  LOC303566  NM_017289  Gabrd  NM_053679  Dffa 
NM_001004444  Zbtb1  NM_001024262  RGD1305424  NM_017291  Gabrr1  NM_053690  Dnajc14 
NM_001004445  Znf183  NM_001024275  Rassf4  NM_017302  Slc16a7  NM_053693  Dmtf1 
NM_001005547  Tspan3  NM_001024292  LOC499330  NM_017303  Kcnab1  NM_053700  Ccl28 
NM_001005560  Pla2g6  NM_001024298  LOC499516  NM_017309  Ppp3r1  NM_053714  Ank 
NM_001005872  Htatip  NM_001024303  LOC499677  NM_017313  Rab3ip  NM_053733  Bcl2l10 
NM_001005886  Nsddr  NM_001024305  LOC499691  NM_017317  Rab27a  NM_053734  Ncf1 
NM_001005889  Rdx  NM_001024307  LOC499732  NM_017321  Aco1  NM_053742  Pitpnb 
NM_001006963  Itm2b  NM_001024313  LOC499900  NM_017325  Runx1  NM_053743  Cdc37 
NM_001006973  mrpl11  NM_001024327  LOC500110  NM_017355  Rab4b  NM_053754  Abcg5 
NM_001006981  Dlst  NM_001024338  LOC500348  NM_017356  Hpcal1  NM_053756  Atp5g3 
NM_001006990  LOC304000  NM_001024343  LOC500445  NM_017361  Nup54  NM_053756  Atp5g3 
NM_001006993  Sgcg  NM_001024344  LOC500449  NM_019123  St6galnac3  NM_053758  Plce1 
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NM_001007005  Arhgdia  NM_001024349  LOC500598  NM_019124  Rabep1  NM_053765  Gne 
NM_001007009  MGC94915  NM_001024741  Chaf1b  NM_019126  Cgm3  NM_053778  Ipo13 
NM_001007607  Pigq  NM_001024763  Nif3l1  NM_019135  Tnfrsf8  NM_053779  Serpini1 
NM_001007609  Mfap3  NM_001024779  Cyp2u1  NM_019146  Bsn  NM_053788  Stx1a 
NM_001007611  F101B_RAT  NM_001024780  Prkra  NM_019152  Capn1  NM_053798  Sacm1l 
NM_001007626  Ggps1  NM_001024795  Rnf44  NM_019158  Aqp8  NM_053801  Sec14l2 
NM_001007628  Cxxc5  NM_001024799  RGD1306302  NM_019172  Galr2  NM_053810  Snap29 
NM_001007629  NTF2  NM_001024865  LOC684557  NM_019187  Coq3  NM_053812  Bak1 
NM_001007636  S100a1  NM_001024991  Fahd1  NM_019191  Smad2  NM_053818  Slc6a9 
NM_001007637  mrpl24  NM_001024992  LOC303332  NM_019202  Pla2g2c  NM_053837  Ap2m1 
NM_001007641  Rnd3  NM_001025008  LOC314996  NM_019214  Slc26a4  NM_053843  FCGR3_RAT 
NM_001007645  MGC95152  NM_001025009  Josd1  NM_019219  Rbbp9  NM_053847  Map3k8 
NM_001007653  Mrps15  NM_001025014  Tmem50b  NM_019225  Slc1a3  NM_053848  Opcml 
NM_001007662  Arcn1  NM_001025016  RGD1309120  NM_019230  Slc22a3  NM_053851  Cacnb2 
NM_001007667  Sat  NM_001025019  RGD1306582  NM_019232  Sgk  NM_053878  Cplx2 
NM_001007669  Zfp672  NM_001025020  RGD1310753  NM_019238  Fdft1  NM_053879  Cntn4 
NM_001007679  RGD1359339  NM_001025022  RGD1308059  NM_019243  Ptgfrn  NM_053883  Dusp6 
NM_001007682  Thtpa  NM_001025025  LOC363267  NM_019250  Ralgds  NM_053893  Sdc3 
NM_001007688  RGD1359600  NM_001025027  Fundc1  NM_019256  P2rx7  NM_053912  Pscd3 
NM_001007689  Ciapin1  NM_001025033  LOC498154  NM_019261  Klrc2  NM_053921  Pex12 
NM_001007701  Tram1  NM_001025034  LOC498796  NM_019262  C1qb  NM_053923  Pik3c2g 
NM_001007705  RGD1359144  NM_001025051  LOC500638  NM_019272  Sema4f  NM_053929  Slc7a9 
NM_001007706  RGD1359191  NM_001025142  Trim35  NM_019280  Gja5  NM_053931  Gp1bb 
NM_001007713  Tmbim1  NM_001025143  LOC498606  NM_019289  Arpc1b  NM_053936  Edg2 
NM_001007714  Morf4l2  NM_001025151  LOC500625  NM_019304  Dgkb  NM_053945  Rims2 
NM_001007727  Lypd1  NM_001025271  Sfpq  NM_019306  Flt1  NM_053959  Bin1 
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NM_001007730  Cabp7  NM_001025402  Umps  NM_019326  Neurod2  NM_053965  Slc25a20 
NM_001007732  MGC94010  NM_001025412  RGD1305651  NM_019329  Cntn3  NM_053967  Spam 
NM_001007737  RGD1359158  NM_001025418  Ppp2r1b  NM_019331  Pcsk3  NM_053972  RragB 
NM_001007738  RGD1359349  NM_001025419  Tax1bp3  NM_019344  Rgs8  NM_053974  Eif4e 
NM_001007742  Ubadc1  NM_001025635  Nars  NM_019345  Slc12a3  NM_053988  Calb2 
NM_001007747  Pomgnt1  NM_001025648  Snapap  NM_019347  Slc14a2_v1  NM_053997  Kcnc3 
NM_001007751  MGC94207  NM_001025684  Pex11b  NM_019351  Timm17a  NM_053998  Rab8a 
NM_001007754  Rassf1  NM_001025688  Palmd  NM_019358  Pdpn  NM_057097  Vamp3 
NM_001007755  Scly  NM_001025693  Cdca7  NM_019365  Rassf5  NM_057122  Psmc4 
NM_001007759  Mar 03  NM_001025711  Atg4b  NM_019371  Egln3  NM_057124  P2ry6 
NM_001008278  RGD1308696  NM_001025721  Colec12  NM_019378  Snip  NM_057133  Nr0b2 
NM_001008279  Fliih  NM_001025726  Srpk1  NM_019623  Cyp4f1  NM_057148  Sep 02 
NM_001008280  Lrrc59  NM_001025739  Rpl11  NM_019630  Gip  NM_057155  Xpnpep2 
NM_001008287  Donson  NM_001025752  Ccrk  NM_019905  Anxa2  NM_057185  Folh1 
NM_001008292  Diablo  NM_001025760  MGC116363  NM_020075  Eif5  NM_057192  Waspip 
NM_001008307  RGD1311257  NM_001025769  C20orf165  NM_020076  Haao  NM_078620  Slc8a3 
NM_001008319  Maea  NM_001029909  CPG2  NM_021266  Fzd1  NM_080477  Pfkfb2 
NM_001008320  Rhoj  NM_001029920  RGD1310423  NM_021579  Nxf1  NM_080480  Pip5k2c 
NM_001008334  Tmem97  NM_001029927  LOC502774  NM_021583  Ptges  NM_080576  Apoa5 
NM_001008336  LOC682784  NM_001031646  Stoml2  NM_021587  Ltbp1  NM_080580  Rab3d 
NM_001008339  Whsc2  NM_001031647  Dnali1  NM_021594  Slc9a3r1  NM_080581  Abcc3 
NM_001008353  Mkks  NM_001031652  St6galnac2  NM_021653  Dio1  NM_080582  Abcb6 
NM_001008354  Mrrf  NM_001031655  Manba  NM_021676  Shank3  NM_080583  Ap2b1 
NM_001008356  Slc39a3  NM_001033683  Vat1  NM_021698  F13a1  NM_080585  Napa 
NM_001008363  Zfand2a  NM_001033693  Slc31a2  NM_021702  Atxn3  NM_080688  Plcd4 
NM_001008370  MGC105830  NM_001033704  Xylb  NM_021740  Ptma  NM_080689  Dnm1 
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NM_001008376  Trappc3  NM_001033862  Ceacam1  NM_021744  Cd14  NM_080780  P2rx5 
NM_001008378  Tspan31  NM_001033864  Cflar  NM_021766  Pgrmc1  NM_080782  Cdkn1a 
NM_001008384  Rac2  NM_001033866  Surf2  NM_021776  Ecel1  NM_080783  Gale 
NM_001008386  LOC493574  NM_001033870  Csnk1g2  NM_021850  Bcl2l2  NM_080786  Slco2b1 
NM_001008517  RGD1310553  NM_001033883  Cxcl12  NM_021868  Cttn  NM_080906  Ddit4 
NM_001008518  MGC105649  NM_001033890  RGD1311072  NM_021997  Cyln2  NM_080907  Ppp4r1 
NM_001008521  Ptk9  NM_001033891  LOC690779  NM_022179  Hk3  NM_130403  Ppp1r14a 
NM_001008557  Mip1  NM_001033951  Npuk68  NM_022198  Clcn4 2  NM_130426  Tnfrsf1b 
NM_001008560  Prss35  NM_001033998  Itgal  NM_022215  Gpd1  NM_130779  Adcy3 
NM_001008561  Rnase9  NM_001034006  Centb2  NM_022218  Cmklr1  NM_130812  Cdkn2b 
NM_001008767  Txnip  NM_001034032  Dnajc12  NM_022224  Pter  NM_133290  Zfp36 
NM_001008768  Prim1  NM_001034079  Thrap4  NM_022240  A4galt  NM_133296  Xtrp3 
NM_001008771  Wdr77  NM_001034112  Mlx  NM_022254  Gpr85  NM_133306  Oldlr1 
NM_001008861  Usp11  NM_001034149  RGD1311815  NM_022257  Masp1  NM_133310  Icmt 
NM_001008880  Scn4b  NM_001034163  Blmh  NM_022280  Lrat  NM_133380  Il4ra 
NM_001008891  Ssr1  NM_001034835  RGD1309220  NM_022281  LOC688339  NM_133393  Lfng 
NM_001009176  Trim10  NM_001034932  C1qtnf6  NM_022289  Snx16  NM_133394  Zdhhc7 
NM_001009264  RGD1306635_predicted  NM_001034934  Arid5a  NM_022294  Eltd1  NM_133395  Tpo1 
NM_001009357  Rqcd1  NM_001037158  Pcdhga9  NM_022388  Fxyd4  NM_133396  Tesk2 
NM_001009424  Eps15  NM_001037187  LOC302680  NM_022392  Insig1  NM_133397  Erg 
NM_001009478  Saa4  NM_001037191  RGD1306873  NM_022396  Gng11  NM_133402  Nap1l3 
NM_001009490  Oas1f  NM_001037209  Mterfd2  NM_022400  Bcat2  NM_133406  Agpat4 
NM_001009494  NP_001009494.1  NM_001037556  Nmnat1  NM_022404  Gbl  NM_133542  Igsf6 
NM_001009540  Tacstd2  NM_001037649  RGD1306676  NM_022441  Acvrl1  NM_133553  B3galt4 
NM_001009599  RGD1307679  NM_001037654  Dixdc1  NM_022498  Ppp1cc  NM_133560  Trak2 
NM_001009600  Arhgdib  NM_001037774  Cldn8  NM_022513  Sult1b1  NM_133567  Centa1 
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NM_001009605  Brms1  NM_001037797  LOC500354  NM_022516  Ptbp1  NM_133568  Rasd2 
NM_001009674  Itm2c  NM_001039002  RGD1304790  NM_022523  Cd151  NM_133571  Cdc25a 
NM_001009675  Tceal1  NM_001039003  Mtrr  NM_022525  Gpx3  NM_133580  Rab26 
NM_001009677  Plekhm1  NM_001039005  Mcoln2  NM_022534  Tcn2  NM_133583  Ndrg2 
NM_001009683  Tor3a  NM_001039016  Zdhhc9  NM_022548  Wig1  NM_133593  Ap3m1 
NM_001009687  Riok2  NM_001039017  RGD1309718  NM_022589  Tspan2  NM_133597  Chrnb3 
NM_001009691  Dclk2_predicted  NM_001039021  Zdhhc8  NM_022596  Golga2  NM_133601  Cblb 
NM_001009701  ITFG3_RAT  NM_001039044  Cdc42se1  NM_022597  Ctsb  NM_133610  Kcnh5 
NM_001009705  MGC109149  NM_001039196  Slc39a13  NM_022598  Cnbp1  NM_133620  Zhx1 
NM_001009708  Lmo4  NM_001039207  Narf  NM_022599  Synj2bp  NM_133651  Cav1 
NM_001009713  Slc17a5  NM_001039455  RGD1309570  NM_022600  Adcy5  NM_134327  Cd69 
NM_001009825  Ppp1r7  NM_001039505  Irx2  NM_022614  Inhbc  NM_134329  Adh7 
NM_001009965  Eiih  NM_001040156  Aste1  NM_022639  Chrna10  NM_134334  Ctsd 
NM_001010945  RGD1311474  NM_001042619  Hsd3b1  NM_022643  Hist1h2ba  NM_134363  Slc12a5 
NM_001011557  RGD1305677  NM_001042621  Pip5k1a_predicted  NM_022671  Onecut1  NM_134371  Trpm8 
NM_001011665  Trim26  NM_001044228  LOC289740  NM_022676  Ppp1r1a  NM_134373  Avpi1 
NM_001011890  Rnps1  NM_001044237  LOC689500  NM_022697  Rpl28  NM_134379  UST4r 
NM_001011893  Sep 04  NM_001044246  Mageb18_predicted  NM_022700  Arl3  NM_134413  Btbd14b 
NM_001011893  Sep 04  NM_001044251  MGC112790  NM_022710  Pde1b  NM_134414  Exoc2 
NM_001011902  Rabl5  NM_001044255  Coq2  NM_022853  Slc30a1  NM_134459  Mic2l1 
NM_001011906  Acbd6  NM_001044267  MGC112775  NM_022860  B4galnt1  NM_138505  Adra2b 
NM_001011914  Dr1  NM_001044274  Apin  NM_022864  Cplx1  NM_138530  Mawbp 
NM_001011918  Anxa11  NM_001044297  LOC689907  NM_022936  Ephx2  NM_138613  Zfp179 
NM_001011919  Gtpbp3  NM_001047110  LOC499770  NM_022944  Inppl1  NM_138833  Snrk 
NM_001011923  Prpf4b  NM_001047743  MGC112883  NM_022953  Slit1  NM_138836  Prss8 
NM_001011924  Mbd1  NM_001048184  Rragc_predicted  NM_022962  Lphn1  NM_138840  Tgoln2 
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NM_001011942  Cnnm2  NM_001048215  Kirrel3_predicted  NM_023023  Dpysl5  NM_138842  Sftpb 
NM_001011947  Rai14  NM_001077641  Plcb1  NM_023092  Myo1c  NM_138848  Podxl 
NM_001011952  Slc39a8  NM_001077648  Prdm2  NM_023969  Edg7  NM_138849  Bk 
NM_001011954  Cybrd1  NM_001079700  Cdc42ep1_predicted  NM_023977  Golph3  NM_138858  Slc9a5 
NM_001011961  Srms  NM_001080783  RGD1311552_predicted  NM_024000  Camkv  NM_138864  Ccdc5 
NM_001011962  Ceecam1  NM_001080789  Arhgap9  NM_024002  Secisbp2  NM_138866  Eif2b5 
NM_001011963  Asb6  NM_012498  Akr1b4  NM_024132  Faah  NM_138873  Nbn 
NM_001011965  LOC652927  NM_012505  Atp1a2  NM_024133  Hap1  NM_138879  Sele 
NM_001011969  Strap  NM_012517  Cacna1c  NM_024134  Ddit3  NM_138884  Akr1d1 
NM_001011974  Akap2  NM_012521  S100g  NM_024135  Limk2  NM_138889  Cdh13 
NM_001011983  Coq6  NM_012523  Cd53  NM_024138  Gng7  NM_138891  Gpr149 
NM_001011985  Mknk2  NM_012526  Chgb  NM_024144  Pigm  NM_138893  Myo16 
NM_001011999  LOC366923  NM_012527  Chrm3  NM_024155  Anxa4  NM_138894  Grasp 
NM_001012012  Snx11  NM_012531  Comt  NM_024162  Fabp3  NM_138896  Pja2 
NM_001012013  Acbd4  NM_012538  Cyp11b2  NM_024163  Begain  NM_138908  Slc22a9 
NM_001012015  Lamp3  NM_012545  Ddc  NM_024379  Grid2  NM_138909  Foxe1 
NM_001012032  Arhgap24  NM_012547  Drd2  NM_024385  Hhex  NM_138915  Drd1ip 
NM_001012038  Mtmr3  NM_012548  Edn1  NM_024396  Abca2  NM_139036  Lhx5 
NM_001012039  Efemp1  NM_012550  Ednra  NM_024400  Adamts1  NM_139040  RGD621098 
NM_001012041  Isgf3g  NM_012555  Ets1  NM_024483  Adra1d  NM_139060  Csnk1d 
NM_001012044  Lcp1  NM_012557  Fancc  NM_030586  Cyb5b  NM_139084  Magi3 
NM_001012051  Zfp367  NM_012571  Got1  NM_030830  Luzp1  NM_139090  Acvr1c 
NM_001012055  Cdh16  NM_012574  Grin2b  NM_030834  Slc16a3  NM_139094  Rbm16 
NM_001012061  Cnksr3  NM_012576  Nr3c1  NM_030836  Arts1  NM_139097  Scn3b 
NM_001012062  Map3k7ip2  NM_012579  Hist1h1t  NM_030838  Slco1a5  NM_139183  Crhbp 
NM_001012064  Pvrl2  NM_012588  Igfbp3  NM_030841  Nptxr  NM_139188  Otos 
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NM_001012065  ADCK4_RAT  NM_012591  Irf1  NM_030842  Itga7  NM_139190  Calcoco1 
NM_001012066  Sphk2  NM_012599  Mbl1  NM_030854  Lect1  NM_139192  Scd1 
NM_001012067  Grwd1  NM_012607  Nefh  NM_030861  Mgat1  NM_139194  Fas 
NM_001012079  Arhgef2  NM_012608  Mme  NM_030864  Mtr  NM_139252  Ppap2c 
NM_001012080  Hfe2  NM_012610  Ngfr  NM_030990  Plp  NM_139255  LOC246120 
NM_001012083  Snx7  NM_012615  Odc1  NM_030991  Snap25  NM_139324  Ehd4 
NM_001012092  Xkr7  NM_012620  Serpine1  NM_030992  Pld1  NM_139331  Lrrc21 
NM_001012119  Nptxr  NM_012631  Prnp  NM_030993  Ddn  NM_144730  Gata4 
NM_001012120  Naga  NM_012634  Prps2  NM_030995  Mtap1a  NM_144747  Slc45a1 
NM_001012122  Ecgf1  NM_012642  Ren1  NM_030996  Oprs1  NM_144748  LOC246263 
NM_001012139  Plscr3  NM_012643  Ret  NM_031012  Anpep  NM_144752  Oas1b 
NM_001012140  Rab34  NM_012648  Scnn1b  NM_031022  Cspg4  NM_144757  Zfp180 
NM_001012147  Pxn  NM_012651  Slc4a1  NM_031026  Dncli2  NM_145081  Optn 
NM_001012148  Ankrd13  NM_012652  Slc9a1  NM_031035  Gnai2  NM_145085  Pcyox1 
NM_001012166  Abcb10  NM_012653  Slc9a2  NM_031047  Jup  NM_145088  Rmt1 
NM_001012167  Pld3  NM_012654  Slc9a3  NM_031050  Lum  NM_145093  Aard 
NM_001012169  Zfp143  NM_012655  Sp1  NM_031062  Mvd  NM_145677  Slc25a25 
NM_001012170  Nap1l4  NM_012663  Vamp2  NM_031069  Nell1  NM_145682  Filip1 
NM_001012174  Fkbp5  NM_012664  Syp  NM_031083  Pik4cb  NM_145723  Stx17 
NM_001012188  Creb3l2  NM_012665  Syt2  NM_031094  Rbl2  NM_145724  ZN394_RAT 
NM_001012189  Mboat5  NM_012666  Tac1  NM_031123  Stc1  NM_145767  Prrxl1 
NM_001012195  Rnf41  NM_012681  Ttr  NM_031127  Suox  NM_145774  Rab38 
NM_001012195  Rnf41  NM_012682  Ucp1  NM_031132  Tgfbr2  NM_145785  Hdgfrp3 
NM_001012206  Phlda3  NM_012693  Cyp2a2  NM_031153  Sharpin  NM_145877  Kif1c 
NM_001012213  Sfxn1  NM_012700  Stx1b2  NM_031241  Cyp8b1  NM_147205  St6gal1 
NM_001012218  Rnf29  NM_012706  Grpr  NM_031320  Celsr3  NM_147211  Cr16 
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NM_001012469  Il21r  NM_012715  Adm  NM_031322  Lrp4  NM_152242  Gpr56 
NM_001012476  Rnase11  NM_012719  Sstr1  NM_031332  Slc22a8  NM_152847  Snx27 
NM_001012740  Cbln2  NM_012721  P2rxl1  NM_031334  Cdh1  NM_152935  Tomm20 
NM_001013043  Sectm1a  NM_012725  Klkb1  NM_031337  St3gal5  NM_152938  Slc4a9 
NM_001013066  Sipa1l3  NM_012728  Glp1r  NM_031339  Parg  NM_153311  Tmprss5 
NM_001013070  Tspan4  NM_012732  Lip1  NM_031351  Atrn  NM_153467  Gsbs 
NM_001013072  Sfxn2  NM_012735  Hk2  NM_031355  Vdac3  NM_153470  Lzts1 
NM_001013077  Plekha3  NM_012740  Th  NM_001034942  Btbd15  NM_153722  Mrgprf 
NM_001013079  Osbpl2  NM_012743  Foxa2  NM_001034998  Ctps2  NM_153724  Dscr1 
NM_001013099  Slc38a6  NM_012747  Stat3  NM_031503  Ascl2  NM_153725  Slc17a8 
NM_001013101  Moap1  NM_012756  Igf2r  NM_031511  Igf2  NM_153735  Nptx1 
NM_001013103  Cdc34_predicted  NM_012758  Syk  NM_031525  Pdgfrb  NM_153740  Sap1 
NM_001013120  Igsf11  NM_012761  Sp4  NM_031544  Ampd3  NM_170789  Cd3z 
NM_001013124  Ung  NM_012764  Gata1  NM_031548  Scnn1a  NM_171992  Ccnd1 
NM_001013135  Sdccag3  NM_012775  Tgfbr1  NM_031559  Cpt1a  NM_172008  Canx 
NM_001013149  Mesdc1  NM_012778  Aqp1  NM_031568  Clcn7  NM_172021  Tbkbp1 
NM_001013154  Pcgf6  NM_012779  Aqp5  NM_031588  Nrg1  NM_172066  Slc30a4 
NM_001013156  Zcchc9  NM_012781  Arnt2  NM_031590  Wisp2  NM_172067  Spon1 
NM_001013165  Lrrc23  NM_012789  Dpp4  NM_031597  Kcnq3  NM_172157  Arid1b 
NM_001013171  Gulp1  NM_012798  Mal  NM_031600  Ptprn2  NM_172243  Ppif 
NM_001013174  Laptm4b  NM_012800  P2ry1  NM_031612  Apln  NM_172327  Aip 
NM_001013182  RGD1305117  NM_012813  St8sia1  NM_031614  Txnrd1  NM_172333  Cthrc1 
NM_001013191  Cbfb  NM_012818  Aanat  NM_031639  Dlgh3  NM_172335  Gm2a 
NM_001013211  Prp2_predicted  NM_012820  Acsl1  NM_031642  Klf6  NM_173105  Aqp11 
NM_001013231  Pea15  NM_012821  Adcy6  NM_031658  Msln  NM_173126  Nid67 
NM_001013238  Pttg1ip  NM_012828  Cacnb3  NM_031662  Camkk1  NM_173147  Vps54 
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NM_001013241  Lzic  NM_012843  Emp1  NM_031664  LOC691960  NM_173309  Elavl2 
NM_001013243  Slc30a3  NM_012845  Ms4a2  NM_031675  Actn4  NM_173324  RGD708449 
NM_001013250  Mageh1  NM_012863  Bhlhb8  NM_031678  Per2  NM_173337  Camk2n1 
NM_001013429  Cldn14  NM_012869  Npy5r  NM_031693  Syt4  NM_175578  Dscr1l1 
NM_001013434  Rras2  NM_012874  Ros1  NM_031696  Gpr88  NM_175579  Wnk4 
NM_001013860  RGD1306819  NM_012879  Slc2a2  NM_031699  Cldn1  NM_175597  Ssx2ip 
NM_001013869  RGD1306108  NM_012884  Cntn2  NM_031711  Arl2  NM_175755  Ppm1f 
NM_001013878  RGD1359592  NM_012888  Tshr  NM_031713  Pirb  NM_175869  Plod2 
NM_001013880  LOC290651  NM_012894  Adarb1  NM_031716  Wisp1  NM_176076  S100vp 
NM_001013894  Gp49b  NM_012896  Adora3  NM_031727  Limk1  NM_176077  G6pc3 
NM_001013898  RGD1311703  NM_012900  Ambn  NM_031735  Stk3  NM_176080  Naglt1 
NM_001013905  RGD1307648  NM_012916  Bcan  NM_031740  B4galt6  NM_176856  Sep 09 
NM_001013906  Lhfpl5  NM_012923  Ccng1  NM_031743  Slc24a2  NM_177421  Slc22a17 
NM_001013907  LOC294513  NM_012924  Cd44  NM_031753  Alcam  NM_178092  Slc4a10 
NM_001013911  Ift80  NM_012928  Cnga2  NM_031781  Apba3  NM_178093  Mtus1 
NM_001013914  RGD1305808  NM_012929  Col2a1  NM_031784  Pias3  NM_178094  Itpkc 
NM_001013919  Galk2  NM_012953  Fosl1  NM_031789  Nfe2l2  NM_178097  Sla 
NM_001013922  RGD1307752  NM_012971  Kcna4  NM_031793  Ppig  NM_178102  Mapkapk2 
NM_001013927  RGD1308734  NM_012980  Mmp11  NM_031802  Gabbr2  NM_178106  Entpd3 
NM_001013930  LOC298139  NM_012981  Mras  NM_031803  Gmeb2  NM_181081  Myst2 
NM_001013931  RGD1311249  NM_012983  Myo1d  NM_031816  Rbbp7  NM_181090  Slc38a2 
NM_001013938  Vwa1  NM_012991  Npap60  NM_031819  Fath  NM_181377  Rtn4rl1 
NM_001013939  Raver1h  NM_012999  Pcsk6  NM_031820  Dvl1  NM_181386  Tmem23 
NM_001013954  RGD1308555  NM_013001  Pax6  NM_031976  Prkab1  NM_181474  Tfb1m 
NM_001013976  RGD1305007  NM_013015  Ptgds  NM_031977  Src  NM_181637  Cdc91l1 
NM_001013979  LOC304131  NM_013016  Ptpns1  NM_031979  Csda  NM_181687  Nnat 
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NM_001013980  LOC304138  NM_013026  Sdc1  NM_031983  Smarcd2  NM_182667  Myocd 
NM_001013981  LOC304396  NM_013031  Slc18a2  NM_032061  Cntnap1  NM_182814  Cct4 
NM_001013984  LOC304860  NM_013045  Tnr  NM_032066  Hsd17b12  NM_182816  Amigo2 
NM_001013986  LOC305076  NM_013055  Map3k12  NM_032073  Kcnq1  NM_182824  Cd276 
NM_001013997  RGD1309522  NM_013059  Alpl  NM_032074  Irs3  NM_182950  Tnfaip1 
NM_001013999  RGD1311738  NM_013064  Hcrtr1  NM_032416  Aldh2  NM_182952  Cxcl11 
NM_001014010  RGD1308147  NM_013068  Fabp2  NM_032613  Lasp1  NM_183052  Ube2v2 
NM_001014011  Gramd3  NM_013070  Utrn  NM_033021  Sec31l1  NM_183054  Rhbg 
NM_001014012  Zmat2  NM_013075  Hoxa1  NM_033352  Abcd2  NM_183326  Gabra1 
NM_001014015  Rbm34  NM_013082  Sdc2  NM_033376  Kcnk3  NM_183329  Sra1 
NM_001014018  RGD1309326  NM_013090  Vamp1  NM_052798  Zfp354a  NM_183332  Myadm 
NM_001014022  Btbd10  NM_013095  Smad3  NM_052804  Fmr1  NM_198731  Chdh 
NM_001014023  RGD1304579  NM_013100  Ptger1  NM_052983  Slc5a5  NM_198739  Ly6g5c 
NM_001014030  RGD1309313  NM_013111  Slc7a1  NM_053301  Hfe  NM_198744  Tpd52l2 
NM_001014041  LOC310721  NM_013113  Atp1b1  NM_053302  Admr  NM_198746  Klra5 
NM_001014043  RGD1305778  NM_013114  Selp  NM_053323  Degs1  NM_198749  Rab15 
NM_001014047  NP_001014069.1  NM_013121  Cd28  NM_053328  Bhlhb2  NM_198755  LHR2A_RAT 
NM_001014051  LOC311548  NM_013125  Scn5a  NM_053329  Igfals  NM_198757  Srr 
NM_001014064  Pars2  NM_013132  Anxa5  NM_053343  Dclk1  NM_198758  Rap2ip 
NM_001014069  Snip1  NM_013136  Mak  NM_053355  Ikbkb  NM_198770  Zmynd19 
NM_001014070  LOC313672  NM_013141  Ppard  NM_053360  Sh3kbp1  NM_198771  Fam3c 
NM_001014072  RGD1311517  NM_013143  Mep1a  NM_053362  Dffb  NM_198777  MGC73003 
NM_001014076  Nol10  NM_013151  Plat  NM_053380  Slc34a2  NM_198778  C11orf8h 
NM_001014077  Clec14a  NM_013152  Slc18a1  NM_053381  Atp1b4  NM_198790  Rgsl2h 
NM_001014087  Ccdc67  NM_013153  Has2  NM_053385  Prelp  NM_198791  NP_942086.1 
NM_001014091  LOC315712  NM_013159  Ide  NM_053390  Il12a  NM_199096  Necap2 
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NM_001014093  Parp16  NM_013168  Hmbs  NM_053394  Klf5  NM_199110  Mfng 
NM_001014095  Dzip1l  NM_013174  Tgfb3  NM_053403  Grb7  NM_199113  Popdc2 
NM_001014100  LOC316326  NM_013187  Plcg1  NM_053427  Slc17a6  NM_199208  Rdh2 
NM_001014130  RGD1309106  NM_013192  Kcnj6  NM_053429  Fgfr3  NM_199253  Pcsk9 
NM_001014133  LOC360910  NM_013214  Acot7  NM_053437  Dgat1  NM_199267  Rela 
NM_001014147  RGD1310571  NM_013222  Gfer  NM_053442  Slc7a8  NM_199269  Mamdc1 
NM_001014162  RGD1309578  NM_016987  Acly  NM_053445  Fads1  NM_199391  RGD735112 
NM_001014164  Cybasc3  NM_016993  Bcl2  NM_053455  Fgl2  NM_199407  Unc5c 
NM_001014166  RGD1311155  NM_017006  G6pdx  NM_053457  Cldn11  NM_199463  Ripk5 
NM_001014176  RGD1312003  NM_017007  Gad1  NM_053463  Nucb1  NM_199491  Fut7 
NM_001014182  Mall  NM_017009  Gfap  NM_053484  Gas7  NM_199493  RGD735029 
NM_001014202  RGD1311835  NM_017011  Grm1  NM_053491  Plg  NM_199495  Ndufa10 
NM_001014209  LOC363060  NM_017020  Il6ra  NM_053502  Abcg1  NM_199501  Cdk2 
NM_001014211  LOC363091  NM_017023  Kcnj1  NM_053503  Jub  NM_199502  Chrdl1 
NM_001014216  RGD1306658  NM_017027  Mpz  NM_053511  Fbxo2  NM_201988  Pgpep1 
NM_001014219  RGD1359242  NM_017037  Pmp22  NM_053516  Nol3  NM_203336  Esrrg 
NM_001014232  RGD1308373  NM_017052  Sord  NM_053517  Shc1  NM_207610  Ube4a 
NM_001014247  Lzts2  NM_017058  Vdr  NM_053520  Elf1  NM_207617  Iqsec3 
NM_001014248  RGD1308127  NM_017061  Lox  NM_053521  Slc5a7  NM_212490  Atp6v1g2 
NM_001014256  LOC365972  NM_017064  Stat5a  NM_053522  Rhoq  NM_212498  RGD1303066 
NM_001014269  Lrrfip1  NM_017065  Gabrb3  NM_053524  Nox4  NM_212499  G7c 
NM_001015009  Zadh1  NM_017070  Srd5a1  NM_053536  Klf15  NM_212505  Ier3 
NM_001015010  Cib2  NM_017076  PVR  NM_053550  Pip5k2b  NM_212508  Nrm 
NM_001015013  Mtvr2  NM_017079  Cd1d1  NM_053558  Trpc1  NM_212549  Ring1 
NM_001015014  Surf6_predicted  NM_017107  Ogt  NM_053560  Chi3l1  NM_213562  Trim39 
NM_001015026  Tm4sf12  NM_017110  Cart  NM_053561  Nap1l1  NM_213629  Arhgap20 
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NM_001015027  Crebl2  NM_017115  Myog  NM_053563  Ddx39  NM_001015034  Tnfrsf14 
NM_001015028  Anks6  NM_017130  Neu2  NM_053568  Pcyt2  NM_017161  Adora2b 
NM_001015032  Galnt3  NM_017156  CP2BC_RAT  NM_053569  Mbtps1  NM_053582  Lcn7 
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NM_001001508  Prg1  NM_001024795  Rnf44  NM_019232  Sgk  NM_053811  Slc9a3r2 
NM_001001510  Klhl10  NM_001024865  LOC684557  NM_019243  Ptgfrn  NM_053818  Slc6a9 
NM_001002279  Rnf166  NM_001024874  Rhox9  NM_019250  Ralgds  NM_053851  Cacnb2 
NM_001002798  Top1mt  NM_001024876  RGD1305156  NM_019253  Ptpn5  NM_053880  Dncic2 
NM_001002819  Gfpt2  NM_001024885  RGD1308637  NM_019261  Klrc2  NM_053883  Dusp6 
NM_001003957  Dnmt3a  NM_001024890  MGC114520  NM_019282  Grem1  NM_053896  Aldh1a2 
NM_001003975  G4  NM_001024965  RGD1306925  NM_019331  Pcsk3  NM_053917  Inpp4b 
NM_001003978  Gspt1  NM_001024968  RGD1307594  NM_019336  Rgs1  NM_053923  Pik3c2g 
NM_001004228  Emcn  NM_001025000  RGD1309288  NM_019344  Rgs8  NM_053947  Mark1 
NM_001004244  RGD1303127  NM_001025009  Josd1  NM_019362  Stk39  NM_053949  Kcnh2 
NM_001004253  Syap1  NM_001025020  RGD1310753  NM_020089  LOC56764  NM_053978  Rab28 
NM_001004255  Dek  NM_001025022  RGD1308059  NM_021653  Dio1  NM_053981  Kcnj12 
NM_001004260  Slc22a18  NM_001025027  Fundc1  NM_021671  Tmem33  NM_053985  H3f3b 
NM_001004277  Lypla3  NM_001025035  Thnsl1  NM_021682  Negr1  NM_053997  Kcnc3 
NM_001004418  Tacc2  NM_001025685  Cd5l  NM_021693  Snf1lk  NM_053998  Rab8a 
NM_001005538  MGC94288  NM_001025701  MGC116373  NM_021702  Atxn3  NM_054000  Kcnb2 
NM_001005539  Smpdl3a  NM_001025756  MGC114379  NM_021766  Pgrmc1  NM_054002  Zbtb7a 
NM_001005544  Morn1  NM_001029909  CPG2  NM_021776  Ecel1  NM_054011  Sh3bp5 
NM_001005902  Abtb1  NM_001029914  LOC291823  NM_021835  Jun  NM_057139  Hnrpu 
NM_001006991  Nudt9  NM_001029919  RGD1306053  NM_022198  Clcn4 2  NM_057141  Hnrpk 
NM_001006993  Sgcg  NM_001030025  Upp1  NM_022224  Pter  NM_057148  Sep 02 
NM_001006994  MGC94555  NM_001031663  LOC500419  NM_022254  Gpr85  NM_057210  Sv2a 
NM_001007020  Hmgn3  NM_001033653  Akap12  NM_022257  Masp1  NM_080394  Reln 
NM_001007145  Catna1  NM_001033680  Syt1  NM_022280  Lrat  NM_080397  Chst10 
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NM_001007235  Itpr1  NM_001033693  Slc31a2  NM_022296  Xylt2  NM_080411  Gpr83 
NM_001007606  Sars1  NM_001033715  Cast  NM_022392  Insig1  NM_080480  Pip5k2c 
NM_001007629  NTF2  NM_001033867  Crkrs  NM_022400  Bcat2  NM_080775  Smgb 
NM_001007646  Fkbp9  NM_001033896  RGD1309886  NM_022403  Tdo2  NM_080888  Bnip3l 
NM_001007660  MGC94183  NM_001033958  Obp3  NM_022407  Aldh1a1  NM_080902  Higd1a 
NM_001007669  Zfp672  NM_001034006  Centb2  NM_022498  Ppp1cc  NM_080906  Ddit4 
NM_001007681  Zfp219  NM_001034010  RGD1310827  NM_022585  Azin1  NM_130739  Acsl6 
NM_001007688  RGD1359600  NM_001034110  Ctsf  NM_022589  Tspan2  NM_130749  Mark3 
NM_001007694  Ifit3  NM_001034830  Zfp384  NM_022631  Wnt5a  NM_130779  Adcy3 
NM_001007698  RGD1560806_predicted  NM_001034918  Iws1  NM_022690  Ube2g1  NM_130813  Kcnk15 
NM_001007706  RGD1359191  NM_001034950  Rup2  NM_022697  Rpl28  NM_133306  Oldlr1 
NM_001007720  Gorasp2  NM_001034994  Rwdd4a  NM_022698  Bad_v2  NM_133317  Tob1 
NM_001007721  Emp2  NM_001035007  Mbtps2  NM_022853  Slc30a1  NM_133396  Tesk2 
NM_001007730  Cabp7  NM_001037184  RGD1307100  NM_022864  Cplx1  NM_133397  Erg 
NM_001007731  Golga7  NM_001037191  RGD1306873  NM_022939  Stx12  NM_133398  Mtdh 
NM_001007737  RGD1359158  NM_001037214  Cdca4  NM_022946  Dlgap1  NM_133423  Yt521 
NM_001007746  MGC94199  NM_001037336  Lrrc4  NM_022957  Serpina5  NM_133425  Ppp1r14c 
NM_001008287  Donson  NM_001037772  LOC300963  NM_023025  Cyp2j3  NM_133427  Cyb5r4 
NM_001008305  RGD1304686  NM_001037774  Cldn8  NM_023092  Myo1c  NM_133551  Pla2g4a 
NM_001008325  RGD1311364  NM_001039005  Mcoln2  NM_023955  Scamp2  NM_133560  Trak2 
NM_001008373  RGD1305356  NM_001039009  Zdhhc21  NM_023979  Apaf1  NM_133561  Brp44l 
NM_001008511  Esrra  NM_001039010  Ppcs  NM_023991  Prkaa2  NM_133578  Dusp5 
NM_001008521  Ptk9  NM_001039099  LOC291967  NM_024001  Mrs2l  NM_133611  Slc2a13 
NM_001008557  Mip1  NM_001039196  Slc39a13  NM_024127  Gadd45a  NM_134327  Cd69 
NM_001008694  LOC361571  NM_001039455  RGD1309570  NM_024151  Arf4  NM_134363  Slc12a5 
NM_001008802  Kb1  NM_001039686  RGD1311934_predicted  NM_024361  Ndst1  NM_134371  Trpm8 
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NM_001008891  Ssr1  NM_001042619  Hsd3b1  NM_024371  Slc6a1  NM_134373  Avpi1 
NM_001009264  RGD1306635_predicted  NM_001047110  LOC499770  NM_024379  Grid2  NM_134392  Spata6 
NM_001009413  RGD1306495  NM_001077641  Plcb1  NM_024398  Aco2  NM_138504  Okl38 
NM_001009622  Sar1b  NM_001079884  Galntl4_predicted  NM_024405  Axin1  NM_138515  Cyp2d4v1 
NM_001009636  RGD1308082  NM_001080149  Ptpn20_predicted  NM_030829  Gprk5  NM_138519  Dkk3 
NM_001009665  Ebag9  NM_001080150  RGD1309969  NM_030830  Luzp1  NM_138535  Grip2_v3 
NM_001009677  Plekhm1  NM_012491  Add2  NM_030835  RAMP4  NM_138710  Dab2ip 
NM_001009691  Dclk2_predicted  NM_012517  Cacna1c  NM_030849  Bmpr1a  NM_138710  Dab2ip 
NM_001009704  Sipa1l2  NM_012527  Chrm3  NM_030990  Plp  NM_138833  Snrk 
NM_001009825  Ppp1r7  NM_012537  C11B1_RAT  NM_031007  Adcy2  NM_138855  Spdy1 
NM_001009967  Pip5k1c  NM_012538  Cyp11b2  NM_031011  Amd1  NM_138861  Prl2b1 
NM_001011557  RGD1305677  NM_012545  Ddc  NM_031022  Cspg4  NM_138871  Tdrd7 
NM_001011900  Tssk1  NM_012587  Ibsp  NM_031024  Dbn1  NM_138879  Sele 
NM_001011914  Dr1  NM_012588  Igfbp3  NM_031123  Stc1  NM_138886  Ick 
NM_001011941  Cdc37l1  NM_012589  Il6  NM_031139  Usf2  NM_138891  Gpr149 
NM_001011944  Slc37a1  NM_012604  Myh3  NM_031351  Atrn  NM_139040  RGD621098 
NM_001011947  Rai14  NM_012607  Nefh  NM_031541  Scarb1  NM_139097  Scn3b 
NM_001011971  XRG4  NM_012619  Pah  NM_031561  LOC685953  NM_139190  Calcoco1 
NM_001011974  Akap2  NM_012651  Slc4a1  NM_031563  Ybx1  NM_139256  Man2c1 
NM_001011985  Mknk2  NM_012652  Slc9a1  NM_031597  Kcnq3  NM_139324  Ehd4 
NM_001012000  Plscr4  NM_012655  Sp1  NM_031601  Cacna1g  NM_144748  LOC246263 
NM_001012010  Rhot1_predicted  NM_012663  Vamp2  NM_031633  Foxm1  NM_144754  Cant1 
NM_001012015  Lamp3  NM_012699  Dnajb9  NM_031656  Stx8  NM_145767  Prrxl1 
NM_001012066  Sphk2  NM_012700  Stx1b2  NM_031657  Gprk6  NM_145774  Rab38 
NM_001012092  Xkr7  NM_012708  Psmb9  NM_031659  Tgm1  NM_145782  Cyp3a18 
NM_001012116  Spag1  NM_012724  Fcer1a  NM_031665  Stx6  NM_147135  Sbk1 
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NM_001012147  Pxn  NM_012765  Htr2c  NM_031678  Per2  NM_147205  St6gal1 
NM_001012148  Ankrd13  NM_012781  Arnt2  NM_031685  Gosr2  NM_147215  Obp3 
NM_001012169  Zfp143  NM_012812  Cox6a2  NM_031696  Gpr88  NM_153297  Cops2 
NM_001012238  RGD1311980  NM_012815  Gclc  NM_031705  Dpys  NM_153310  St18 
NM_001012464  Terf1  NM_012843  Emp1  NM_031722  Tmed2  NM_153467  Gsbs 
NM_001012473  Polr2c  NM_012864  Mmp7  NM_031729  Ppp5c  NM_153629  Hspa4 
NM_001013033  Tspyl  NM_012866  Nfyc  NM_031730  Kcnd2  NM_153728  Soat2 
NM_001013040  Ptpn9  NM_012887  Tmpo  NM_031743  Slc24a2  NM_153735  Nptx1 
NM_001013066  Sipa1l3  NM_012909  Aqp2  NM_031772  Rpo1 4  NM_153814  Cacna1h 
NM_001013082  Pon2  NM_012922  Casp3  NM_031785  Atp6ap1  NM_172019  Ifi47 
NM_001013084  Akr1b10  NM_012941  Cyp51  NM_031786  Trim3  NM_172045  Ppp1r14b 
NM_001013094  Ccnl2  NM_012942  Cyp7a1  NM_031795  Ugcg  NM_172047  Eaf2 
NM_001013161  Cstf1  NM_012950  F2r  NM_031798  Slc12a2  NM_172066  Slc30a4 
NM_001013171  Gulp1  NM_012983  Myo1d  NM_031802  Gabbr2  NM_172157  Arid1b 
NM_001013172  Fhl4  NM_013026  Sdc1  NM_031821  Plk2  NM_172223  Pxmp4 
NM_001013192  Olfml1  NM_013037  Il1rl1  NM_031976  Prkab1  NM_172243  Ppif 
NM_001013196  Dnajc4  NM_013045  Tnr  NM_031979  Csda  NM_172321  Slc6a15 
NM_001013209  Dnajb6  NM_013049  Tnfrsf4  NM_032061  Cntnap1  NM_172328  Tac4 
NM_001013218  Reep6  NM_013051  Scgb1a1  NM_032067  Ralbp1  NM_173096  Mx1 
NM_001013224  Nmnat3  NM_013065  Ppp1cb  NM_032077  Pon1  NM_173098  Slc9a4 
NM_001013228  Tcte1l  NM_013081  Ptk2  NM_032614  Txnl2  NM_173130  LOC286914 
NM_001013907  LOC294513  NM_013102  Fkbp1a  NM_032617  Rab11b  NM_173141  Tfpi2 
NM_001013933  Ube2a  NM_013113  Atp1b1  NM_033096  Ppm1b  NM_173300  Olr1271 
NM_001013956  RGD1309049  NM_013127  Cd38  NM_033442  Gata2  NM_173328  Lgr4 
NM_001013980  LOC304138  NM_013131  Nr3c2  NM_052804  Fmr1  NM_173339  Ceacam10 
NM_001013992  LOC305691  NM_013133  Glra1  NM_053293  Gstt1  NM_175578  Dscr1l1 
Table A2 continued overleaf   204
RefSeq  Gene ID  RefSeq  Gene ID  RefSeq  Gene ID  RefSeq  Gene ID 
NM_001013994  Rcor2  NM_013159  Ide  NM_053297  Pkm2  NM_175758  Slc1a5 
NM_001014011  Gramd3  NM_013179  Hcrt  NM_053301  Hfe  NM_177927  Serpinf1 
NM_001014045  RGD1311463  NM_013192  Kcnj6  NM_053343  Dclk1  NM_178093  Mtus1 
NM_001014064  Pars2  NM_017006  G6pdx  NM_053356  Col1a2  NM_178102  Mapkapk2 
NM_001014073  RGD1305486  NM_017011  Grm1  NM_053358  Ssbp3  NM_178106  Entpd3 
NM_001014075  RGD1311648  NM_017025  Ldha  NM_053394  Klf5  NM_178866  Igf1 
NM_001014082  Ncln  NM_017029  Nef3  NM_053421  Arid4b  NM_178866  Igf1 
NM_001014094  LOC315883  NM_017031  Pde4b  NM_053427  Slc17a6  NM_181090  Slc38a2 
NM_001014109  LOC317379  NM_017044  Pth  NM_053429  Fgfr3  NM_181626  Hbld2 
NM_001014122  Mif4gd  NM_017066  Ptn  NM_053455  Fgl2  NM_181631  Fbxo11 
NM_001014126  RGD1306410  NM_017067  Chm  NM_053457  Cldn11  NM_181633  Gpr151 
NM_001014130  RGD1309106  NM_017097  Ctsc  NM_053458  Rab9  NM_181636  Col23a1 
NM_001014133  LOC360910  NM_017116  Capn2  NM_053502  Abcg1  NM_182817  Smagp 
NM_001014149  RGD1305276  NM_017127  Chka  NM_053503  Jub  NM_183056  Lyk4 
NM_001014172  Rsrc1  NM_017131  Casq2  NM_053521  Slc5a7  NM_183326  Gabra1 
NM_001014175  LOC500378  NM_017156  CP2BC_RAT  NM_053530  Twist1  NM_184051  Prkag2 
NM_001014177  LOC362056  NM_017159  Hal  NM_053536  Klf15  NM_198735  Art2b 
NM_001014185  LOC362264  NM_017226  Padi2  NM_053549  Dnajc4  NM_198760  Slc16a6 
NM_001014190  RGD1307218  NM_017238  Vipr2  NM_053557  Hrmt1l3  NM_198771  Fam3c 
NM_001014231  RGD1308513  NM_017259  Btg2  NM_053577  SPP24_RAT  NM_198779  RGD735140 
NM_001014245  RGD1305441  NM_017261  Gria2  NM_053591  Dpep1  NM_198783  Hrpap20 
NM_001014275  Tceal8  NM_017263  Gria4  NM_053603  Clic5  NM_198972  Gkn1 
NM_001015020  Tgif  NM_017288  Scn1b  NM_053610  Prdx5  NM_199237  Fshr 
NM_001015025  Stk38  NM_017290  Atp2a2  NM_053633  Egr2  NM_199267  Rela 
NM_001017485  LOC498145  NM_017298  Cacna1d_v3  NM_053650  Pdlim3  NM_199407  Unc5c 
NM_001017498  LOC498350  NM_017305  Gclm  NM_053722  Clasp2  NM_199409  Panx2 
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NM_001024252  Pcaf  NM_017336  Ptpro  NM_053733  Bcl2l10  NM_199502  Chrdl1 
NM_001024252  Pcaf  NM_017348  Slc6a8  NM_053736  Casp4  NM_201560  RGD1303142 
NM_001024252  Pcaf  NM_019146  Bsn  NM_053738  Wif1  NM_203334  Slc6a5 
NM_001024262  RGD1305424  NM_019147  Jag1  NM_053750  Nppc  NM_203336  Esrrg 
NM_001024275  Rassf4  NM_019155  Cav3  NM_053769  Dusp1  NM_207586  Chia 
NM_001024278  LOC367171  NM_019157  Aqp7  NM_053779  Serpini1  NM_207595  Ankra2 
NM_001024296  LOC499418  NM_019194  Tef  NM_053801  Sec14l2  NM_207603  Fcgr3a 
NM_001024305  LOC499691  NM_019207  Neurod3  NM_053805  Snai1  NM_207610  Ube4a 
NM_001024316  LOC499951  NM_019218  Neurod1  NM_053806  Kcnk6  NM_212498  RGD1303066 
NM_001024349  LOC500598  NM_019219  Rbbp9  NM_019221  Trp63  NM_212504  Hspa1b 
NM_001024355  LOC500909             
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